false--12-31 Q1 2020 0000765880 P6M P5Y 4565000 8594000 1000000 0.37 0.37 1.00 1.00 750000000 750000000 505221643 538135188 505221643 538135188 P5Y 0.67 0.47 0.90 0.20 0.41 0.50 0 0 0 0 0000765880 2020-01-01 2020-03-31 0000765880 2020-05-04 0000765880 2019-12-31 0000765880 2020-03-31 0000765880 2019-01-01 2019-03-31 0000765880 us-gaap:CommonStockMember 2018-12-31 0000765880 2018-12-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2018-12-31 0000765880 us-gaap:NoncontrollingInterestMember 2019-03-31 0000765880 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000765880 us-gaap:ParentMember 2019-01-01 2019-03-31 0000765880 us-gaap:NoncontrollingInterestMember 2018-12-31 0000765880 us-gaap:ParentMember 2018-12-31 0000765880 us-gaap:ParentMember 2019-03-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-01-01 2019-03-31 0000765880 2019-03-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000765880 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-03-31 0000765880 us-gaap:CommonStockMember 2019-03-31 0000765880 us-gaap:ParentMember 2020-01-01 2020-03-31 0000765880 us-gaap:CommonStockMember 2019-12-31 0000765880 us-gaap:NoncontrollingInterestMember 2019-12-31 0000765880 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-12-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-03-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-01-01 2020-03-31 0000765880 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000765880 us-gaap:CommonStockMember 2020-03-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000765880 us-gaap:ParentMember 2019-12-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000765880 us-gaap:NoncontrollingInterestMember 2020-03-31 0000765880 us-gaap:ParentMember 2020-03-31 0000765880 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-01-01 0000765880 hcp:BrookdaleMTCAMember hcp:CcrcJvInvestmentMember us-gaap:AssetsLeasedToOthersMember hcp:OtherNonReportingSegmentMember 2020-01-31 0000765880 hcp:CcrcJvInvestmentMember us-gaap:AssetsLeasedToOthersMember hcp:OtherNonReportingSegmentMember 2020-01-31 0000765880 hcp:SeniorHousingOperatingPortfolioMember 2020-03-31 0000765880 us-gaap:AccountingStandardsUpdate201613Member 2020-01-01 0000765880 us-gaap:AssetsLeasedToOthersMember hcp:SeniorHousingTripleNetMember 2018-01-01 0000765880 hcp:CCRCJVMember 2017-11-30 0000765880 hcp:BrookdaleMTCAMember hcp:A2019AmendedMasterLeaseMember us-gaap:AssetsLeasedToOthersMember 2020-01-31 2020-01-31 0000765880 hcp:RIDEAFacilitiesMember 2017-11-01 2017-11-30 0000765880 hcp:RIDEAFacilitiesMember us-gaap:AssetsLeasedToOthersMember hcp:SeniorHousingOperatingPortfolioMember 2017-11-01 2017-11-30 0000765880 hcp:BrookdaleMTCAMember hcp:A2019AmendedMasterLeaseMember us-gaap:AssetsLeasedToOthersMember 2020-01-31 0000765880 hcp:BrookdaleMTCAMember hcp:CcrcJvInvestmentMember 2020-01-31 0000765880 us-gaap:AssetsLeasedToOthersMember hcp:SeniorHousingTripleNetMember 2017-11-30 0000765880 srt:MaximumMember hcp:MeasurementInputAnnualRentEscalatorsMember 2020-01-31 0000765880 hcp:BrookdaleMTCAMember 2020-01-31 2020-01-31 0000765880 hcp:BrookdaleMTCAMember hcp:CcrcJvInvestmentMember 2020-01-31 2020-01-31 0000765880 hcp:CcrcJvInvestmentMember us-gaap:AssetsLeasedToOthersMember hcp:OtherNonReportingSegmentMember 2019-10-31 0000765880 hcp:BrookdaleMTCAMember hcp:CcrcJvInvestmentMember 2020-01-31 0000765880 srt:MaximumMember us-gaap:MeasurementInputCapRateMember 2020-01-31 0000765880 srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2020-01-31 0000765880 hcp:CcrcJvInvestmentMember 2020-01-31 0000765880 srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2020-01-31 0000765880 2018-03-01 2018-03-31 0000765880 hcp:BrookdaleMTCAMember hcp:A2019AmendedMasterLeaseMember us-gaap:AssetsLeasedToOthersMember us-gaap:SubsequentEventMember 2020-01-01 2020-12-31 0000765880 hcp:BrookdaleMTCAMember hcp:CcrcJvInvestmentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-31 2020-01-31 0000765880 hcp:RIDEAFacilitiesMember us-gaap:AssetsLeasedToOthersMember hcp:SeniorHousingOperatingPortfolioMember 2017-11-30 0000765880 us-gaap:AssetsLeasedToOthersMember hcp:SeniorHousingTripleNetMember 2019-10-31 0000765880 hcp:BrookdaleMTCAMember hcp:CcrcJvInvestmentMember us-gaap:SubsequentEventMember 2020-12-31 0000765880 2017-12-01 2017-12-31 0000765880 hcp:BrookdaleMTCAMember hcp:CcrcJvInvestmentMember 2020-01-31 2020-01-31 0000765880 us-gaap:AssetsLeasedToOthersMember hcp:SeniorHousingTripleNetMember 2017-11-01 2017-11-30 0000765880 us-gaap:AssetsLeasedToOthersMember hcp:SeniorHousingOperatingPortfolioMember 2019-01-01 2019-03-31 0000765880 us-gaap:AssetsLeasedToOthersMember hcp:SeniorHousingTripleNetMember 2019-01-01 2019-03-31 0000765880 srt:MinimumMember hcp:MeasurementInputAnnualRentEscalatorsMember 2020-01-31 0000765880 hcp:RIDEAFacilitiesMember us-gaap:AssetsLeasedToOthersMember 2017-11-30 0000765880 hcp:BrookdaleMTCAMember hcp:A2019AmendedMasterLeaseMember us-gaap:AssetsLeasedToOthersMember us-gaap:SubsequentEventMember 2020-12-31 0000765880 srt:MinimumMember us-gaap:MeasurementInputCapRateMember 2020-01-31 0000765880 hcp:BrookdaleMTCAMember us-gaap:AssetsLeasedToOthersMember hcp:SeniorHousingOperatingPortfolioMember 2017-11-30 0000765880 hcp:BrookdaleMTCAMember hcp:A2019AmendedMasterLeaseMember 2020-01-31 2020-01-31 0000765880 us-gaap:AssetsLeasedToOthersMember 2019-01-01 2019-03-31 0000765880 hcp:BrookdaleMTCAMember us-gaap:AssetsLeasedToOthersMember hcp:SeniorHousingTripleNetMember 2017-11-01 2017-11-30 0000765880 hcp:BrookdaleMTCAMember hcp:A2019AmendedMasterLeaseMember us-gaap:AssetsLeasedToOthersMember 2019-10-01 2019-10-31 0000765880 hcp:SeniorHousingTripleNetMember 2020-01-01 2020-03-31 0000765880 hcp:SeniorHousingMember hcp:SeniorHousingMember 2019-07-01 2019-07-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember hcp:SeniorHousingOperatingPortfolioMember 2020-03-31 0000765880 hcp:MedicalOfficeMember 2019-01-01 2019-03-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember us-gaap:RealEstateMember 2020-03-31 0000765880 hcp:LifeScienceJVsMember 2019-06-01 2019-06-30 0000765880 hcp:CambridgeMassachusettsMember hcp:LifeScienceFacilityMember hcp:LifescienceMember 2019-12-01 2019-12-31 0000765880 hcp:SHOPJVMember 2019-12-01 2019-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember us-gaap:RealEstateMember hcp:SeniorHousingTripleNetSeniorHousingOperatingPortfolioandMedicalOfficeMember 2019-12-31 0000765880 hcp:UndevelopedLifeScienceMember 2019-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember us-gaap:RealEstateMember 2019-12-31 0000765880 hcp:BrookdaleMTCAMember 2020-01-01 2020-03-31 0000765880 hcp:MedicalOfficeMember 2019-01-01 2019-12-31 0000765880 hcp:UndevelopedLifeScienceMember 2019-01-01 2019-12-31 0000765880 hcp:SeniorHousingMember hcp:SeniorHousingMember 2019-04-01 2019-04-30 0000765880 hcp:LifeScienceFacilityMember hcp:LifescienceMember 2019-01-01 2019-03-31 0000765880 us-gaap:SecuredDebtMember 2019-05-31 0000765880 hcp:TwentysevenShopAssetsEightSeniorHousingTriplenetAssetsThreeMOBsandOneOtherNonReportableAssetMember 2020-03-31 0000765880 hcp:SeniorHousingMember hcp:SeniorHousingMember 2019-05-01 2019-05-31 0000765880 hcp:LifescienceMember 2019-01-01 2019-03-31 0000765880 hcp:SanDiegoMember hcp:LifeScienceFacilityMember hcp:LifescienceMember 2019-01-01 2019-12-31 0000765880 stpr:KS hcp:MedicalOfficeMember 2019-01-01 2019-12-31 0000765880 hcp:SHOPJVMember us-gaap:AssetsLeasedToOthersMember hcp:SeniorHousingOperatingPortfolioMember 2019-12-01 2019-12-31 0000765880 stpr:MA hcp:LifescienceMember 2020-01-01 2020-01-31 0000765880 us-gaap:LandMember hcp:LifescienceMember 2019-01-01 2019-03-31 0000765880 stpr:MA hcp:LifescienceMember us-gaap:SubsequentEventMember 2020-04-01 2020-04-30 0000765880 hcp:SHOPJVMember 2019-12-31 0000765880 srt:MinimumMember 2020-03-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember hcp:MedicalOfficeMember 2020-03-31 0000765880 hcp:SeniorHousingTripleNetMember 2020-03-31 0000765880 hcp:BostonMember hcp:LifeScienceFacilityMember hcp:LifescienceMember 2019-07-01 2019-07-31 0000765880 hcp:SeniorHousingOperatingPortfolioMember 2020-01-01 2020-03-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember 2019-12-31 0000765880 hcp:SeniorHousingTripleNetSHOPMOBandOtherNonReportableMember 2020-01-01 2020-03-31 0000765880 hcp:SeniorHousingMember 2019-06-01 2019-06-30 0000765880 srt:MinimumMember 2020-01-01 2020-03-31 0000765880 stpr:TX hcp:MedicalOfficeMember 2019-01-01 2019-12-31 0000765880 hcp:SeniorHousingTripleNetMember 2020-01-01 2020-03-31 0000765880 hcp:SanDiegoMember hcp:LifescienceMember 2019-01-01 2019-12-31 0000765880 hcp:SeniorHousingTripleNetMember 2019-03-31 0000765880 hcp:SeniorHousingTripleNetMember 2019-12-31 0000765880 srt:MaximumMember 2020-01-01 2020-03-31 0000765880 hcp:SHOPJVMember hcp:SeniorHousingOperatingPortfolioMember 2019-12-31 0000765880 hcp:SeniorHousingOperatingPortfolioMember 2019-03-31 0000765880 srt:MaximumMember 2020-03-31 0000765880 hcp:OtherNonReportingSegmentMember 2019-01-01 2019-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember hcp:SeniorHousingTripleNetMember 2020-03-31 0000765880 hcp:MedicalOfficeMember 2020-01-01 2020-03-31 0000765880 srt:WeightedAverageMember 2020-03-31 0000765880 hcp:LifescienceMember 2019-03-31 0000765880 hcp:OtherNonReportingSegmentMember 2019-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember us-gaap:RealEstateMember hcp:SeniorHousingTripleNetSeniorHousingOperatingPortfolioandMedicalOfficeMember 2020-03-31 0000765880 hcp:LifescienceMember 2019-01-01 2019-12-31 0000765880 hcp:LifescienceMember 2019-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember hcp:MedicalOfficeMember 2019-12-31 0000765880 hcp:SeniorHousingTripleNetMember 2019-01-01 2019-12-31 0000765880 hcp:SeniorHousingOperatingPortfolioMember 2019-01-01 2019-12-31 0000765880 us-gaap:SecuredDebtMember 2019-07-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember 2020-03-31 0000765880 hcp:BrookdaleMTCAMember 2019-01-01 2019-12-31 0000765880 hcp:SeniorHousingOperatingPortfolioMember 2019-01-01 2019-03-31 0000765880 hcp:SeniorHousingMember 2019-06-30 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember hcp:SeniorHousingTripleNetMember 2019-12-31 0000765880 hcp:SeniorHousingOperatingPortfolioMember 2019-12-31 0000765880 hcp:SeniorHousingOperatingPortfolioMember 2020-01-01 2020-03-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember hcp:SeniorHousingOperatingPortfolioMember 2019-12-31 0000765880 srt:WeightedAverageMember 2020-01-01 2020-03-31 0000765880 hcp:MedicalOfficeMember 2019-12-31 0000765880 hcp:SeniorHousingTripleNetMember 2019-01-01 2019-03-31 0000765880 hcp:DFLPortfolioMember us-gaap:FiniteLivedIntangibleAssetsMember hcp:WatchListFinancingReceivableMember hcp:SeniorHousingTripleNetMember 2019-03-31 0000765880 hcp:DFLPortfolioMember hcp:WatchListFinancingReceivableMember hcp:SeniorHousingTripleNetMember 2019-01-01 2019-03-31 0000765880 hcp:SeniorHousingOperatingPortfolioMember 2019-04-01 2019-06-30 0000765880 hcp:DFLPortfolioMember hcp:WatchListFinancingReceivableMember hcp:SeniorHousingOperatingPortfolioMember 2019-01-01 2019-03-31 0000765880 hcp:DFLPortfolioMember us-gaap:RealEstateInvestmentMember hcp:WatchListFinancingReceivableMember hcp:SeniorHousingTripleNetMember 2019-03-31 0000765880 hcp:DFLPortfolioMember hcp:WatchListFinancingReceivableMember hcp:SeniorHousingOperatingPortfolioMember 2019-03-31 0000765880 hcp:WatchListFinancingReceivableMember 2020-03-31 0000765880 us-gaap:PerformingFinancingReceivableMember 2020-03-31 0000765880 hcp:WatchListFinancingReceivableMember hcp:OtherNonReportingSegmentMember 2020-03-31 0000765880 hcp:OtherNonReportingSegmentMember 2020-03-31 0000765880 us-gaap:PerformingFinancingReceivableMember hcp:OtherNonReportingSegmentMember 2020-03-31 0000765880 hcp:WorkoutFinancingReceivableMember hcp:OtherNonReportingSegmentMember 2020-03-31 0000765880 hcp:WorkoutFinancingReceivableMember 2020-03-31 0000765880 us-gaap:MortgageReceivablesMember us-gaap:PerformingFinancingReceivableMember 2020-03-31 0000765880 us-gaap:MortgageReceivablesMember hcp:WatchListFinancingReceivableMember 2020-03-31 0000765880 hcp:MezzanineAndOtherLoansReceivableSecuredMember hcp:WatchListFinancingReceivableMember 2020-03-31 0000765880 us-gaap:MortgageReceivablesMember 2020-03-31 0000765880 hcp:MezzanineAndOtherLoansReceivableSecuredMember 2020-03-31 0000765880 hcp:MezzanineAndOtherLoansReceivableSecuredMember hcp:WorkoutFinancingReceivableMember 2020-03-31 0000765880 us-gaap:MortgageReceivablesMember hcp:WorkoutFinancingReceivableMember 2020-03-31 0000765880 hcp:MezzanineAndOtherLoansReceivableSecuredMember us-gaap:PerformingFinancingReceivableMember 2020-03-31 0000765880 2019-01-01 2019-12-31 0000765880 hcp:ParticipatingDevelopmentLoansAndOtherMember 2020-01-01 2020-03-31 0000765880 hcp:MezzanineMember 2019-12-31 0000765880 hcp:MezzanineMember 2020-01-01 2020-03-31 0000765880 hcp:ParticipatingDevelopmentLoansAndOtherMember 2019-12-31 0000765880 hcp:MezzanineMember 2020-03-31 0000765880 hcp:ParticipatingDevelopmentLoansAndOtherMember 2020-03-31 0000765880 hcp:MbkDevelopmentJvMember 2020-03-31 0000765880 hcp:KYJVsMember 2019-12-31 0000765880 hcp:WaldwickMember 2020-03-31 0000765880 hcp:OtayRanchMember 2020-03-31 0000765880 hcp:KYJVsMember 2019-10-01 2019-10-31 0000765880 hcp:SuburbanPropertiesLLCMember 2020-03-31 0000765880 hcp:DiscoverySarasotaJVMember 2020-03-31 0000765880 hcp:CcrcJvInvestmentMember 2019-12-31 0000765880 hcp:HCPVenturesIVLLCMember 2020-03-31 0000765880 hcp:CcrcJvInvestmentMember 2019-01-01 2019-12-31 0000765880 hcp:U.K.JVMember 2019-12-01 2019-12-31 0000765880 hcp:MedicalOfficeJVsMember 2020-03-31 0000765880 hcp:KYJVsMember 2020-01-01 2020-01-31 0000765880 hcp:CcrcJvInvestmentMember 2019-07-01 2019-09-30 0000765880 hcp:KYJVsMember 2019-10-31 0000765880 hcp:U.K.JVMember 2019-12-31 0000765880 hcp:HCPVenturesIIILLCMember 2020-03-31 0000765880 hcp:BrookdaleMTCAMember hcp:CcrcJvInvestmentMember us-gaap:AssetsLeasedToOthersMember hcp:OtherNonReportingSegmentMember 2020-01-01 2020-01-31 0000765880 hcp:DiscoveryNaplesJVMember 2020-01-01 2020-03-31 0000765880 hcp:DiscoveryNaplesJVMember 2020-03-31 0000765880 hcp:MbkJvMember 2019-12-31 0000765880 hcp:SHOPJVMember 2020-03-31 0000765880 hcp:MbkJvMember 2020-03-31 0000765880 hcp:OtherSeniorHousingOperatingPortfolioJVsMember 2020-03-31 0000765880 hcp:CcrcJvInvestmentMember 2020-03-31 0000765880 hcp:OtherPortfolioJVsMember 2020-03-31 0000765880 hcp:OtherSeniorHousingOperatingPortfolioJVsMember 2019-12-31 0000765880 hcp:MedicalOfficeJVsMember 2019-12-31 0000765880 hcp:OtherPortfolioJVsMember 2019-12-31 0000765880 srt:MinimumMember hcp:MedicalOfficeJVsMember 2020-03-31 0000765880 srt:MinimumMember hcp:OtherPortfolioJVsMember 2020-03-31 0000765880 srt:MaximumMember hcp:MedicalOfficeJVsMember 2020-03-31 0000765880 srt:MinimumMember hcp:OtherSeniorHousingOperatingPortfolioJVsMember 2020-03-31 0000765880 srt:MaximumMember hcp:OtherPortfolioJVsMember 2020-03-31 0000765880 srt:MaximumMember hcp:OtherSeniorHousingOperatingPortfolioJVsMember 2020-03-31 0000765880 hcp:AccountingStandardsUpdate201612Member 2019-01-01 0000765880 hcp:CommercialPaperProgramMember 2020-03-31 0000765880 hcp:SeniorNotesDue20202022and2023Member us-gaap:UnsecuredDebtMember 2019-07-01 2019-07-31 0000765880 hcp:LineOfCreditAndTermLoanMember 2020-03-31 0000765880 hcp:A2019TermLoanMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-03-31 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-05-23 0000765880 us-gaap:UnsecuredDebtMember 2020-01-01 2020-03-31 0000765880 srt:MaximumMember us-gaap:SecuredDebtMember 2020-03-31 0000765880 srt:MinimumMember us-gaap:UnsecuredDebtMember 2020-03-31 0000765880 us-gaap:SecuredDebtMember 2020-03-31 0000765880 us-gaap:SecuredDebtMember 2020-01-01 2020-03-31 0000765880 us-gaap:UnsecuredDebtMember 2020-03-31 0000765880 hcp:SeniorUnsecuredNotesDue2020Member us-gaap:UnsecuredDebtMember 2019-12-31 0000765880 srt:MinimumMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember us-gaap:LineOfCreditMember 2020-03-31 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-01-01 2020-03-31 0000765880 hcp:SeniorNotesDue2023Member us-gaap:UnsecuredDebtMember 2019-12-31 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-03-31 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-03-31 0000765880 hcp:A2019TermLoanMember us-gaap:LineOfCreditMember 2020-03-31 0000765880 hcp:SeniorNotesDue2022Member us-gaap:UnsecuredDebtMember 2019-12-31 0000765880 srt:MaximumMember us-gaap:UnsecuredDebtMember 2020-03-31 0000765880 hcp:UnsecuredNote4.000PercentMember us-gaap:UnsecuredDebtMember 2019-11-21 2019-11-21 0000765880 srt:MinimumMember us-gaap:SecuredDebtMember 2020-03-31 0000765880 hcp:A2019TermLoanMember us-gaap:LineOfCreditMember 2019-05-31 0000765880 us-gaap:LineOfCreditMember 2020-03-31 0000765880 us-gaap:CommercialPaperMember 2020-03-31 0000765880 us-gaap:LoansPayableMember 2020-03-31 0000765880 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember us-gaap:CommercialPaperMember 2020-03-31 0000765880 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember us-gaap:SecuredDebtMember 2020-03-31 0000765880 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-03-31 0000765880 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember us-gaap:UnsecuredDebtMember 2020-03-31 0000765880 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember us-gaap:LineOfCreditMember 2020-03-31 0000765880 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember us-gaap:LoansPayableMember 2020-03-31 0000765880 hcp:SeniorUnsecuredNotesDue2026Member us-gaap:UnsecuredDebtMember 2019-07-05 0000765880 hcp:SeniorUnsecuredNotesDue2030Member us-gaap:UnsecuredDebtMember 2019-11-21 0000765880 hcp:SeniorUnsecuredNotesDue2029Member us-gaap:UnsecuredDebtMember 2019-07-05 0000765880 hcp:SeniorUnsecuredNotesDue2020Member us-gaap:UnsecuredDebtMember 2019-07-22 2019-07-22 0000765880 hcp:UnsecuredNote4.250PercentMember us-gaap:UnsecuredDebtMember 2019-07-08 2019-07-08 0000765880 hcp:SeniorNotesDue2022Member us-gaap:UnsecuredDebtMember 2019-07-08 2019-07-08 0000765880 hcp:UnsecuredNote4.250PercentMember us-gaap:UnsecuredDebtMember 2019-07-08 0000765880 hcp:SeniorUnsecuredNotesDue2020Member us-gaap:UnsecuredDebtMember 2019-07-22 0000765880 hcp:SeniorNotesDue2022Member us-gaap:UnsecuredDebtMember 2019-07-08 0000765880 hcp:UnsecuredNote4.000PercentMember us-gaap:UnsecuredDebtMember 2019-11-21 0000765880 us-gaap:UnsecuredDebtMember 2019-01-01 2019-03-31 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-05-23 2019-05-23 0000765880 hcp:ForwardEquityOfferingMember 2018-12-01 2018-12-31 0000765880 hcp:ForwardEquityOfferingMember 2019-12-01 2019-12-31 0000765880 hcp:A2020ATMProgramMember 2020-02-01 2020-02-29 0000765880 hcp:ForwardEquityOfferingMember 2019-03-31 0000765880 hcp:A2019ForwardEquityOfferingMember 2020-01-01 2020-03-31 0000765880 hcp:A2019ATMProgramMember 2019-01-01 2019-03-31 0000765880 hcp:A2019ATMProgramSettledMember 2020-01-01 2020-03-31 0000765880 hcp:A2019ForwardEquityOfferingMember 2019-11-01 2019-11-30 0000765880 hcp:A2019ATMProgramSettledMember 2020-03-31 0000765880 hcp:A2019ForwardEquityOfferingMember 2020-03-31 0000765880 srt:MaximumMember hcp:ForwardEquityOfferingMember 2019-12-31 0000765880 hcp:A2019ATMProgramSettledMember 2019-03-31 0000765880 hcp:A2019ATMProgramMember 2020-01-01 2020-03-31 0000765880 hcp:AtTheMarketProgramMember 2020-01-01 2020-03-31 0000765880 hcp:ForwardEquityOfferingMember 2019-12-31 0000765880 hcp:A2020ATMProgramMember 2020-01-01 2020-03-31 0000765880 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000765880 hcp:A2019ATMProgramMember 2019-02-01 2019-02-28 0000765880 2019-12-01 2020-03-31 0000765880 srt:MaximumMember hcp:A2019ForwardEquityOfferingMember 2020-03-31 0000765880 hcp:A2019ForwardEquityOfferingMember 2019-01-01 2019-12-31 0000765880 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000765880 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0000765880 hcp:ForwardEquityOfferingMember 2020-01-01 2020-03-31 0000765880 hcp:ConvertibleUnitsMember 2019-01-01 2019-03-31 0000765880 hcp:DownREITMember 2019-01-01 2019-03-31 0000765880 hcp:ConvertibleUnitsMember 2020-01-01 2020-03-31 0000765880 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0000765880 us-gaap:OperatingSegmentsMember hcp:OtherNonReportingSegmentMember 2019-01-01 2019-03-31 0000765880 us-gaap:OperatingSegmentsMember hcp:SeniorHousingTripleNetMember 2019-01-01 2019-03-31 0000765880 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0000765880 us-gaap:OperatingSegmentsMember hcp:MedicalOfficeMember 2019-01-01 2019-03-31 0000765880 us-gaap:OperatingSegmentsMember hcp:MedicalOfficeMember 2020-01-01 2020-03-31 0000765880 us-gaap:OperatingSegmentsMember hcp:LifescienceMember 2020-01-01 2020-03-31 0000765880 us-gaap:OperatingSegmentsMember hcp:SeniorHousingTripleNetMember 2020-01-01 2020-03-31 0000765880 us-gaap:OperatingSegmentsMember hcp:CCRCSegmentMember 2019-01-01 2019-03-31 0000765880 us-gaap:OperatingSegmentsMember hcp:SeniorHousingOperatingPortfolioMember 2020-01-01 2020-03-31 0000765880 us-gaap:OperatingSegmentsMember hcp:OtherNonReportingSegmentMember 2020-01-01 2020-03-31 0000765880 us-gaap:OperatingSegmentsMember hcp:CCRCSegmentMember 2020-01-01 2020-03-31 0000765880 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0000765880 us-gaap:OperatingSegmentsMember hcp:SeniorHousingOperatingPortfolioMember 2019-01-01 2019-03-31 0000765880 us-gaap:OperatingSegmentsMember hcp:LifescienceMember 2019-01-01 2019-03-31 0000765880 hcp:SeniorHousingTripleNetMember 2019-01-01 2019-03-31 0000765880 hcp:BrookdaleMTCAMember hcp:CcrcJvInvestmentMember us-gaap:AssetsLeasedToOthersMember hcp:OtherNonReportingSegmentMember 2020-03-31 0000765880 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0000765880 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0000765880 hcp:VariableInterestEntityNotPrimaryBeneficiaryInvestmentInJointVentureMember 2020-03-31 0000765880 hcp:DevelopmentJVsMember 2020-03-31 0000765880 hcp:VariableInterestEntityNotPrimaryBeneficiarySellerFinancingMember 2020-03-31 0000765880 hcp:VariableInterestEntityNotPrimaryBeneficiaryTenantsWithOperatingLeasesMember 2020-03-31 0000765880 hcp:VariableInterestEntityNotPrimaryBeneficiaryDebtInvestmentMember 2020-03-31 0000765880 hcp:SeniorHousingTripleNetMember hcp:VariableInterestEntityNotPrimaryBeneficiarySellerFinancingMember 2020-03-31 0000765880 hcp:VariableInterestEntityNotPrimaryBeneficiaryInvestmentInJointVentureMember 2020-01-01 2020-03-31 0000765880 hcp:WatertownJVMember 2020-01-01 2020-03-31 0000765880 hcp:DownreitPartnershipsMember 2020-01-01 2020-03-31 0000765880 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryAggregatedDisclosureMember 2020-03-31 0000765880 hcp:LifeScienceJVsMember 2020-01-01 2020-03-31 0000765880 us-gaap:VariableInterestEntityPrimaryBeneficiaryAggregatedDisclosureMember 2020-03-31 0000765880 hcp:WaldwickMember 2020-01-01 2020-03-31 0000765880 hcp:SeniorHousingTripleNetMember hcp:VariableInterestEntityNotPrimaryBeneficiarySellerFinancingMember 2020-01-01 2020-03-31 0000765880 hcp:MorganStanleyRealEstateInvestmentJVMember 2020-01-01 2020-03-31 0000765880 hcp:HcpVenturesVMember 2020-01-01 2020-03-31 0000765880 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2019-12-31 0000765880 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-03-31 0000765880 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000765880 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000765880 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000765880 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0000765880 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0000765880 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000765880 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-03-31 0000765880 srt:MaximumMember us-gaap:InterestRateSwapMember 2020-01-01 2020-03-31 0000765880 hcp:SanDiegoMember hcp:MedicalOfficeMember us-gaap:SubsequentEventMember 2020-04-30 0000765880 hcp:MedicalOfficeMember hcp:SanDiegoMember us-gaap:SubsequentEventMember 2020-04-01 2020-04-30 0000765880 hcp:SeniorHousingOperatingPortfolioMember us-gaap:SubsequentEventMember 2020-04-30 0000765880 hcp:SeniorHousingOperatingPortfolioMember us-gaap:SubsequentEventMember 2020-04-01 2020-04-30 0000765880 hcp:SanDiegoMember hcp:MedicalOfficeMember us-gaap:SubsequentEventMember 2020-05-01 2020-05-01 xbrli:pure hcp:property hcp:facility xbrli:shares iso4217:USD hcp:item hcp:lease iso4217:USD xbrli:shares hcp:joint_venture iso4217:GBP hcp:renewal_option iso4217:USD hcp:asset hcp:derivative hcp:tenant hcp:loan
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended March 31, 2020
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission file number 001-08895

Healthpeak Properties, Inc.
(Exact name of registrant as specified in its charter)

Maryland |  | 33-0091377
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

1920 Main Street, Suite 1200
Irvine, CA 92614
(Address of principal executive offices) (Zip code)
(949) 407-0700
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading symbol(s) | Name of each exchange on which registered
Common stock, $1.00 par value | PEAK | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer | ☒ | Accelerated Filer | ☐
Non-accelerated Filer | ☐ | Smaller Reporting Company | ☐
|  | Emerging Growth Company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of May 4, 2020, there were 538,270,263 shares of the registrant’s $1.00 par value common stock outstanding.

Table of Contents
HEALTHPEAK PROPERTIES, INC.
INDEX

PART I. FINANCIAL INFORMATION
Item 1. | Financial Statements (Unaudited): |
| Consolidated Balance Sheets | 3
| Consolidated Statements of Operations | 4
| Consolidated Statements of Comprehensive Income (Loss) | 5
| Consolidated Statements of Equity | 6
| Consolidated Statements of Cash Flows | 7
| Notes to the Consolidated Financial Statements | 8
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 33
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 53
Item 4. | Controls and Procedures | 54
PART II. OTHER INFORMATION
Item 1. | Legal Proceedings | 55
Item 1A. | Risk Factors | 55
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 76
Item 6. | Exhibits | 77
Signatures |

2

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
(Unaudited)

| March 31, 2020 |  | December 31, 2019
ASSETS |  |  |  |  |
Real estate: |  |  |  |  |
Buildings and improvements | $ | 12,720,111 |  |  | $ | 11,120,039 |
Development costs and construction in progress | 588,343 |  |  | 692,336 |
Land | 2,114,024 |  |  | 1,992,602 |
Accumulated depreciation and amortization | (2,840,632 | ) |  | (2,771,922 | )
Net real estate | 12,581,846 |  |  | 11,033,055 |
Net investment in direct financing leases | 44,706 |  |  | 84,604 |
Loans receivable, net of reserves of $9,314 and $0 | 220,652 |  |  | 190,579 |
Investments in and advances to unconsolidated joint ventures | 479,900 |  |  | 825,515 |
Accounts receivable, net of allowance of $8,594 and $4,565 | 85,037 |  |  | 59,417 |
Cash and cash equivalents | 783,542 |  |  | 144,232 |
Restricted cash | 106,557 |  |  | 40,425 |
Intangible assets, net | 550,348 |  |  | 331,693 |
Assets held for sale, net | 271,861 |  |  | 504,394 |
Right-of-use asset, net | 171,843 |  |  | 172,486 |
Other assets, net | 776,387 |  |  | 646,491 |
Total assets | $ | 16,072,679 |  |  | $ | 14,032,891 |
LIABILITIES AND EQUITY |  |  |  |  |
Bank line of credit and commercial paper | $ | — |  |  | $ | 93,000 |
Term loan | 249,002 |  |  | 248,942 |
Senior unsecured notes | 5,650,053 |  |  | 5,647,993 |
Mortgage debt | 490,049 |  |  | 276,907 |
Intangible liabilities, net | 72,137 |  |  | 74,991 |
Liabilities of assets held for sale, net | 31,724 |  |  | 36,369 |
Lease liability | 156,808 |  |  | 156,611 |
Accounts payable, accrued liabilities, and other liabilities | 856,031 |  |  | 540,924 |
Deferred revenue | 753,432 |  |  | 289,680 |
Total liabilities | 8,259,236 |  |  | 7,365,417 |
Commitments and contingencies |  |  |  |  |
Common stock, $1.00 par value: 750,000,000 shares authorized; 538,135,188 and 505,221,643 shares issued and outstanding | 538,135 |  |  | 505,222 |
Additional paid-in capital | 10,213,011 |  |  | 9,183,892 |
Cumulative dividends in excess of earnings | (3,512,143 | ) |  | (3,601,199 | )
Accumulated other comprehensive income (loss) | (2,495 | ) |  | (2,857 | )
Total stockholders' equity | 7,236,508 |  |  | 6,085,058 |
Joint venture partners | 373,495 |  |  | 378,061 |
Non-managing member unitholders | 203,440 |  |  | 204,355 |
Total noncontrolling interests | 576,935 |  |  | 582,416 |
Total equity | 7,813,443 |  |  | 6,667,474 |
Total liabilities and equity | $ | 16,072,679 |  |  | $ | 14,032,891 |

See accompanying Notes to the Unaudited Consolidated Financial Statements.
3

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

| Three Months Ended March 31,
| 2020 |  | 2019
Revenues: |  |  |
Rental and related revenues | $ | 314,688 |  |  | $ | 294,222 |
Resident fees and services | 263,505 |  |  | 126,695 |
Income from direct financing leases | 3,269 |  |  | 13,524 |
Interest income | 3,688 |  |  | 1,713 |
Total revenues | 585,150 |  |  | 436,154 |
Costs and expenses: |  |  |
Interest expense | 58,376 |  |  | 49,327 |
Depreciation and amortization | 189,276 |  |  | 131,951 |
Operating | 376,013 |  |  | 168,927 |
General and administrative | 22,349 |  |  | 21,355 |
Transaction costs | 14,848 |  |  | 4,518 |
Impairments and loan loss reserves (recoveries), net | 39,123 |  |  | 8,858 |
Total costs and expenses | 699,985 |  |  | 384,936 |
Other income (expense): |  |  |
Gain (loss) on sales of real estate, net | 164,869 |  |  | 8,044 |
Loss on debt extinguishments | 833 |  |  | — |
Other income (expense), net | 210,608 |  |  | 3,133 |
Total other income (expense), net | 376,310 |  |  | 11,177 |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures | 261,475 |  |  | 62,395 |
Income tax benefit (expense) | 33,044 |  |  | 3,458 |
Equity income (loss) from unconsolidated joint ventures | (11,979 | ) |  | (863 | )
Net income (loss) | 282,540 |  |  | 64,990 |
Noncontrolling interests' share in earnings | (3,460 | ) |  | (3,520 | )
Net income (loss) attributable to Healthpeak Properties, Inc. | 279,080 |  |  | 61,470 |
Participating securities' share in earnings | (1,616 | ) |  | (441 | )
Net income (loss) applicable to common shares | $ | 277,464 |  |  | $ | 61,029 |
Earnings per common share: |  |  |
Basic | $ | 0.55 |  |  | $ | 0.13 |
Diluted | $ | 0.54 |  |  | $ | 0.13 |
Weighted average shares outstanding: |  |  |
Basic | 506,476 |  |  | 477,766 |
Diluted | 515,045 |  |  | 479,131 |

See accompanying Notes to the Unaudited Consolidated Financial Statements.
4

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands)
(Unaudited)

| Three Months Ended March 31,
| 2020 |  | 2019
Net income (loss) | $ | 282,540 |  |  | $ | 64,990 |
Other comprehensive income (loss): |  |  |
Net unrealized gains (losses) on derivatives | 301 |  |  | 94 |
Change in Supplemental Executive Retirement Plan obligation and other | 61 |  |  | 69 |
Foreign currency translation adjustment | — |  |  | 662 |
Total other comprehensive income (loss) | 362 |  |  | 825 |
Total comprehensive income (loss) | 282,902 |  |  | 65,815 |
Total comprehensive income (loss) attributable to noncontrolling interests | (3,460 | ) |  | (3,520 | )
Total comprehensive income (loss) attributable to Healthpeak Properties, Inc. | $ | 279,442 |  |  | $ | 62,295 |

See accompanying Notes to the Unaudited Consolidated Financial Statements.
5

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED STATEMENTS OF EQUITY
(In thousands, except per share data)
(Unaudited)
For the three months ended March 31, 2020:

| Common Stock |  | Additional Paid-In Capital |  | Cumulative Dividends In Excess Of Earnings |  | Accumulated Other Comprehensive Income (Loss) |  | Total Stockholders’ Equity |  | Total Noncontrolling Interests |  | Total Equity
| Shares |  | Amount |  |  |  |  |  |
December 31, 2019 | 505,222 |  |  | $ | 505,222 |  |  | $ | 9,183,892 |  |  | $ | (3,601,199 | ) |  | $ | (2,857 | ) |  | $ | 6,085,058 |  |  | $ | 582,416 |  |  | $ | 6,667,474 |
Impact of adoption of ASU No. 2016-13(1) | — |  |  | — |  |  | — |  |  | (1,524 | ) |  | — |  |  | (1,524 | ) |  | — |  |  | (1,524 | )
January 1, 2020 | 505,222 |  |  | 505,222 |  |  | 9,183,892 |  |  | (3,602,723 | ) |  | (2,857 | ) |  | 6,083,534 |  |  | 582,416 |  |  | 6,665,950 |
Net income (loss) | — |  |  | — |  |  | — |  |  | 279,080 |  |  | — |  |  | 279,080 |  |  | 3,460 |  |  | 282,540 |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | 362 |  |  | 362 |  |  | — |  |  | 362 |
Issuance of common stock, net | 33,104 |  |  | 33,104 |  |  | 1,031,518 |  |  | — |  |  | — |  |  | 1,064,622 |  |  | — |  |  | 1,064,622 |
Conversion of DownREIT units to common stock | 23 |  |  | 23 |  |  | 486 |  |  | — |  |  | — |  |  | 509 |  |  | (509 | ) |  | — |
Repurchase of common stock | (268 | ) |  | (268 | ) |  | (9,469 | ) |  | — |  |  | — |  |  | (9,737 | ) |  | — |  |  | (9,737 | )
Exercise of stock options | 54 |  |  | 54 |  |  | 1,752 |  |  | — |  |  | — |  |  | 1,806 |  |  | — |  |  | 1,806 |
Amortization of deferred compensation | — |  |  | — |  |  | 4,832 |  |  | — |  |  | — |  |  | 4,832 |  |  | — |  |  | 4,832 |
Common dividends ($0.37 per share) | — |  |  | — |  |  | — |  |  | (188,500 | ) |  | — |  |  | (188,500 | ) |  | — |  |  | (188,500 | )
Distributions to noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (8,432 | ) |  | (8,432 | )
March 31, 2020 | 538,135 |  |  | $ | 538,135 |  |  | $ | 10,213,011 |  |  | $ | (3,512,143 | ) |  | $ | (2,495 | ) |  | $ | 7,236,508 |  |  | $ | 576,935 |  |  | $ | 7,813,443 |

For the three months ended March 31, 2019:

| Common Stock |  | Additional Paid-In Capital |  | Cumulative Dividends In Excess Of Earnings |  | Accumulated Other Comprehensive Income (Loss) |  | Total Stockholders’ Equity |  | Total Noncontrolling Interests |  | Total Equity
| Shares |  | Amount |  |  |  |  |  |
December 31, 2018 | 477,496 |  |  | $ | 477,496 |  |  | $ | 8,398,847 |  |  | $ | (2,927,196 | ) |  | $ | (4,708 | ) |  | $ | 5,944,439 |  |  | $ | 568,152 |  |  | $ | 6,512,591 |
Impact of adoption of ASU No. 2016-02(2) | — |  |  | — |  |  | — |  |  | 590 |  |  | — |  |  | 590 |  |  | — |  |  | 590 |
January 1, 2019 | 477,496 |  |  | 477,496 |  |  | 8,398,847 |  |  | (2,926,606 | ) |  | (4,708 | ) |  | 5,945,029 |  |  | 568,152 |  |  | 6,513,181 |
Net income (loss) | — |  |  | — |  |  | — |  |  | 61,470 |  |  | — |  |  | 61,470 |  |  | 3,520 |  |  | 64,990 |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | 825 |  |  | 825 |  |  | — |  |  | 825 |
Issuance of common stock, net | 342 |  |  | 342 |  |  | 1,190 |  |  | — |  |  | — |  |  | 1,532 |  |  | — |  |  | 1,532 |
Conversion of DownREIT units to common stock | 184 |  |  | 184 |  |  | 3,890 |  |  | — |  |  | — |  |  | 4,074 |  |  | (4,074 | ) |  | — |
Repurchase of common stock | (95 | ) |  | (95 | ) |  | (2,824 | ) |  | — |  |  | — |  |  | (2,919 | ) |  | — |  |  | (2,919 | )
Exercise of stock options | 2 |  |  | 2 |  |  | 44 |  |  | — |  |  | — |  |  | 46 |  |  | — |  |  | 46 |
Amortization of deferred compensation | — |  |  | — |  |  | 4,111 |  |  | — |  |  | — |  |  | 4,111 |  |  | — |  |  | 4,111 |
Common dividends ($0.37 per share) | — |  |  | — |  |  | — |  |  | (177,286 | ) |  | — |  |  | (177,286 | ) |  | — |  |  | (177,286 | )
Distributions to noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (5,415 | ) |  | (5,415 | )
March 31, 2019 | 477,929 |  |  | $ | 477,929 |  |  | $ | 8,405,258 |  |  | $ | (3,042,422 | ) |  | $ | (3,883 | ) |  | $ | 5,836,882 |  |  | $ | 562,183 |  |  | $ | 6,399,065 |

_______________________________________

(1) | On January 1, 2020, the Company adopted a series of Accounting Standards Updates (“ASUs”) related to accounting for credit losses and recognized the cumulative-effect of adoption to beginning retained earnings. Refer to Note 2 for a detailed impact of adoption.

(2) | On January 1, 2019, the Company adopted a series of ASUs related to accounting for leases and recognized the cumulative-effect of adoption to beginning retained earnings. Refer to Note 2 for a detailed impact of adoption.

See accompanying Notes to the Unaudited Consolidated Financial Statements.
6

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

| Three Months Ended March 31,
| 2020 |  | 2019
Cash flows from operating activities: |  |  |
Net income (loss) | $ | 282,540 |  |  | $ | 64,990 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |  |  |
Depreciation and amortization of real estate, in-place lease and other intangibles | 189,276 |  |  | 131,951 |
Amortization of deferred compensation | 4,832 |  |  | 4,111 |
Amortization of deferred financing costs | 2,582 |  |  | 2,699 |
Straight-line rents | (6,229 | ) |  | (5,091 | )
Amortization of nonrefundable entrance fees and above/below market lease intangibles | (15,943 | ) |  | — |
Equity loss (income) from unconsolidated joint ventures | 11,979 |  |  | 863 |
Distributions of earnings from unconsolidated joint ventures | 9,513 |  |  | 5,232 |
Loss (gain) on sale of real estate under direct financing leases | (41,707 | ) |  | — |
Deferred income tax expense (benefit) | (24,911 | ) |  | (3,800 | )
Impairments and loan loss reserves (recoveries), net | 39,123 |  |  | 8,858 |
Loss on extinguishment of debt | (833 | ) |  | — |
Loss (gain) on sales of real estate, net | (164,869 | ) |  | (8,044 | )
Loss (gain) upon change of control, net | (167,434 | ) |  | — |
Other non-cash items | 502 |  |  | 560 |
Changes in: |  |  |
Decrease (increase) in accounts receivable and other assets, net | (5,036 | ) |  | (11,114 | )
Increase (decrease) in accounts payable, accrued liabilities and deferred revenue | (18,343 | ) |  | (32,633 | )
Net cash provided by (used in) operating activities | 95,042 |  |  | 158,582 |
Cash flows from investing activities: |  |  |
Acquisitions of real estate | (20,018 | ) |  | (106,298 | )
Development, redevelopment, and other major improvements of real estate | (209,418 | ) |  | (136,654 | )
Leasing costs, tenant improvements, and recurring capital expenditures | (21,791 | ) |  | (19,220 | )
Proceeds from sales of real estate, net | 419,381 |  |  | 122,678 |
Acquisition of CCRC Portfolio | (396,352 | ) |  | — |
Contributions to unconsolidated joint ventures | (1,722 | ) |  | (3,870 | )
Distributions in excess of earnings from unconsolidated joint ventures | 2,639 |  |  | 5,497 |
Proceeds from sales/principal repayments on debt investments and direct financing leases | 84,336 |  |  | 481 |
Investments in loans receivable, direct financing leases and other | (8,066 | ) |  | (22,891 | )
Net cash provided by (used in) investing activities | (151,011 | ) |  | (160,277 | )
Cash flows from financing activities: |  |  |
Borrowings under bank line of credit and commercial paper | 2,025,600 |  |  | 320,000 |
Repayments under bank line of credit and commercial paper | (2,118,600 | ) |  | (125,000 | )
Repayments and repurchase of debt, excluding bank line of credit and commercial paper | (5,338 | ) |  | (2,437 | )
Issuance of common stock and exercise of options | 1,066,428 |  |  | 1,578 |
Repurchase of common stock | (9,737 | ) |  | (2,919 | )
Dividends paid on common stock | (188,500 | ) |  | (177,286 | )
Distributions to and purchase of noncontrolling interests | (8,432 | ) |  | (5,415 | )
Net cash provided by (used in) financing activities | 761,421 |  |  | 8,521 |
Effect of foreign exchanges on cash, cash equivalents and restricted cash | (10 | ) |  | (20 | )
Net increase (decrease) in cash, cash equivalents and restricted cash | 705,442 |  |  | 6,806 |
Cash, cash equivalents and restricted cash, beginning of period | 184,657 |  |  | 139,846 |
Cash, cash equivalents and restricted cash, end of period | $ | 890,099 |  |  | $ | 146,652 |

See accompanying Notes to the Unaudited Consolidated Financial Statements.
7

Table of Contents
Healthpeak Properties, Inc.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1. Business

Overview
Healthpeak Properties, Inc., a Standard & Poor’s 500 company, is a Maryland corporation that is organized to qualify as a real estate investment trust (“REIT”) which, together with its consolidated entities (collectively, “Healthpeak” or the “Company”), invests primarily in real estate serving the healthcare industry in the United States (“U.S.”). Healthpeak TM acquires, develops, leases, owns, and manages healthcare real estate. The Company’s diverse portfolio is comprised of investments in the following reportable healthcare segments: (i) senior housing triple-net; (ii) senior housing operating portfolio (“SHOP”); (iii) continuing care retirement community (“CCRC”); (iv) life science; and (v) medical office.
NOTE 2. Summary of Significant Accounting Policies

Basis of Presentation
The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from management’s estimates.
The consolidated financial statements include the accounts of Healthpeak Properties, Inc., its wholly-owned subsidiaries, joint ventures (“JVs”), and variable interest entities (“VIEs”) that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations, and cash flows have been included. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”).
Recent Accounting Pronouncements
Adopted
Leases. In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 (codified under Accounting Standards Codification (“ASC”) 842, Leases) amends the previous accounting for leases to: (i) require lessees to put most leases on their balance sheets (not required for short-term leases with lease terms of 12 months or less), but continue recognizing expenses on their income statements in a manner similar to requirements under prior accounting guidance, (ii) eliminate real estate specific lease provisions, and (iii) modify the classification criteria and accounting for sales-type leases for lessors. Additionally, ASU 2016-02 provides a practical expedient, which the Company elected, that allows an entity to not reassess the following upon adoption (must be elected as a group): (i) whether an expired or existing contract contains a lease arrangement, (ii) lease classification related to expired or existing lease arrangements, or (iii) whether costs incurred on expired or existing leases qualify as initial direct costs.
As a result of adopting ASU 2016-02 on January 1, 2019 using the modified retrospective transition approach, the Company recognized a cumulative-effect adjustment to equity of $1 million as of January 1, 2019. Under ASU 2016-02, the Company began capitalizing fewer costs related to the drafting and negotiation of its lease agreements. Additionally, the Company began recognizing all of its significant operating leases for which it is the lessee, including corporate office leases, equipment leases, and ground leases, on its consolidated balance sheets as a lease liability and corresponding right-of-use asset. As such, the Company recognized a lease liability of $153 million and right-of-use asset of $166 million on January 1, 2019. The aggregate lease liability is calculated as the present value of minimum lease payments, discounted using a rate that approximates the Company’s secured incremental borrowing rate, adjusted for the noncancelable term of each lease. The right-of-use asset is calculated as the aggregate lease liability, adjusted for the existing accrued straight-line rent liability balance of $20 million and net unamortized above/below market ground lease intangible assets of $33 million.
8

Table of Contents
Other. E ffective January 1, 2019, the Company adopted ASU No. 2017-12, Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). The amendments in ASU 2017-12 expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. For cash flow and net investment hedges existing at the date of adoption, the Company adopted the amendments in ASU 2017-12 using the modified retrospective approach. For amendments impacting presentation and disclosure, the Company adopted ASU 2017-12 using a prospective approach. The adoption of ASU 2017-12 did not have a material impact to the Company’s consolidated financial position, results of operations, cash flows, or disclosures.
Credit Losses. In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments held by financial institutions and other organizations. The amendments in ASU 2016-13 eliminate the “probable” initial threshold for recognition of credit losses in current accounting guidance and, instead, reflect an entity’s current estimate of all expected credit losses over the life of the financial instrument. Previously, when credit losses were measured under current accounting guidance, an entity generally only considered past events and current conditions in measuring the incurred loss. The amendments in ASU 2016-13 broaden the information that an entity must consider in developing its expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss.
As a result of adopting ASU 2016-13 on January 1, 2020 using the modified retrospective transition approach, the Company recognized a cumulative-effect adjustment to equity of $2 million as of January 1, 2020. Under ASU 2016-13, the Company began using a loss model that relies on future expected credit losses, rather than incurred losses, as was required under historical U.S. GAAP. Under the new model, the Company is required to recognize future credit losses expected to be incurred over the life of its financing receivables, including loans receivable, direct financing leases (“DFLs”), and certain accounts receivable, at inception of those instruments. The model emphasizes historical experience and future market expectations to determine a loss to be recognized at inception. However, the model continues to be applied on an individual basis and rely on counter-party specific information to ensure the most accurate estimate is recognized. The Company will reassess its reserves on financing receivables at each balance sheet date to determine if an adjustment to the previous reserve is necessary.
Not Yet Adopted
Accounting for Lease Concessions Related to COVID-19. In April 2020, the FASB staff issued a question-and-answer document (the “Lease Modification Q&A”) focused on the application of lease accounting guidance to lease concessions provided as a result of the coronavirus pandemic (“COVID-19”). Under ASC 842, the Company would have to determine, on a lease-by-lease basis, if a lease concession was the result of a new arrangement reached with the tenant (treated within the lease modification accounting framework) or if a lease concession was under the enforceable rights and obligations within the existing lease agreement (precluded from applying the lease modification accounting framework). Under the lease modification framework, rent abatements would be recognized evenly over the remaining lease term, while abatements accounted for outside of the lease modification framework would be recognized as a reduction in revenue in during the abatement period (i.e., the Company would recognize revenue equal to cash received during the concession period). The Lease Modification Q&A allows the Company, if certain criteria have been met, to bypass the lease-by-lease analysis, and instead elect to either apply the lease modification accounting framework or not, with such election applied consistently to leases with similar characteristics and similar circumstances. During the three months ended March 31, 2020, the Company did not provide any lease concessions as a result of COVID-19 and as such, has not yet had to make an election. The future impact of the Lease Modification Q&A is dependent upon the nature and extent of lease concessions granted to tenants as a result of the COVID-19 pandemic in future periods and the elections made by the Company at the time of granting such concessions.
Segment Reporting
The Company’s reportable segments, based on how it evaluates its business and allocates resources, are as follows: (i) senior housing triple-net, (ii) SHOP, (iii) CCRC, (iv) life science, and (v) medical office. In January 2020, primarily as a result of: (i) consolidating 13 of 15 CCRCs previously held by a CCRC joint venture (see discussion of the Brookdale 2019 Master Transaction and Cooperation Agreement in Note 3) and (ii) deconsolidating 19 SHOP assets into a new joint venture in December 2019, the Company's chief operating decision makers (“CODMs”) began reviewing operating results of CCRCs on a stand-alone basis and financial information for each respective segment inclusive of the Company’s share of unconsolidated joint ventures and exclusive of noncontrolling interests’ share of consolidated joint ventures. Therefore, during the first quarter of 2020, the Company began reporting CCRCs as a separate segment and segment measures inclusive of the Company’s share of unconsolidated joint ventures and exclusive of noncontrolling interests’ share of consolidated joint ventures. Accordingly, all prior period segment information has been recast to conform to the current period presentation.
9

Table of Contents
NOTE 3. Master Transactions and Cooperation Agreement with Brookdale

2019 Master Transactions and Cooperation Agreement with Brookdale
In October 2019, the Company and Brookdale Senior Living Inc. (“Brookdale”) entered into a Master Transactions and Cooperation Agreement (the “2019 MTCA”), which includes a series of transactions related to its previously jointly owned 15-campus CCRC portfolio (the “CCRC JV”) and the portfolio of senior housing properties Brookdale triple-net leased from the Company, which, at the time, included 43 properties.
In connection with the 2019 MTCA, the Company and Brookdale, and certain of their respective subsidiaries, closed the following transactions related to the CCRC JV on January 31, 2020:

• | The Company, which owned a 49% interest in the CCRC JV, purchased Brookdale’s 51% interest in 13 of the 15 communities in the CCRC JV based on a valuation of $1.06 billion (the “CCRC Acquisition”);

• | The management agreements related to the CCRC Acquisition communities were terminated and management transitioned (under new management agreements) from Brookdale to Life Care Services LLC (“LCS”); and

• | The Company paid a $100 million management termination fee to Brookdale.

In addition, pursuant to the 2019 MTCA, the Company and Brookdale closed the following transactions related to properties Brookdale triple-net leased from the Company on January 31, 2020:

• | Brookdale acquired 18 of the properties from the Company (the “Brookdale Acquisition Assets”) for cash proceeds of $385 million;

• | The remaining 24 properties (excludes the one property to be transitioned to LCS, as discussed below) were restructured into a single master lease with 2.4% annual rent escalators and a maturity date of December 31, 2027 (the “2019 Amended Master Lease”);

• | A portion of annual rent (amount in excess of 6.5% of sales proceeds) related to 14 of the 18 Brookdale Acquisition Assets was reallocated to the remaining properties under the 2019 Amended Master Lease; and

• | Brookdale paid down $20 million of future rent under the 2019 Amended Master Lease.

Additionally, under the 2019 MTCA, the Company and Brookdale agreed to the following transactions which have not yet occurred:

• | The remaining two CCRCs will be jointly marketed for sale to third parties.

• | The Company will terminate the triple-net lease related to one property and transition it to a RIDEA structure with LCS as the manager;

• | The Company will provide up to $35 million of capital investment in the 2019 Amended Master Lease properties over a five-year term, which will increase rent by 7% of the amount spent, per annum.

As a result of the above transactions, on January 31, 2020, the Company began consolidating the 13 CCRCs in which it acquired Brookdale’s interest. Accordingly, the Company derecognized its investment in the CCRC JV of $323 million and recognized a gain upon change of control of $170 million, which is included in other income (expense), net. In connection with consolidating the 13 CCRCs during the first quarter of 2020, the Company recognized real estate and intangible assets of $1.8 billion, refundable entrance fee liabilities of $308 million, contractual liabilities associated with previously collected non-refundable entrance fees of $436 million, debt assumed of $215 million, other net assets of $48 million, and cash paid of $396 million.
Upon sale of the 18 triple-net assets to Brookdale, the Company recognized an aggregate gain on sales of real estate of $164 million.
Fair Value Measurement Techniques and Quantitative Information
At January 31, 2020, the Company performed a fair value assessment of each of the 2019 MTCA components that provided measurable economic benefit or detriment to the Company. Each fair value calculation was based on an income or market approach and relied on historical and forecasted net operating income, actuarial assumptions about the expected resident length of stay, and market data, including, but not limited to, discount rates ranging from 10% to 12%, annual rent escalators of ranging from 2% to 3%, and a real estate capitalization rates ranging from 7% to 9%. All assumptions were supported by independent market data and considered to be Level 3 measurements within the fair value hierarchy.
10

Table of Contents
2017 MTCA with Brookdale
In November 2017, the Company and Brookdale entered into a Master Transactions and Cooperation Agreement (the “2017 MTCA”) to provide the Company with the ability to significantly reduce its concentration of assets leased to and/or managed by Brookdale. In connection with the overall transaction pursuant to the 2017 MTCA, the Company and Brookdale, and certain of their respective subsidiaries, agreed to the following:

• | The Company, which owned 90% of the interests in its RIDEA I and RIDEA III joint ventures with Brookdale at the time the 2017 MTCA was executed, agreed to purchase Brookdale’s 10% noncontrolling interest in each joint venture. At the time the 2017 MTCA was executed, these joint ventures collectively owned and operated 58 independent living, assisted living, memory care, and/or skilled nursing facilities (the “RIDEA Facilities”). The Company completed its acquisitions of the RIDEA III noncontrolling interest for $32 million in December 2017 and the RIDEA I noncontrolling interest for $63 million in March 2018;

• | The Company received the right to sell, or transition to other operators, 32 of the 78 total assets under an Amended and Restated Master Lease and Security Agreement (the “2017 Amended Master Lease”) with Brookdale and 36 of the RIDEA Facilities (and terminate related management agreements with an affiliate of Brookdale without penalty), certain of which were sold during 2018 and 2019;

• | The Company provided an aggregate $5 million annual reduction in rent on three assets, effective January 1, 2018; and

• | Brookdale agreed to purchase two of the assets under the 2017 Amended Master Lease for $35 million and four of the RIDEA Facilities for $240 million, all of which were sold in 2018.

During 2018, the Company terminated the previous management agreements or leases with Brookdale on 37 assets contemplated under the 2017 MTCA and completed the transition of 20 SHOP assets and 17 senior housing triple-net assets to other managers.
NOTE 4. Real Estate Transactions

2020 Real Estate Investments
The Post Acquisition
In January 2020, the Company entered into definitive agreements to acquire a life science campus in Waltham, Massachusetts for $320 million. The Company made a $20 million nonrefundable deposit upon completing due diligence in January 2020 and closed the acquisition in April 2020.
2019 Real Estate Investments
Cambridge Acquisition
During the first quarter of 2019, the Company acquired a life science facility for $71 million and development rights at an adjacent undeveloped land parcel for consideration of up to $27 million. The existing facility and land parcel are located in Cambridge, Massachusetts.
Discovery Portfolio Acquisition
In April 2019, the Company acquired a portfolio of nine senior housing properties for $445 million. The properties are located across Florida, Georgia, and Texas and are operated by Discovery Senior Living, LLC.
Oakmont Portfolio Acquisitions
In May 2019, the Company acquired three senior housing communities in California for $113 million and in July 2019, the Company acquired an additional five senior housing communities for $284 million. Both portfolios were acquired from and continue to be operated by Oakmont Senior Living LLC (“Oakmont”). Each portfolio was contributed to a DownREIT joint venture in which the sellers received non-controlling interests in lieu of cash for a portion of the sales price. The Company consolidates each DownREIT joint venture.
As part of the May and July 2019 Oakmont transactions, the Company assumed $50 million and $112 million, respectively, of secured mortgage debt, both of which were recorded at their relative fair values through asset acquisition accounting.
Sierra Point Towers Acquisition
In June 2019, the Company acquired two life science buildings in South San Francisco, California adjacent to the Company’s The Shore at Sierra Point development, for $245 million.
11

Table of Contents
Vintage Park JV Interest Purchase
In June 2019, the Company acquired the outstanding equity interests of a senior housing joint venture structure (which owned one senior housing facility), in which the Company previously held an unconsolidated equity investment, for $24 million. Subsequent to acquisition, the Company owned 100% of the equity. Upon consolidating the facility at acquisition, the Company derecognized the existing investment in the joint venture structure, marked the real estate to fair value (using a relative fair value allocation), and recognized a gain upon change of control of $12 million, net of a tax impact of $1 million. The gain upon change in control is recognized within other income (expense), net and the tax impact is recognized within income tax benefit (expense).
Hartwell Innovation Campus Acquisition
In July 2019, the Company acquired a life science campus in the suburban Boston submarket of Lexington, Massachusetts, for $228 million. The campus is comprised of four buildings.
West Cambridge Acquisition
In December 2019, the Company acquired one life science building, adjacent to the Company’s existing properties in Cambridge, Massachusetts, for $333 million.
Sovereign Wealth Fund Senior Housing Joint Venture
In December 2019, the Company formed a new joint venture (the “SWF SH JV”) with a sovereign wealth fund that owns 19 SHOP assets operated by Brookdale. The Company owns 53.5% of the SWF SH JV and contributed all 19 assets with a fair value of $790 million. The SWF SH JV partner owns the other 46.5% and purchased its interest for $367 million. Upon formation of the SWF SH JV, the Company recognized its retained equity method investment at fair value, deconsolidated the 19 SHOP assets, and recognized a gain upon change of control of $161 million, which is recorded in other income (expense), net.
Other Real Estate Acquisitions
During the year ended December 31, 2019, the Company acquired one medical office building (“MOB”) in Kansas for $15 million, one MOB in Texas for $9 million, and one life science building in the Sorrento Mesa submarket of San Diego, California for $16 million.
Development Activities
The Company’s commitments related to development and redevelopment projects decreased by $77 million, to $284 million at March 31, 2020, when compared to December 31, 2019, primarily as a result of completed development and redevelopment projects.
Held for Sale
At March 31, 2020, 9 senior housing triple-net facilities, 2 MOBs, and 25 SHOP facilities were classified as held for sale, with an aggregate carrying value of $272 million, primarily comprised of real estate assets of $269 million (net of accumulated depreciation of $160 million). Liabilities of assets held for sale was primarily comprised of mortgage debt of $28 million and other liabilities of $4 million at March 31, 2020.
At December 31, 2019, 27 senior housing triple-net facilities (inclusive of 18 facilities sold to Brookdale under the 2019 MTCA - see Note 3), 28 SHOP facilities, and 2 MOBs were classified as held for sale, with an aggregate carrying value of $504 million, primarily comprised of real estate assets of $476 million (net of accumulated depreciation of $243 million). Liabilities of assets held for sale were primarily comprised of mortgage debt of $32 million and other liabilities of $4 million at December 31, 2019.
2020 Dispositions of Real Estate
During the quarter ended March 31, 2020, the Company sold 7 SHOP assets for $36 million and 18 senior housing triple-net assets for $385 million (representative of the 18 facilities sold to Brookdale under the 2019 MTCA - see Note 3), resulting in total gain on sales of $165 million.
2019 Dispositions of Real Estate
During the quarter ended March 31, 2019, the Company sold nine SHOP assets for $68 million, two senior housing triple-net assets for $26 million, and one undeveloped life science land parcel for $35 million, resulting in total gain on sales of $8 million.
During the year ended December 31, 2019, the Company sold 18 SHOP assets for $181 million, 2 senior housing triple-net assets for $26 million, 10 MOBs for $23 million, 1 life science asset for $7 million, 1 undeveloped life science land parcel for $35 million, and 2 facilities from the other non-reportable segment for $20 million.
12

Table of Contents
Impairments of Real Estate
During the three months ended March 31, 2020, the Company recognized an aggregate impairment charge of $31 million related to 15 SHOP assets, 2 senior housing triple-net assets, and 2 MOBs that are classified as held for sale and wrote down their aggregate carrying value of $200 million to their aggregate fair value, less estimated costs to sell, of $169 million.
The fair value of the impaired assets was based on forecasted sales prices, which are considered to be Level 3 measurements within the fair value hierarchy. Forecasted sales prices were determined using a direct capitalization model or a market approach (comparable sales model), which rely on certain assumptions by management, including: (i) market capitalization rates, (ii) comparable market transactions, (iii) estimated prices per unit or per square foot, (iv) negotiations with prospective buyers, and (v) forecasted cash flow streams (lease revenue rates, expense rates, growth rates, etc.). There are inherent uncertainties in making these assumptions. For the Company’s impairment calculations during the three months ended March 31, 2020, the Company estimated the fair value of each asset using either (i) market capitalization rates ranging from 7.16% to 9.92%, with a weighted average rate of 9.32% or (ii) prices per unit ranging from $38,000 to $95,000, with a weighted average price of $68,000.
During the three months ended March 31, 2019, the Company determined the carrying value of two MOBs that were candidates for potential future sale were no longer recoverable due to the Company’s shortened intended hold period under the held-for-use impairment model. Accordingly, the Company wrote-down the carrying amount of these two assets to their respective fair value, which resulted in an aggregate impairment charge of $9 million. The fair value of the assets are considered to be Level 2 measurements within the fair value hierarchy.
NOTE 5. Leases

Lease Income
The following table summarizes the Company’s lease income (dollars in thousands):

| Three Months Ended March 31,
| 2020 |  | 2019
Fixed income from operating leases | $ | 253,859 |  |  | $ | 237,223 |
Variable income from operating leases | 60,829 |  |  | 56,999 |
Interest income from direct financing leases | 3,269 |  |  | 13,524 |

Direct Financing Leases
Net investment in DFLs consists of the following (dollars in thousands):

| March 31, 2020 |  | December 31, 2019
Present value of minimum lease payments receivable | $ | 16,255 |  |  | $ | 19,138 |
Present value of estimated residual value | 44,706 |  |  | 84,604 |
Less deferred selling profits | (16,255 | ) |  | (19,138 | )
Net investment in direct financing leases before allowance | 44,706 |  |  | 84,604 |
Allowance for direct financing lease losses | — |  |  | — |
Net investment in direct financing leases | $ | 44,706 |  |  | $ | 84,604 |
Properties subject to direct financing leases | 1 |  |  | 2 |

13

Table of Contents
Direct Financing Lease Internal Ratings
The following table summarizes the Company’s internal ratings for DFLs at March 31, 2020 (dollars in thousands):

|  | Carrying Amount |  | Percentage of DFL Portfolio |  | Internal Ratings
Segment |  |  |  | Performing DFLs |  | Watch List DFLs |  | Workout DFLs
Other non-reportable segments |  | $ | 44,706 |  |  | 100 |  | $ | 44,706 |  |  | — |  |  | — |
|  | $ | 44,706 |  |  | 100 |  | $ | 44,706 |  |  | $ | — |  |  | $ | — |

2020 Direct Financing Lease Sale
During the first quarter of 2020, the Company sold a hospital under a DFL for $82 million and recognized a gain on sale of $42 million, which is included in other income (expense), net.
2019 Direct Financing Lease Conversion
During the first quarter of 2019, the Company converted a DFL portfolio of 14 senior housing triple-net properties, previously on “Watch List” status, to a RIDEA structure, requiring the Company to recognize net assets equal to the lower of the net assets’ fair value or the carrying value of the net investment in the DFL. As a result, the Company derecognized the $351 million carrying value of the net investment in DFL related to the 14 properties and recognized a combination of net real estate ($331 million) and net intangibles assets ($20 million) for the same aggregate amount, with no gain or loss recognized. As a result of the transaction, the 14 properties were transitioned from the senior housing triple-net segment to the SHOP segment during the first quarter of 2019.
2019 Direct Financing Lease Sale
During the second quarter of 2019, the Company entered into agreements to sell 13 senior housing facilities under DFLs (the “DFL Sale Portfolio”) for $274 million. Upon entering into the agreements, the Company recognized an allowance for DFL losses and related impairment charge of $10 million to write-down the carrying value of the DFL Sale Portfolio to its fair value. The fair value of the DFL Sale Portfolio was based upon the agreed upon sale price, less estimated costs to sell, which is considered to be a Level 2 measurement within the fair value hierarchy. In conjunction with the entering into agreements to sell the DFL Sale Portfolio, the Company placed the portfolio on nonaccrual status and began recognizing income equal to the amount of cash received.
The Company completed the sale of the DFL Sale Portfolio in September 2019.
During the three months ended March 31, 2019, income from DFLs and cash payments received were $5.9 million and $4.8 million, respectively, for the DFL Sale Portfolio.
NOTE 6. Loans Receivable

The following table summarizes the Company’s loans receivable (in thousands):

| March 31, 2020 |  | December 31, 2019
Secured mortgage loans(1) | $ | 169,176 |  |  | $ | 161,964 |
Mezzanine and other | 59,998 |  |  | 27,752 |
Unamortized discounts, fees, and costs | 792 |  |  | 863 |
Reserve for loan losses | (9,314 | ) |  | — |
| $ | 220,652 |  |  | $ | 190,579 |

_______________________________________

(1) | At March 31, 2020, the Company had $16 million remaining of commitments to fund $174 million of senior housing development projects. At December 31, 2019, the Company had $25 million remaining of commitments to fund $174 million of senior housing development projects.

14

Table of Contents
2020 Loans Receivable Transactions
For certain residents that qualify, CCRCs may offer to lend residents the necessary funds to satisfy the entrance fee requirements so that they are able to move into a community while still continuing the process of selling their previous home. The loans are due upon sale of the previous residence. Upon completing the CCRC Acquisition (see Note 3) in January 2020, the Company began consolidating 13 CCRCs, which hold approximately $30 million of such notes receivable from various community residents.
Loans Receivable Internal Ratings
In connection with the Company’s quarterly review process or upon the occurrence of a significant event, loans receivable are reviewed and assigned an internal rating of Performing, Watch List, or Workout. Loans that are deemed Performing meet all present contractual obligations, and collection and timing, of all amounts owed is reasonably assured. Watch List Loans are defined as loans that do not meet the definition of Performing or Workout. Workout Loans are defined as loans in which the Company has determined, based on current information and events, that: (i) it is probable it will be unable to collect all amounts due according to the contractual terms of the agreement, (ii) the borrower is delinquent on making payments under the contractual terms of the agreement, and (iii) the Company has commenced action or anticipates pursuing action in the near term to seek recovery of its investment.
The following table summarizes, by year of origination, the Company’s internal ratings for loans receivables as of March 31, 2020 (dollars in thousands):

Investment Type |  | Year of Origination |  | Total
| 2020 |  | 2019 |  | 2018 |  | 2017 |  | 2016 |
Secured mortgage loans |  |  |  |  |  |  |  |  |  |  |  |
Risk rating: |  |  |  |  |  |  |  |  |  |  |  |
Performing loans |  | $ | — |  |  | $ | 55,955 |  |  | $ | — |  |  | $ | 108,484 |  |  | $ | — |  |  | $ | 164,439 |
Watch list loans |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Workout loans |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total secured mortgage loans |  | $ | — |  |  | $ | 55,955 |  |  | $ | — |  |  | $ | 108,484 |  |  | $ | — |  |  | $ | 164,439 |
Mezzanine and other |  |  |  |  |  |  |  |  |  |  |  |
Risk rating: |  |  |  |  |  |  |  |  |  |  |  |
Performing loans |  | $ | 2,901 |  |  | $ | 36,114 |  |  | $ | — |  |  | $ | 8,896 |  |  | $ | 8,302 |  |  | $ | 56,213 |
Watch list loans |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Workout loans |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total mezzanine and other |  | $ | 2,901 |  |  | $ | 36,114 |  |  | $ | — |  |  | $ | 8,896 |  |  | $ | 8,302 |  |  | $ | 56,213 |

Reserve for Loan Losses
The Company evaluates the liquidity and creditworthiness of its borrowers on a quarterly basis. The Company’s evaluation considers industry and economic conditions, individual and portfolio property performance, credit enhancements, liquidity, and other factors. The Company’s borrowers furnish property, portfolio, and guarantor/operator-level financial statements, among other information, on a monthly or quarterly basis; the Company utilizes this financial information to calculate the debt service coverages that it uses in its assessment of internal ratings, which is a primary credit quality indicator. Debt service coverage information is evaluated together with other property, portfolio, and operator performance information, including revenue, expense, net operating income, occupancy, rental rates, capital expenditures, and EBITDA (defined as earnings before interest, tax, and depreciation and amortization), along with other liquidity measures.
In its assessment of credit losses for loans receivable and unfunded loan commitments, the Company utilizes past payment history of its borrowers, current economic conditions, and forecasts future economic conditions through the maturity date of each loan to estimate a probability of default and a resulting loss for each loan receivable. Future economic conditions are based primarily on near-term economic forecasts from the Federal Reserve and reasonable assumptions for long-term economic trends.
15

Table of Contents
The following table summarizes the Company’s reserve for loan losses at March 31, 2020 (in thousands):

| March 31, 2020
| Secured Mortgage Loans |  | Mezzanine and Other |  | Total
Reserve for loan losses, January 1, 2020 | $ | — |  |  | $ | — |  |  | $ | — |
Cumulative-effect of adopting of ASU 2016-13 to beginning retained earnings | 513 |  |  | 907 |  |  | 1,420 |
Provision for expected loan losses | 4,224 |  |  | 3,670 |  |  | 7,894 |
Reserve for loan losses, March 31, 2020 | $ | 4,737 |  |  | $ | 4,577 |  |  | $ | 9,314 |

At March 31, 2020, a liability of $1 million related to expected credit losses for unfunded loan commitments was included in accounts payable, accrued liabilities, and other liabilities.
Credit loss expenses are recorded in impairments and loan loss reserves (recoveries), net. The change in the provision for expected loan losses during the quarter ended March 31, 2020 is primarily due to the current and anticipated economic impact of COVID-19.
NOTE 7. Investments in and Advances to Unconsolidated Joint Ventures

The Company owns interests in the following entities that are accounted for under the equity method (dollars in thousands):

|  |  |  |  |  |  |  |  | Carrying Amount
|  |  |  |  |  |  |  |  |  |  | March 31, |  | December 31,
Entity(1) |  | Segment |  |  | Property Count(2) |  |  | Ownership %(2) |  |  | 2020 |  | 2019
SWF SH JV(3) |  | SHOP |  |  | 19 |  |  | 54 |  |  | $ | 411,057 |  |  | $ | 428,258 |
MBK JV |  | SHOP |  |  | 5 |  |  | 50 |  |  | 32,821 |  |  | 33,415 |
Other SHOP JVs(4) |  | SHOP |  |  | 4 |  |  | 50 - 90 |  |  | 16,843 |  |  | 17,719 |
Medical Office JVs(5) |  | MOB |  |  | 3 |  |  | 20 - 67 |  |  | 9,809 |  |  | 9,845 |
Other JVs(6) |  | Other |  |  | — |  |  | 41 - 47 |  |  | 9,370 |  |  | 10,372 |
CCRC JV(7) |  | CCRC |  |  | 2 |  |  | 49 |  |  | — |  |  | 325,830 |
Advances to unconsolidated joint ventures, net |  |  |  |  |  |  |  |  |  |  | — |  |  | 76 |
|  |  |  |  |  |  |  |  |  |  | $ | 479,900 |  |  | $ | 825,515 |

_______________________________________

(1) | These entities are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.

(2) | Property count and ownership percentage are as of March 31, 2020.

(3) | In December 2019, the Company formed the SWF SH JV with a sovereign wealth fund. See Note 4 for discussion of the formation of the SWF SH JV.

(4) | In June 2019, the Company acquired the outstanding equity interests in, and began consolidating, the Vintage Park JV (see Note 4). Remaining unconsolidated SHOP joint ventures (and the Company’s ownership percentage) include: (i) Waldwick JV (85%); (ii) Otay Ranch JV (90%); and (iii) MBK Development JV (50%).

(5) | Includes three unconsolidated medical office joint ventures (and the Company’s ownership percentage): (i) Ventures IV (20%); (ii) Ventures III (30%); and (iii) Suburban Properties, LLC (67%).

(6) | Unconsolidated other joint ventures (and the Company’s ownership percentage) include: (i) Discovery Naples JV (41%) and (ii) Discovery Sarasota JV (47%). The Discovery Naples JV and Discovery Sarasota JV are joint ventures that are developing senior housing facilities and the Company’s investments in those joint ventures are preferred equity investments earning a 10% per annum fixed-rate return. In January 2020, the Company sold its interest in the remaining K&Y joint venture for $12 million. At December 31, 2019, K&Y joint venture includes an ownership percentage of 80% and one unconsolidated joint venture. In October 2019, the Company sold its interest in one of the K&Y joint ventures for $4 million.

(7) | See Note 3 for discussion of the 2019 MTCA with Brookdale, including the acquisition of Brookdale’s interest in 13 of the 15 communities in the CCRC JV in January 2020.

CCRC JV. During 2019, the CCRC JV classified one property that Brookdale and the Company committed to sell to a third-party as held for sale in the joint venture’s stand-alone financial statements. In conjunction with classifying the property as held for sale, the CCRC JV recognized an impairment charge of $12 million to reflect the write-down of the property’s previous carrying value to the estimated selling price, less costs to sell. The Company recognized its 49% share of the impairment charge ($6 million) through equity income (loss) from unconsolidated joint ventures during the quarter ended September 30, 2019.
Additionally, in January 2020, the Company acquired Brookdale’s 51% interest in 13 of the 15 communities held by the CCRC JV. Refer to Note 3 for a detailed discussion of the 2019 MTCA with Brookdale.
16

Table of Contents
U.K. JV. In December 2019, the Company sold its remaining 49% interest in the U.K. JV for proceeds of £70 million ($91 million) and recognized a loss on sale of real estate of $7 million (based on exchange rates at the time the transaction was completed), including $1 million of loss in accumulated other comprehensive income (loss) that was reclassified to gain (loss) on sales of real estate, net. As of December 31, 2019, the Company no longer owned real estate in the U.K.
NOTE 8. Intangibles

Intangible assets primarily consist of lease-up intangibles and above market tenant lease intangibles. The following table summarizes the Company’s intangible lease assets (in thousands):

Intangible lease assets |  | March 31, 2020 |  | December 31, 2019
Gross intangible lease assets |  | $ | 887,516 |  |  | $ | 615,538 |
Accumulated depreciation and amortization |  | (337,168 | ) |  | (283,845 | )
Intangible assets, net |  | $ | 550,348 |  |  | $ | 331,693 |

Intangible liabilities primarily consist of below market lease intangibles. The following table summarizes the Company’s intangible lease liabilities (in thousands):

Intangible lease liabilities |  | March 31, 2020 |  | December 31, 2019
Gross intangible lease liabilities |  | $ | 113,213 |  |  | $ | 113,213 |
Accumulated depreciation and amortization |  | (41,076 | ) |  | (38,222 | )
Intangible liabilities, net |  | $ | 72,137 |  |  | $ | 74,991 |

During the three months ended March 31, 2020, including intangible assets that were recognized in conjunction with consolidating 13 CCRCs in which the Company acquired Brookdale’s interest as part of the 2019 Brookdale MTCA (see Note 3), the Company acquired intangible assets of $273 million, with a weighted average amortization period of 6 years. No intangible liabilities were acquired during the three months ended March 31, 2020.
On January 1, 2019, in conjunction with the adoption of ASU 2016-12 (see Note 2), the Company reclassified $39 million of intangible assets, net and $6 million of intangible liabilities, net related to above and below market ground leases to right-of-use asset, net.
NOTE 9. Debt

Bank Line of Credit and Term Loans
On May 23, 2019, the Company executed a $2.5 billion unsecured revolving line of credit facility (the “Revolving Facility”), which matures on May 23, 2023 and contains two, six month extension options, subject to certain customary conditions. Borrowings under the Revolving Facility accrue interest at LIBOR plus a margin that depends on credit ratings of the Company’s senior unsecured long-term debt. The Company pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on those credit ratings at March 31, 2020, the margin on the Revolving Facility was 0.825% and the facility fee was 0.15%. At March 31, 2020, the Company had no balance outstanding under the Revolving Facility.
In May 2019, the Company also entered into a $250 million unsecured term loan facility, which the Company fully drew down on June 20, 2019 (the “2019 Term Loan” and, together with the Revolving Facility, the “Facilities”). The 2019 Term Loan matures on May 23, 2024. Based on credit ratings for the Company’s senior unsecured long-term debt at March 31, 2020, the 2019 Term Loan accrues interest at a rate of LIBOR plus 0.90%, with a weighted average effective interest rate of 1.98%.
The Facilities include a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to $750 million, subject to securing additional commitments. The Facilities also contain certain financial restrictions and other customary requirements, including cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the agreements: (i) limit the ratio of Enterprise Total Indebtedness to Enterprise Gross Asset Value to 60%; (ii) limit the ratio of Enterprise Secured Debt to Enterprise Gross Asset Value to 40%; (iii) limit the ratio of Enterprise Unsecured Debt to Enterprise Unencumbered Asset Value to 60%; (iv) require a minimum Fixed Charge Coverage ratio of 1.5 times; and (v) require a minimum Consolidated Tangible Net Worth of $7.0 billion. At March 31, 2020, the Company believes it was in compliance with each of these restrictions and requirements of the Facilities.
17

Table of Contents
Commercial Paper Program
In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, unsecured short-term debt securities with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time, with the maximum aggregate face or principal amount outstanding at any one time not exceeding $1.0 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company intends to use its Revolving Facility as a liquidity backstop for the repayment of unsecured short-term debt securities issued under the Commercial Paper Program. As of March 31, 2020, the Company had no balance outstanding under the Commercial Paper Program.
Senior Unsecured Notes
At March 31, 2020, the Company had senior unsecured notes outstanding with an aggregate principal balance of $5.7 billion. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions and other customary terms. The Company believes it was in compliance with these covenants at March 31, 2020.
During the three months ended March 31, 2020 and 2019, the Company had no senior unsecured note issuances or payoffs.
The following table summarizes the Company’s senior unsecured notes issuances during the year ended December 31, 2019 (dollars in thousands):

Date |  | Amount |  | Coupon Rate |  | Maturity Date
November 21, 2019 |  | $ | 750,000 |  |  | 3.000 | % |  | 2030
July 5, 2019 |  | $ | 650,000 |  |  | 3.250 | % |  | 2026
July 5, 2019 |  | $ | 650,000 |  |  | 3.500 | % |  | 2029

The following table summarizes the Company’s senior unsecured notes payoffs during the year ended December 31, 2019 (dollars in thousands):

Date |  | Amount |  | Coupon Rate |  | Maturity Date
November 21, 2019(1) |  | $ | 350,000 |  |  | 4.000 | % |  | 2022
July 22, 2019(2) |  | $ | 800,000 |  |  | 2.625 | % |  | 2020
July 8, 2019(2) |  | $ | 250,000 |  |  | 4.000 | % |  | 2022
July 8, 2019(2) |  | $ | 250,000 |  |  | 4.250 | % |  | 2023

_______________________________________

(1) | The Company recognized a $22 million loss on debt extinguishment related to the repurchase of senior notes.

(2) | Upon completing the redemption of the 2.625% senior unsecured notes due February 2020 and repurchasing a portion of the 4.250% senior unsecured notes due 2023 and the 4.000% senior unsecured notes due 2022, the Company recognized a $35 million loss on debt extinguishment.

Mortgage Debt
At March 31, 2020, the Company had $472 million in aggregate principal of mortgage debt outstanding (excluding mortgage debt on assets held for sale), which is secured by 20 healthcare facilities with an aggregate carrying value of $995 million.
Mortgage debt generally requires monthly principal and interest payments, is collateralized by real estate assets, and is generally non-recourse. Mortgage debt typically restricts transfer of the encumbered assets, prohibits additional liens, restricts prepayment, requires payment of real estate taxes, requires maintenance of the assets in good condition, requires insurance on the assets, and includes conditions to obtain lender consent to enter into or terminate material leases. Some of the mortgage debt may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets.
In May 2019, upon acquiring three senior housing assets from Oakmont, the Company assumed $50 million of secured mortgage debt maturing in 2028 and having a weighted average interest rate of 4.83%. In July 2019, upon acquiring five additional senior housing assets from Oakmont, the Company assumed an additional $112 million of secured mortgage debt with maturity dates ranging from 2027 to 2033 and a weighted average interest rate of 4.89% (see Note 4).
18

Table of Contents
Debt Maturities
The following table summarizes the Company’s stated debt maturities and scheduled principal repayments at March 31, 2020 (in thousands):

Year |  | Bank Line of Credit |  | Commercial Paper |  | Term Loan |  | Senior Unsecured Notes(1) |  | Mortgage Debt(2) |  | Total
2020 (nine months) |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 6,202 |  |  | $ | 6,202 |
2021 |  | — |  |  | — |  |  | — |  |  | — |  |  | 16,165 |  |  | 16,165 |
2022 |  | — |  |  | — |  |  | — |  |  | 300,000 |  |  | 8,417 |  |  | 308,417 |
2023 |  | — |  |  | — |  |  | — |  |  | 550,000 |  |  | 93,609 |  |  | 643,609 |
2024 |  | — |  |  | — |  |  | 250,000 |  |  | 1,150,000 |  |  | 6,939 |  |  | 1,406,939 |
Thereafter |  | — |  |  | — |  |  | — |  |  | 3,700,000 |  |  | 340,925 |  |  | 4,040,925 |
|  | — |  |  | — |  |  | 250,000 |  |  | 5,700,000 |  |  | 472,257 |  |  | 6,422,257 |
(Discounts), premium and debt costs, net |  | — |  |  | — |  |  | (998 | ) |  | (49,947 | ) |  | 17,792 |  |  | (33,153 | )
|  | — |  |  | — |  |  | 249,002 |  |  | 5,650,053 |  |  | 490,049 |  |  | 6,389,104 |
Debt on assets held for sale(3) |  | — |  |  | — |  |  | — |  |  | — |  |  | 27,837 |  |  | 27,837 |
|  | $ | — |  |  | $ | — |  |  | $ | 249,002 |  |  | $ | 5,650,053 |  |  | $ | 517,886 |  |  | $ | 6,416,941 |

_______________________________________

(1) | Effective interest rates on the senior notes range from 3.14% to 6.87% with a weighted average effective interest rate of 3.94% and a weighted average maturity of 7 years.

(2) | Excluding mortgage debt on assets held for sale, effective interest rates on the mortgage debt range from 2.16% to 5.91% with a weighted average effective interest rate of 3.91% and a weighted average maturity of 9 years.

(3) | Represents mortgage debt on assets held for sale with an interest rate of 3.45% and maturity in 2044.

NOTE 10. Commitments and Contingencies

Legal Proceedings
From time to time, the Company is a party to, or has a significant relationship to, legal proceedings, lawsuits and other claims. Except as described below, the Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company’s financial condition, results of operations or cash flows. The Company’s policy is to expense legal costs as they are incurred.
Class Action. On May 9, 2016, a purported stockholder of the Company filed a putative class action complaint, Boynton Beach Firefighters’ Pension Fund v. HCP, Inc., et al., Case No. 3:16-cv-01106-JJH, in the U.S. District Court for the Northern District of Ohio against the Company, certain of its officers, HCR ManorCare, Inc. (“HCRMC”), and certain of its officers, asserting violations of the federal securities laws. The suit asserts claims under sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and alleges that the Company made certain false or misleading statements relating to the value of and risks concerning its investment in HCRMC by allegedly failing to disclose that HCRMC had engaged in billing fraud, as alleged by the U.S. Department of Justice (“DoJ”) in a suit against HCRMC arising from the False Claims Act that the DoJ voluntarily dismissed with prejudice. The plaintiff in the class action suit demands compensatory damages (in an unspecified amount), costs and expenses (including attorneys’ fees and expert fees), and equitable, injunctive, or other relief as the Court deems just and proper. On November 28, 2017, the Court appointed Societe Generale Securities GmbH (SGSS Germany) and the City of Birmingham Retirement and Relief Systems (Birmingham) as Co-Lead Plaintiffs in the class action. The motion to dismiss was fully briefed on May 21, 2018 and oral arguments were held on October 23, 2018. Subsequently, on December 6, 2018, HCRMC and its officers were voluntarily dismissed from the class action lawsuit without prejudice to such claims being refiled. On November 22, 2019, the Court granted the motion to dismiss. On December 20, 2019, Co-Lead plaintiffs filed a motion to amend the Court's judgment. Defendants' opposition brief was filed on February 18, 2020, and Co-Lead Plaintiffs' reply brief was filed on April 2, 2020. The Company believes the suit to be without merit and intends to vigorously defend against it.
19

Table of Contents
Derivative Actions. On June 16, 2016 and July 5, 2016, purported stockholders of the Company filed two derivative actions, Subodh v. HCR ManorCare Inc., et al., Case No. 30-2016-00858497-CU-PT-CXC and Stearns v. HCR ManorCare, Inc., et al., Case No. 30-2016-00861646-CU-MC-CJC, in the Superior Court of California, County of Orange, against certain of the Company’s current and former directors and officers and HCRMC. The Company is named as a nominal defendant. As both derivative actions contained substantially the same allegations, they have been consolidated into a single action (the “California derivative action”). The consolidated action alleges that the defendants engaged in various acts of wrongdoing, including, among other things, breaching fiduciary duties by publicly making false or misleading statements of fact regarding HCRMC’s finances and prospects and failing to maintain adequate internal controls. On April 18, 2017, the Court approved the parties’ stipulation to stay the case pending disposition of the motion to dismiss the class action litigation.
On April 10, 2017, a purported stockholder of the Company filed a derivative action, Weldon v. Martin et al., Case No. 3:17-cv-755, in federal court in the Northern District of Ohio, Western Division, against certain of the Company’s current and former directors and officers and HCRMC. The Company is named as a nominal defendant. The Weldon complaint asserts similar claims to those asserted in the California derivative action. In addition, the complaint asserts a claim under Section 14(a) of the Exchange Act, alleging that the Company made false statements in its 2016 proxy statement by not disclosing that the Company’s performance issues in 2015 were the direct result of alleged billing fraud at HCRMC. On April 18, 2017, the Court re-assigned and transferred this action to the judge presiding over the related federal securities class action. On July 11, 2017, the Court approved a stipulation by the parties to stay the case pending disposition of the motion to dismiss the class action.
On July 21, 2017, a purported stockholder of the Company filed another derivative action, Kelley v. HCR ManorCare, Inc., et al., Case No. 8:17-cv-01259, in federal court in the Central District of California, against certain of the Company’s current and former directors and officers and HCRMC. The Company is named as a nominal defendant. The Kelley complaint asserts similar claims to those asserted in Weldon and in the California derivative action. Like Weldon, the Kelley complaint also additionally alleges that the Company made false statements in its 2016 proxy statement, and asserts a claim for a violation of Section 14(a) of the Exchange Act. On November 28, 2017, the federal court in the Central District of California granted Defendants’ motion to transfer the action to the Northern District of Ohio (i.e., the court where the class action and other federal derivative action are pending). The Court in the Northern District of Ohio is currently considering whether to consolidate the Weldon and Kelley actions, appointment of lead plaintiffs and counsel, and whether the stay in Weldon should continue as to either or both actions.
The Company’s Board of Directors received letters dated August 17, 2016, April 19, 2017, and April 20, 2017 from private law firms acting on behalf of clients who are purported stockholders of the Company, each asserting allegations similar to those made in the California derivative action matters discussed above. Each letter demands that the Board of Directors take action to assert the Company’s rights. The Board of Directors completed its evaluation and rejected the demand letters in December of 2017. One of the law firms has more recently requested that the Board of Directors reconsider its determination after a ruling on the motion to dismiss in the class action litigation.
The Company believes that the plaintiffs lack standing or the lawsuits and demands are without merit, but cannot predict the outcome of these proceedings or reasonably estimate any potential loss at this time. Accordingly, no loss contingency has been recorded for these matters as of March 31, 2020, as the likelihood of loss is not considered probable or estimable.
NOTE 11. Equity

At-The-Market Equity Offering Program
In June 2015, the Company established an at-the-market equity offering program (“ATM Program”) to sell shares of its common stock from time to time through a consortium of banks acting as sales agents or directly to the banks acting as principals. In February 2019, the Company terminated its previous ATM Program and established a new ATM Program (the “2019 ATM Program”) pursuant to which shares of common stock having an aggregate gross sales price of up to $1.0 billion could be sold.
In February 2020, the Company terminated the 2019 ATM Program and established a new ATM Program (the “2020 ATM Program”) pursuant to which shares of common stock having an aggregate gross sales price of up to approximately $1.25 billion may be sold (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement allows the Company to lock in a share price on the sale of shares at the time the forward sales agreement is effective, but defer receiving the proceeds from the sale of shares until a later date.
ATM forward sales generally have a one year term. At any time during the term, the Company may settle a forward sale by delivery of physical shares of common stock to the forward seller or, at the Company’s election, in cash or net shares. The forward sale price the Company expects to receive upon settlement of outstanding forward contracts will be the initial forward price established upon the effective date, subject to adjustments for: (i) accrued interest, (ii) the forward purchasers’ stock borrowing costs, and (iii) certain fixed price reductions during the term of the forward sale agreement.
20

Table of Contents
ATM Forward Contracts
During the three months ended March 31, 2020 and 2019, the Company utilized the forward provisions under the 2019 ATM Program to allow for the sale of up to an aggregate of 2.0 million and 3.6 million shares of its common stock, respectively, at an initial weighted average net price of $35.23 and $31.19 per share, after commissions, respectively.
During the three months ended March 31, 2020, the Company settled all 16.8 million shares previously outstanding under ATM forward contracts at a weighted average net price of $31.38 per share, after commissions, resulting in net proceeds of $528 million. At March 31, 2020, no shares remained outstanding under ATM forward contracts.
At March 31, 2020, approximately $1.25 billion of the Company’s common stock remained available for sale under the 2020 ATM Program.
The Company did no t settle any ATM forward contracts during the three months ended March 31, 2019.
ATM Direct Issuances
During the three months ended March 31, 2020 and 2019, no shares of common stock were issued under the 2019 ATM Program or the 2020 ATM Program, as applicable.
Forward Equity Offerings
November 2019 Offering. In November 2019, the Company entered into a forward equity sales agreement (the "2019 forward equity sales agreement") to sell an aggregate of 15.6 million shares of its common stock (including shares sold through the exercise of underwriters’ options) at an initial net price of $34.46 per share, after underwriting discounts and commissions, which was subject to adjustments for: (i) accrued interest, (ii) the forward purchasers’ stock borrowing costs, and (iii) certain fixed price reductions during the term of the agreement. During the year ended December 31, 2019, no shares were settled under the 2019 forward equity sales agreement. During the three months ended March 31, 2020, the Company settled all 15.6 million shares under the 2019 forward equity sales agreement at a weighted average net price of $34.18 per share, resulting in net proceeds of $534 million (total net proceeds of $1.06 billion, when aggregated with the net proceeds from settling ATM forward contracts, as discussed above). Therefore, at March 31, 2020, no shares remained outstanding under the 2019 forward equity sales agreement.
December 2018 Offering. In December 2018, the Company entered into a forward equity sales agreement (the “2018 forward equity sales agreement”) to sell an aggregate of 15.3 million shares of its common stock (including shares sold through the exercise of underwriters’ options) at an initial net price of $28.60 per share, after underwriting discounts and commissions. The 2018 forward equity sales agreement had a one year term that expired on December 13, 2019 during which time the Company could settle the forward sales agreement by delivery of physical shares of common stock to the forward seller or, at the Company’s election, settle in cash or net shares. During the three months ended March 31, 2019, no shares were settled under the 2018 forward equity sales agreement. During the year ended December 31, 2019, the Company settled all 15.3 million shares under the 2018 forward equity sales agreement at a weighted average net price of $27.66 per share resulting in net proceeds of $422 million. Therefore, at December 31, 2019, no shares remained outstanding under the 2018 forward equity sales agreement.
Accumulated Other Comprehensive Income (Loss)
The following table summarizes the Company’s accumulated other comprehensive income (loss) (in thousands):

| March 31, 2020 |  | December 31, 2019
Cumulative foreign currency translation adjustment(1) | $ | — |  |  | $ | (1,023 | )
Unrealized gains (losses) on derivatives, net | 592 |  |  | 1,314 |
Supplemental Executive Retirement plan minimum liability and other | (3,087 | ) |  | (3,148 | )
Total accumulated other comprehensive income (loss) | $ | (2,495 | ) |  | $ | (2,857 | )

_______________________________________

(1) | See Note 7 for a discussion of the U.K. JV transaction.

21

Table of Contents
NOTE 12. Earnings Per Common Share

Basic income (loss) per common share (“EPS”) is computed based on the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed based on the weighted average number of common shares outstanding plus the impact of forward equity sales agreements using the treasury stock method and common shares issuable from the assumed conversion of DownREIT units, stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on the Company’s basic income (loss) per share are included in diluted income (loss) per share during the periods presented.
Restricted stock and certain performance restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share.
During the three months ended March 31, 2020 and 2019, the Company utilized the forward sale provisions under the 2019 ATM Program to sell up to an aggregate of 2.0 million and 3.6 million shares of common stock, respectively, with a one year term. During the three months ended March 31, 2020, the Company settled all 16.8 million shares previously outstanding under ATM forward contracts, leaving no shares outstanding thereunder. The Company did not settle any shares under ATM forward contracts during the three months ended March 31, 2019.
In November 2019, the Company entered into the 2019 forward equity sales agreement to sell an aggregate of 15.6 million shares of its common stock, including shares sold through the exercise of underwriters’ options. During the three months ended March 31, 2020, the Company settled all 15.6 million shares under the 2019 forward equity sales agreement.
Additionally, in December 2018, the Company entered into the 2018 forward equity sales agreement to sell an aggregate of 15.3 million shares of its common stock, including shares sold through the exercise of underwriters’ options. During the three months ended March 31, 2019, no shares were settled under the 2018 forward equity sales agreement.
The Company considered the potential dilution resulting from the forward agreements to the calculation of earnings per share. At inception, the agreements do not have an effect on the computation of basic EPS as no shares are delivered until settlement. However, the Company uses the treasury stock method to determine the dilution, if any, resulting from the forward sales agreements during the period of time prior to settlement. The aggregate effect on the Company’s diluted weighted-average common shares for the three months ended March 31, 2020 and 2019, was 0.8 million and 1.1 million weighted-average incremental shares, respectively, from the forward equity sales agreements.
22

Table of Contents
The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):

| Three Months Ended March 31,
| 2020 |  | 2019
Numerator |  |  |
Net income (loss) | $ | 282,540 |  |  | $ | 64,990 |
Noncontrolling interests' share in earnings | (3,460 | ) |  | (3,520 | )
Net income (loss) attributable to Healthpeak Properties, Inc. | 279,080 |  |  | 61,470 |
Less: Participating securities' share in earnings | (1,616 | ) |  | (441 | )
Net income (loss) applicable to common shares | $ | 277,464 |  |  | $ | 61,029 |
Numerator - Dilutive |  |  |  |  |
Net income (loss) applicable to common shares | $ | 277,464 |  |  | $ | 61,029 |
Add: distributions on dilutive convertible units and other | 2,515 |  |  | — |
Dilutive net income (loss) available to common shares | $ | 279,979 |  |  | $ | 61,029 |
Denominator |  |  |  |  |
Basic weighted average shares outstanding | 506,476 |  |  | 477,766 |
Dilutive potential common shares - equity awards | 318 |  |  | 272 |
Dilutive potential common shares - forward equity agreements(1) | 808 |  |  | 1,093 |
Dilutive potential common shares - DownREIT conversions | 7,443 |  |  | — |
Diluted weighted average common shares | 515,045 |  |  | 479,131 |
Earnings per common share: |  |  |
Basic | $ | 0.55 |  |  | $ | 0.13 |
Diluted | $ | 0.54 |  |  | $ | 0.13 |

_______________________________________

(1) | For the three months ended March 31, 2020, represents the dilutive impact of 32 million shares that were settled during the three months then ended. For the three months ended March 31, 2019, represents the dilutive impact of 19 million shares of common stock under forward sales agreements that had not been settled as of March 31, 2019.

For the three months ended March 31, 2020, all 7 million DownREIT shares were dilutive. For the three months ended March 31, 2019, 6 million shares issuable upon conversion of DownREIT units were not included because they are anti-dilutive. Additionally, for the three months ended March 31, 2020 and 2019, 31 million and 18 million shares of common stock, respectively, issuable pursuant to the settlement of forward equity sales agreements were not included because they are anti-dilutive (see discussion above). For all periods presented in the table above, approximately 1 million shares of common stock subject to outstanding equity awards (restricted stock units and stock options) were not included because they are anti-dilutive.
NOTE 13. Segment Disclosures

The Company evaluates its business and allocates resources based on its reportable business segments: (i) senior housing triple-net, (ii) SHOP, (iii) CCRC, (iv) life science, and (v) medical office. The Company has non-reportable segments that are comprised primarily of the Company’s hospital properties and debt investments. The accounting policies of the segments are the same as those in Note 2 to the Consolidated Financial Statements in the Company’s 2019 Annual Report on Form 10-K filed with the SEC, as updated by Note 2 herein.
During the first quarter of 2020, primarily as a result of: (i) acquiring 100% ownership interest in 13 of 15 CCRCs previously held by a CCRC joint venture (see discussion of the 2019 MTCA with Brookdale in Note 3) and (ii) deconsolidating 19 SHOP assets into a new joint venture in December 2019, the Company's chief operating decision makers began reviewing operating results of CCRCs on a stand-alone basis and financial information for each respective segment inclusive of the Company’s share of unconsolidated joint ventures and exclusive of noncontrolling interests’ share on consolidated joint ventures. Therefore, during the first quarter of 2020, the Company began reporting CCRCs as a separate segment and began reporting segment measures inclusive of the Company’s share of unconsolidated joint ventures and exclusive of noncontrolling interests’ share of consolidated joint ventures. Accordingly, all prior period segment information has been recast to conform to the current period presentation.
23

Table of Contents
During the three months ended March 31, 2020 and 2019, 7 and 18 senior housing triple-net facilities, respectively, were transferred to the Company’s SHOP segment as a result of terminating the triple-net leases and transitioning the assets to a RIDEA structure. When an asset is transferred from one segment to another, the results associated with that asset are included in the original segment until the date of transfer. Results generated after the transfer date are included in the new segment.
The Company evaluates performance based on property Adjusted NOI. NOI is defined as real estate revenues (inclusive of rental and related revenues, resident fees and services, and income from direct financing leases and exclusive of interest income), less property level operating expenses (which exclude transition costs); NOI excludes all other financial statement amounts included in net income (loss). Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense.
NOI and Adjusted NOI include the Company’s share of income (loss) from unconsolidated joint ventures and exclude noncontrolling interests’ share of income (loss) from consolidated joint ventures. Management believes Adjusted NOI is an important supplemental measure because it provides relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and presenting it on an unlevered basis.
Non-segment assets consist of assets in the Company's other non-reportable segments and corporate non-segment assets. Corporate non-segment assets consist primarily of corporate assets, including cash and cash equivalents, restricted cash, accounts receivable, net, marketable equity securities, and real estate assets and liabilities held for sale.
24

Table of Contents
The following tables summarize information for the reportable segments (in thousands):
For the three months ended March 31, 2020:

|  | Senior Housing Triple-Net |  | SHOP |  | CCRC |  | Life Science |  | Medical Office |  | Other Non-reportable |  | Corporate Non-segment |  | Total
Total revenues |  | $ | 33,135 |  |  | $ | 170,961 |  |  | $ | 91,780 |  |  | $ | 128,883 |  |  | $ | 145,146 |  |  | $ | 15,245 |  |  | $ | — |  |  | $ | 585,150 |
Less: Interest income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (3,688 | ) |  | — |  |  | (3,688 | )
Healthpeak's share of unconsolidated joint venture real estate revenues |  | — |  |  | 25,765 |  |  | 21,647 |  |  | — |  |  | 695 |  |  | 86 |  |  | — |  |  | 48,193 |
Noncontrolling interests' share of consolidated joint venture real estate revenues |  | — |  |  | (538 | ) |  | — |  |  | (52 | ) |  | (8,640 | ) |  | — |  |  | — |  |  | (9,230 | )
Operating expenses |  | (506 | ) |  | (138,130 | ) |  | (156,482 | ) |  | (30,201 | ) |  | (50,687 | ) |  | (7 | ) |  | — |  |  | (376,013 | )
Healthpeak's share of unconsolidated joint venture operating expenses |  | — |  |  | (17,956 | ) |  | (18,037 | ) |  | — |  |  | (275 | ) |  | 2 |  |  | — |  |  | (36,266 | )
Noncontrolling interests' share of consolidated joint venture operating expenses |  | — |  |  | 377 |  |  | — |  |  | 17 |  |  | 2,600 |  |  | — |  |  | — |  |  | 2,994 |
Adjustments to NOI(1) |  | (3,374 | ) |  | 531 |  |  | 91,561 |  |  | (4,280 | ) |  | (1,457 | ) |  | 461 |  |  | — |  |  | 83,442 |
Adjusted NOI |  | 29,255 |  |  | 41,010 |  |  | 30,469 |  |  | 94,367 |  |  | 87,382 |  |  | 12,099 |  |  | — |  |  | 294,582 |
Plus: Adjustments to NOI(1) |  | 3,374 |  |  | (531 | ) |  | (91,561 | ) |  | 4,280 |  |  | 1,457 |  |  | (461 | ) |  | — |  |  | (83,442 | )
Interest income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 3,688 |  |  | — |  |  | 3,688 |
Interest expense |  | (82 | ) |  | (2,855 | ) |  | (1,304 | ) |  | (63 | ) |  | (102 | ) |  | — |  |  | (53,970 | ) |  | (58,376 | )
Depreciation and amortization |  | (7,160 | ) |  | (57,003 | ) |  | (20,229 | ) |  | (50,211 | ) |  | (53,148 | ) |  | (1,525 | ) |  | — |  |  | (189,276 | )
General and administrative |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (22,349 | ) |  | (22,349 | )
Transaction costs |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (14,848 | ) |  | (14,848 | )
Impairments and loan loss reserves (recoveries), net |  | (4,670 | ) |  | (23,285 | ) |  | — |  |  | — |  |  | (2,706 | ) |  | (8,462 | ) |  | — |  |  | (39,123 | )
Gain (loss) on sales of real estate, net |  | 164,043 |  |  | (1,243 | ) |  | — |  |  | — |  |  | 2,109 |  |  | (40 | ) |  | — |  |  | 164,869 |
Loss on debt extinguishments |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 833 |  |  | 833 |
Other income (expense), net |  | — |  |  | — |  |  | 170,332 |  |  | — |  |  | — |  |  | 41,707 |  |  | (1,431 | ) |  | 210,608 |
Income tax benefit (expense)(2) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 33,044 |  |  | 33,044 |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | — |  |  | (7,809 | ) |  | (3,610 | ) |  | — |  |  | (420 | ) |  | (88 | ) |  | — |  |  | (11,927 | )
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | — |  |  | 161 |  |  | — |  |  | 35 |  |  | 6,040 |  |  | — |  |  | — |  |  | 6,236 |
Equity income (loss) from unconsolidated joint ventures |  | — |  |  | (18,150 | ) |  | (1,880 | ) |  | — |  |  | 196 |  |  | 7,855 |  |  | — |  |  | (11,979 | )
Net income (loss) |  | $ | 184,760 |  |  | $ | (69,705 | ) |  | $ | 82,217 |  |  | $ | 48,408 |  |  | $ | 40,808 |  |  | $ | 54,773 |  |  | $ | (58,721 | ) |  | $ | 282,540 |

_______________________________________

(1) | Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

(2) | Income tax benefit (expense) for the quarter ended March 31, 2020 includes: (i) a $52 million tax benefit recognized in conjunction with internal restructuring activities, which resulted in the transfer of assets subject to certain deferred tax liabilities from taxable REIT subsidiaries to the REIT in connection with the 2019 MTCA (see Note 3) and (ii) a $2.9 million net tax benefit recognized due to changes under the Coronavirus Aid, Relief, and Economic Security (“CARES”) act, which resulted in net operating losses being utilized at a higher income tax rate than previously available.

25

Table of Contents
For the three months ended March 31, 2019:

|  | Senior Housing Triple-Net |  | SHOP |  | CCRC |  | Life Science |  | Medical Office |  | Other Non-reportable |  | Corporate Non-segment |  | Total
Total revenues |  | $ | 58,831 |  |  | $ | 126,181 |  |  | $ | — |  |  | $ | 94,473 |  |  | $ | 142,195 |  |  | $ | 14,474 |  |  | $ | — |  |  | $ | 436,154 |
Less: Interest income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,713 | ) |  | — |  |  | (1,713 | )
Healthpeak's share of unconsolidated joint venture real estate revenues |  | — |  |  | 5,649 |  |  | 52,238 |  |  | — |  |  | 705 |  |  | 5,532 |  |  | — |  |  | 64,124 |
Noncontrolling interests' share of consolidated joint venture real estate revenues |  | (2 | ) |  | (472 | ) |  | — |  |  | (40 | ) |  | (8,303 | ) |  | — |  |  | — |  |  | (8,817 | )
Operating expenses |  | (994 | ) |  | (96,947 | ) |  | — |  |  | (21,992 | ) |  | (48,987 | ) |  | (7 | ) |  | — |  |  | (168,927 | )
Healthpeak's share of unconsolidated joint venture operating expenses |  | — |  |  | (4,161 | ) |  | (41,377 | ) |  | — |  |  | (275 | ) |  | (17 | ) |  | — |  |  | (45,830 | )
Noncontrolling interests' share of consolidated joint venture operating expenses |  | — |  |  | 350 |  |  | — |  |  | 13 |  |  | 2,424 |  |  | — |  |  | — |  |  | 2,787 |
Adjustments to NOI(1) |  | 566 |  |  | 1,182 |  |  | 3,452 |  |  | (2,479 | ) |  | (1,748 | ) |  | (279 | ) |  | — |  |  | 694 |
Adjusted NOI |  | 58,401 |  |  | 31,782 |  |  | 14,313 |  |  | 69,975 |  |  | 86,011 |  |  | 17,990 |  |  | — |  |  | 278,472 |
Plus: Adjustments to NOI(1) |  | (566 | ) |  | (1,182 | ) |  | (3,452 | ) |  | 2,479 |  |  | 1,748 |  |  | 279 |  |  | — |  |  | (694 | )
Interest income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,713 |  |  | — |  |  | 1,713 |
Interest expense |  | (589 | ) |  | (663 | ) |  | — |  |  | (73 | ) |  | (111 | ) |  | — |  |  | (47,891 | ) |  | (49,327 | )
Depreciation and amortization |  | (16,677 | ) |  | (24,086 | ) |  | — |  |  | (36,248 | ) |  | (53,020 | ) |  | (1,920 | ) |  | — |  |  | (131,951 | )
General and administrative |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (21,355 | ) |  | (21,355 | )
Transaction costs |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (4,518 | ) |  | (4,518 | )
Impairments and loan loss reserves (recoveries), net |  | — |  |  | — |  |  | — |  |  | — |  |  | (8,858 | ) |  | — |  |  | — |  |  | (8,858 | )
Gain (loss) on sales of real estate, net |  | 3,557 |  |  | 4,487 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 8,044 |
Other income (expense), net |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 3,133 |  |  | 3,133 |
Income tax benefit (expense) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 3,458 |  |  | 3,458 |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | — |  |  | (1,488 | ) |  | (10,861 | ) |  | — |  |  | (430 | ) |  | (5,515 | ) |  | — |  |  | (18,294 | )
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | 2 |  |  | 122 |  |  | — |  |  | 27 |  |  | 5,879 |  |  | — |  |  | — |  |  | 6,030 |
Equity income (loss) from unconsolidated joint ventures |  | — |  |  | (477 | ) |  | (2,096 | ) |  | — |  |  | 211 |  |  | 1,499 |  |  | — |  |  | (863 | )
Net income (loss) |  | $ | 44,128 |  |  | $ | 8,495 |  |  | $ | (2,096 | ) |  | $ | 36,160 |  |  | $ | 31,430 |  |  | $ | 14,046 |  |  | $ | (67,173 | ) |  | $ | 64,990 |

_______________________________________

(1) | Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

26

Table of Contents
The following table summarizes the Company’s revenues by segment (in thousands):

|  | Three Months Ended March 31,
Segment |  | 2020 |  | 2019
Senior housing triple-net |  | $ | 33,135 |  |  | $ | 58,831 |
SHOP |  | 170,961 |  |  | 126,181 |
CCRC |  | 91,780 |  |  | — |
Life science |  | 128,883 |  |  | 94,473 |
Medical office |  | 145,146 |  |  | 142,195 |
Other non-reportable segments |  | 15,245 |  |  | 14,474 |
Total revenues |  | $ | 585,150 |  |  | $ | 436,154 |

See Notes 3, 4, 5, 6, and 7 for significant transactions impacting the Company’s segment assets during the periods presented.
NOTE 14. Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in thousands):

| Three Months Ended March 31,
| 2020 |  | 2019
Supplemental cash flow information: |  |  |  |  |
Interest paid, net of capitalized interest | $ | 71,621 |  |  | $ | 53,475 |
Income taxes paid (refunded) | (1,673 | ) |  | (769 | )
Capitalized interest | 6,970 |  |  | 8,369 |
Supplemental schedule of non-cash investing and financing activities: |  |  |
Accrued construction costs | 126,185 |  |  | 94,904 |
Vesting of restricted stock units and conversion of non-managing member units into common stock | 1,077 |  |  | 4,341 |
Liabilities assumed with real estate acquisitions | 523,289 |  |  | — |
Conversion of DFLs to real estate | — |  |  | 350,540 |
Net noncash impact from the consolidation of previously unconsolidated joint ventures | 323,138 |  |  | — |

See Note 3 for a discussion of the impact of the 2019 MTCA with Brookdale on the Company’s consolidated balance sheet and statement of operations. See Note 5 for a discussion related to the conversion of a DFL to real estate.
The following table summarizes cash, cash equivalents and restricted cash (in thousands):

|  | March 31,
|  | 2020 |  | 2019
Cash and cash equivalents |  | $ | 783,542 |  |  | $ | 120,117 |
Restricted cash |  | 106,557 |  |  | 26,535 |
Cash, cash equivalents and restricted cash |  | $ | 890,099 |  |  | $ | 146,652 |

27

Table of Contents
NOTE 15. Variable Interest Entities

Unconsolidated Variable Interest Entities
At March 31, 2020, the Company had investments in: (i) two properties leased to VIE tenants, (ii) five unconsolidated VIE joint ventures, (iii) marketable debt securities of one VIE, and (iv) one loan to a VIE borrower. The Company determined it is not the primary beneficiary of and therefore does not consolidate these VIEs because it does not have the ability to control the activities that most significantly impact their economic performance. Except for the Company’s equity interest in the unconsolidated joint ventures (CCRC OpCo, development investments, Waldwick JV, and the LLC investment discussed below), it has no formal involvement in these VIEs beyond its investments.
VIE Tenant. The Company leases two properties to one tenant that has been identified as a VIE (“VIE tenant”). The VIE tenant is a “thinly capitalized” entity that relies on the operating cash flows generated from the senior housing facilities to pay operating expenses, including the rent obligations under its leases.
CCRC OpCo. The Company holds a 49% ownership interest in CCRC OpCo, a joint venture entity formed in August 2014 that operates senior housing properties in a RIDEA structure and has been identified as a VIE. The equity members of CCRC OpCo “lack power” because they share certain operating rights with Brookdale, as manager of the CCRCs. The assets of CCRC OpCo primarily consist of the CCRCs that it owns and leases, resident fees receivable, notes receivable, and cash and cash equivalents; its obligations primarily consist of operating lease obligations to CCRC PropCo, debt service payments, capital expenditures, accounts payable, and expense accruals. Assets generated by the CCRC operations (primarily rents from CCRC residents) of CCRC OpCo may only be used to settle its contractual obligations (primarily from debt service payments, capital expenditures, and rental costs and operating expenses incurred to manage such facilities). Refer to Note 3 for additional discussion related to transactions impacting the CCRC OpCo.
Waldwick Development JV. The Company holds an 85% ownership interest in a joint venture (the “Waldwick JV”), which has been identified as a VIE as power is shared with a member that does not have a substantive equity investment at risk. The assets of the joint venture primarily consist of a senior housing facility that it owns and cash and cash equivalents; its obligations primarily consist of capital expenditures, accounts payable, and expense accruals. Any assets generated by the joint venture may only be used to settle its contractual obligations (primarily capital expenditures and rental costs and operating expenses incurred to manage such facilities).
LLC Investment. The Company holds a limited partner ownership interest in an unconsolidated LLC that has been identified as a VIE. The Company’s involvement in the entity is limited to its equity investment as a limited partner and it does not have any substantive participating rights or kick-out rights over the general partner. The assets and liabilities of the entity primarily consist of those associated with its senior housing real estate and development activities. Any assets generated by the entity may only be used to settle its contractual obligations (primarily development expenses and debt service payments).
Development Investments. The Company holds investments (consisting of mezzanine debt and/or preferred equity) in two senior housing development joint ventures. The joint ventures are also capitalized by senior loans from a third party and equity from the third party managing-member, but are considered to be “thinly capitalized” as there is insufficient equity investment at risk.
Debt Securities Investment. The Company holds commercial mortgage-backed securities (“CMBS”) issued by Federal Home Loan Mortgage Corporation (commonly referred to as Freddie MAC) through a special purpose entity that has been identified as a VIE because it is “thinly capitalized.” The CMBS issued by the VIE are backed by mortgage debt obligations on real estate assets.
Seller Financing Loan. The Company provided seller financing of $10 million related to its sale of seven senior housing triple-net facilities. The financing was provided in the form of a secured five–year mezzanine loan to a “thinly capitalized” borrower created to acquire the facilities.
28

Table of Contents
The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company’s involvement with these VIEs at March 31, 2020 was as follows (in thousands):

VIE Type |  | Asset/Liability Type |  | Maximum Loss Exposure and Carrying Amount(1)
VIE tenant - operating leases(2) |  | Lease intangibles, net and straight-line rent receivables |  | $ | 1,379 |
CCRC OpCo |  | Investments in unconsolidated joint ventures |  | — |
Unconsolidated development joint ventures |  | Loans receivable, net and Investments in unconsolidated joint ventures |  | 27,476 |
Loan - seller financing |  | Loans receivable, net |  | 9,750 |
CMBS and LLC investment |  | Marketable debt and LLC investment |  | 35,037 |

_______________________________________

(1) | The Company’s maximum loss exposure represents the aggregate carrying amount of such investments (including accrued interest).

(2) | The Company’s maximum loss exposure may be mitigated by re-leasing the underlying properties to new tenants upon an event of default.

As of March 31, 2020, the Company had not provided, and is not required to provide, financial support through a liquidity arrangement or otherwise, to its unconsolidated VIEs, including circumstances in which it could be exposed to further losses (e.g., cash shortfalls).
See Notes 3, 4, 5, 6, and 7 for additional descriptions of the nature, purpose, and operating activities of the Company’s unconsolidated VIEs and interests therein.
Consolidated Variable Interest Entities
The Company’s consolidated total assets and total liabilities at March 31, 2020 and December 31, 2019 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to the Company. Total assets and total liabilities include VIE assets and liabilities as follows (in thousands):

| March 31, 2020 |  | December 31, 2019
Assets |  |  |
Buildings and improvements | $ | 2,983,887 |  |  | $ | 3,236,105 |
Development costs and construction in progress | 90,536 |  |  | 67,285 |
Land | 447,758 |  |  | 526,576 |
Accumulated depreciation and amortization | (594,085 | ) |  | (568,574 | )
Net real estate | 2,928,096 |  |  | 3,261,392 |
Accounts receivable, net | 10,884 |  |  | 11,986 |
Cash and cash equivalents | 44,880 |  |  | 47,027 |
Restricted cash | 13,631 |  |  | 13,596 |
Intangible assets, net | 159,272 |  |  | 206,840 |
Right-of-use asset, net | 92,225 |  |  | 92,664 |
Other assets, net | 60,343 |  |  | 52,124 |
Total assets | $ | 3,309,331 |  |  | $ | 3,685,629 |
Liabilities |  |  |
Mortgage debt | 218,027 |  |  | 218,767 |
Intangible liabilities, net | 19,221 |  |  | 39,545 |
Lease liability | 91,078 |  |  | 90,875 |
Accounts payable, accrued liabilities, and other liabilities | 114,350 |  |  | 122,832 |
Deferred revenue | 91,845 |  |  | 96,985 |
Total liabilities | $ | 534,521 |  |  | $ | 569,004 |

29

Table of Contents
Ventures V, LLC. The Company holds a 51% ownership interest in and is the managing member of a joint venture entity formed in October 2015 that owns and leases MOBs (“Ventures V”). The Company classifies Ventures V as a VIE due to the non-managing member lacking substantive participation rights in the management of Ventures V or kick-out rights over the managing member. The Company consolidates Ventures V as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of Ventures V primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by Ventures V may only be used to settle its contractual obligations (primarily from capital expenditures).
Watertown JV. The Company holds a 95% ownership interest in and is the managing member of joint venture entities formed in November 2017 that own and operate a senior housing property in a RIDEA structure (“Watertown JV”). Watertown PropCo is a VIE as the Company and the non-managing member share in control of the entity, but substantially all of the entity's activities are performed on behalf of the Company. Watertown OpCo is a VIE as the non-managing member, through its equity interest, lacks substantive participation rights in the management of Watertown OpCo or kick-out rights over the managing member. The Company consolidates Watertown PropCo and Watertown OpCo as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of Watertown PropCo primarily consist of a leased property (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of notes payable to a non-VIE consolidated subsidiary of the Company. The assets of Watertown OpCo primarily consist of leasehold interests in a senior housing facility (operating lease), resident fees receivable, and cash and cash equivalents; its obligations primarily consist of lease payments to Watertown PropCo and operating expenses of its senior housing facilities (accounts payable and accrued expenses). Assets generated by the senior housing operations (primarily from senior housing resident rents) of the Watertown structure may only be used to settle its contractual obligations (primarily from the rental costs, operating expenses incurred to manage such facilities, and debt costs).
Life Science JVs. The Company holds a 99% ownership interest in multiple joint venture entities that own and lease life science assets (the “Life Science JVs”). The Life Science JVs are VIEs as the members share in control of the entities, but substantially all of the activities are performed on behalf of the Company. The Company consolidates the Life Science JVs as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Life Science JVs primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the Life Science JVs may only be used to settle their contractual obligations (primarily from capital expenditures).
MSREI MOB JV. The Company holds a 51% ownership interest in, and is the managing member of, a joint venture entity formed in August 2018 that owns and leases MOBs (the “MSREI JV”). The MSREI JV is a VIE due to the non-managing member lacking substantive participation rights in the management of the joint venture or kick-out rights over the managing member. The Company consolidates the MSREI JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of the MSREI JV primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by the MSREI JV may only be used to settle its contractual obligations (primarily from capital expenditures).
Consolidated Lessees. The Company leases two senior housing properties to a lessee entity under a cash flow lease through which the Company receives monthly rent equal to the residual cash flows of the property. The lessee entity is classified as a VIE as it is a "thinly capitalized" entity. The Company consolidates the lessee entity as it has the ability to control the activities that most significantly impact the economic performance of the lessee entity. The lessee entity’s assets primarily consist of leasehold interests in a senior housing facility (operating leases), resident fees receivable, and cash and cash equivalents; its obligations primarily consist of lease payments to the Company and operating expenses of the senior housing facility (accounts payable and accrued expenses). Assets generated by the senior housing operations (primarily from senior housing resident rents) may only be used to settle its contractual obligations (primarily from the rental costs, operating expenses incurred to manage such facilities, and debt costs).
DownREITs. The Company holds a controlling ownership interest in and is the managing member of seven limited liability companies (“DownREITs”). The Company classifies the DownREITs as VIEs due to the non-managing members lacking substantive participation rights in the management of the DownREITs or kick-out rights over the managing member. The Company consolidates the DownREITs as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the DownREITs primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the DownREITs (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).
30

Table of Contents
Other Consolidated Real Estate Partnerships. The Company holds a controlling ownership interest in and is the general partner (or managing member) of multiple partnerships that own and lease real estate assets (the “Partnerships”). The Company classifies the Partnerships as VIEs due to the limited partners (non-managing members) lacking substantive participation rights in the management of the Partnerships or kick-out rights over the general partner (managing member). The Company consolidates the Partnerships as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Partnerships primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the Partnerships (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).
Other consolidated VIEs. The Company made a loan to an entity that entered into a tax credit structure (“Tax Credit Subsidiary”) and a loan to an entity that made an investment in a development joint venture (“Development JV”) both of which are considered VIEs. The Company consolidates the Tax Credit Subsidiary and Development JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIEs’ economic performance. The assets and liabilities of the Tax Credit Subsidiary and Development JV substantially consist of a development in progress, notes receivable, prepaid expenses, notes payable, and accounts payable and accrued liabilities generated from their operating activities. Any assets generated by the operating activities of the Tax Credit Subsidiary and Development JV may only be used to settle their contractual obligations.
NOTE 16. Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets are immaterial at March 31, 2020.
The table below summarizes the carrying amounts and fair values of the Company’s financial instruments (in thousands):

| March 31, 2020(3) |  | December 31, 2019(3)
| Carrying Value |  | Fair Value |  | Carrying Value |  | Fair Value
Loans receivable, net(2) | $ | 220,652 |  |  | $ | 216,624 |  |  | $ | 190,579 |  |  | $ | 190,579 |
Marketable debt securities(2) | 19,902 |  |  | 19,902 |  |  | 19,756 |  |  | 19,756 |
Bank line of credit and commercial paper(2) | — |  |  | — |  |  | 93,000 |  |  | 93,000 |
Term loan(2) | 249,002 |  |  | 249,002 |  |  | 248,942 |  |  | 248,942 |
Senior unsecured notes(1) | 5,650,053 |  |  | 5,835,325 |  |  | 5,647,993 |  |  | 6,076,150 |
Mortgage debt(2) | 490,049 |  |  | 470,521 |  |  | 276,907 |  |  | 280,373 |
Interest-rate swap liabilities(2) | 252 |  |  | 252 |  |  | 553 |  |  | 553 |

_______________________________________

(1) | Level 1: Fair value calculated based on quoted prices in active markets.

(2) | Level 2: Fair value based on (i) for marketable debt securities, quoted prices for similar or identical instruments in active or inactive markets, respectively, or (ii) for loans receivable, net, mortgage debt and swaps, calculated utilizing standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit, commercial paper, and term loans, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating.

(3) | During the three months ended March 31, 2020 and year ended December 31, 2019, there were no material transfers of financial assets or liabilities within the fair value hierarchy.

NOTE 17. Derivative Financial Instruments

The following table summarizes the Company’s outstanding swap contracts as of March 31, 2020 (dollars in thousands):

Date Entered |  | Maturity Date |  | Hedge Designation |  | Notional |  | Pay Rate |  | Receive Rate |  | Fair Value(1)
Interest rate: |  |  |  |  |  |  |  |  |  |  |  |  |  |
July 2005(2) |  | July 2020 |  | Cash Flow |  | $ | 42,000 |  |  | 3.82% |  | BMA Swap Index |  | $ | (252 | )

______________________________________

(1) | Derivative liabilities are recorded in accounts payable, accrued liabilities, and other liabilities in the consolidated balance sheets.

(2) | Represents three interest-rate swap contracts, which hedge fluctuations in interest payments on variable-rate secured debt due to overall changes in hedged cash flows.

31

Table of Contents
The Company uses derivative instruments to mitigate the effects of interest rate fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. Utilizing derivative instruments allows the Company to manage the risk of fluctuations in interest rates related to the potential impact these changes could have on future earnings and forecasted cash flows. The Company does not use derivative instruments for speculative or trading purposes. Assuming a one percentage point shift in the underlying interest rate curve, the estimated change in fair value of each of the underlying derivative instruments would not exceed $1 million.
Concurrent with the sale of its remaining interest in the U.K. JV in December 2019 (see Note 7), the Company paid-off the remainder of its GBP-denominated borrowings under the Revolving Facility and terminated its previously-designated net investment hedge.
NOTE 18. Subsequent Events

COVID-19 Pandemic
In March 2020, the World Health Organization declared the outbreak caused by COVID-19 to be a global pandemic. While COVID-19 continues to evolve daily and its ultimate outcome is uncertain, it has caused significant disruption to individuals, governments, financial markets, and businesses, including the Company. In response to the COVID-19 pandemic, local, state and federal agencies have instituted stay-at-home or shelter-in-place orders, which resulted in closure of many businesses deemed to be non-essential. These health and safety measures, which may remain in place for a significant amount of time, are placing a substantial strain on the business operations of many of the Company’s tenants, operators, and borrowers. The Company evaluated the impacts of COVID-19 on its business thus far and incorporated, wherever possible, information concerning the impact of COVID-19 into its assessments of liquidity, impairments, and collectibility from tenants and borrowers as of March 31, 2020.
Subsequent to March 31, 2020, the Company has agreed to defer rent for May and June 2020 from certain tenants in the MOB segment, with the requirement that all deferred rent is repaid by the end of 2020. Additionally, the Company has received rent relief requests from certain tenants, which we are assessing on a tenant-by-tenant basis, but at this time has not agreed to grant any such relief. The extent of the impact of the COVID-19 pandemic on the Company’s business and financial results will depend on future developments, including the duration, severity, and spread of the pandemic, health and safety actions taken to contain its spread, any possible resurgence of COVID-19 that may occur after the initial outbreak subsides, and how quickly and to what extent normal economic and operating conditions can resume within the markets in which the Company operates, each of which are highly uncertain at this time and outside of the Company’s control. At this time, the Company is unable to estimate the impact of this event on its operations or future financial results.
The Post Acquisition
As discussed in Note 4, in January 2020, the Company entered into definitive agreements to acquire a life science campus in Waltham, Massachusetts for $320 million. The Company made a $20 million nonrefundable deposit upon completing due diligence in January 2020 and closed the acquisition in April 2020.
Dispositions of Real Estate
In April 2020, the Company sold one SHOP asset for $12 million.
Additionally, in April 2020, one of the Company’s tenants exercised its option to acquire three MOBs in San Diego, California for $106 million. The Company received a $5 million nonrefundable deposit in May 2020. The sale is scheduled to close during the second quarter of 2020.
32

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
All references in this report to “Healthpeak,” the “Company,” “we,” “us” or “our” mean Healthpeak Properties, Inc., together with its consolidated subsidiaries. Unless the context suggests otherwise, references to “Healthpeak Properties, Inc.” mean the parent company without its subsidiaries.
Cautionary Language Regarding Forward-Looking Statements
Statements in this Quarterly Report on Form 10-Q that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include, among other things, statements regarding our and our officers’ intent, belief or expectation as identified by the use of words such as “may,” “will,” “project,” “expect,” “believe,” “intend,” “anticipate,” “seek,” “target,” “forecast,” “plan,” “potential,” “estimate,” “could,” “would,” “should” and other comparable and derivative terms or the negatives thereof. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. As more fully set forth under Part II, Item 1A. “Risk Factors” in this report, risks and uncertainties that may cause our actual results to differ materially from the expectations contained in the forward-looking statements include, among other things:

• | the severity and duration of the COVID-19 pandemic;

• | actions that may be taken by governmental authorities to contain the COVID-19 outbreak or to treat its impact;

• | the impact of the COVID-19 pandemic and health and safety measures taken to slow its spread;

• | operational risks associated with third party management contracts, including the additional regulation and liabilities of our RIDEA lease structures;

• | the ability of our existing and future tenants, operators and borrowers to conduct their respective businesses in a manner sufficient to maintain or increase their revenues and manage their expenses in order to generate sufficient income to make rent and loan payments to us and our ability to recover investments made, if applicable, in their operations;

• | the imposition of laws or regulations prohibiting eviction of our tenants or operators, including new governmental efforts in response to COVID-19;

• | the financial condition of our existing and future tenants, operators and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings, which may result in uncertainties regarding our ability to continue to realize the full benefit of such tenants’ and operators’ leases and borrowers’ loans;

• | our concentration in the healthcare property sector, particularly in senior housing, life sciences and medical office buildings, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries;

• | the effect on us and our tenants and operators of legislation, executive orders and other legal requirements, including compliance with the Americans with Disabilities Act, fire, safety and health regulations, environmental laws, the Affordable Care Act, licensure, certification and inspection requirements, and laws addressing entitlement programs and related services, including Medicare and Medicaid, which may result in future reductions in reimbursements or fines for noncompliance;

• | our ability to identify replacement tenants and operators and the potential renovation costs and regulatory approvals associated therewith;

• | the risks associated with property development and redevelopment, including costs above original estimates, project delays and lower occupancy rates and rents than expected;

• | the potential impact of uninsured or underinsured losses, including as a result of hurricanes, earthquakes and other natural disasters, pandemics such as COVID-19, acts of war and/or terrorism and other events that may cause such losses and/or performance declines by us or our tenants and operators;

• | the risks associated with our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners’ financial condition and continued cooperation;

• | competition for the acquisition and financing of suitable healthcare properties as well as competition for tenants and operators, including with respect to new leases and mortgages and the renewal or rollover of existing leases;

33

Table of Contents

• | our, or our counterparties’, ability to fulfill obligations, such as financing conditions and/or regulatory approval requirements, required to successfully consummate acquisitions, dispositions, transitions, developments, redevelopments, joint venture transactions or other transactions;

• | our ability to achieve the benefits of acquisitions or other investments within expected time frames or at all, or within expected cost projections;

• | the potential impact on us and our tenants, operators and borrowers from current and future litigation matters, including the possibility of larger than expected litigation costs, adverse results and related developments;

• | changes in federal, state or local laws and regulations, including those affecting the healthcare industry that affect our costs of compliance or increase the costs, or otherwise affect the operations, of our tenants and operators;

• | our ability to foreclose on collateral securing our real estate-related loans;

• | volatility or uncertainty in the capital markets, the availability and cost of capital as impacted by interest rates, changes in our credit ratings, and the value of our common stock, and other conditions that may adversely impact our ability to fund our obligations or consummate transactions, or reduce the earnings from potential transactions;

• | changes in global, national and local economic and other conditions, including the ongoing economic downturn, volatility in the financial markets and high unemployment rates;

• | our ability to manage our indebtedness level and changes in the terms of such indebtedness;

• | competition for skilled management and other key personnel;

• | our reliance on information technology systems and the potential impact of system failures, disruptions or breaches; and

• | our ability to maintain our qualification as a real estate investment trust (“REIT”).

Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.
The information set forth in this Item 2 is intended to provide readers with an understanding of our financial condition, changes in financial condition and results of operations. We will discuss and provide our analysis in the following order:

• | Executive Summary

• | COVID-19 Update

• | 2020 Transaction Overview

• | Dividends

• | Results of Operations

• | Liquidity and Capital Resources

• | Contractual Obligations and Off-Balance Sheet Arrangements

• | Non-GAAP Financial Measures Reconciliations

• | Critical Accounting Policies and Recent Accounting Pronouncements

Executive Summary
Healthpeak Properties, Inc. is a Standard & Poor’s (“S&P”) 500 company that acquires, develops, owns, leases and manages healthcare real estate across the United States (“U.S.”). We are a Maryland corporation and qualify as a self-administered REIT. We are headquartered in Irvine, California, with additional offices in Nashville and San Francisco.
We invest in a diversified portfolio of high-quality healthcare properties across our three core asset classes of senior housing, life science, and medical office real estate. Our senior housing properties are either operated under triple-net leases in our senior housing triple-net segment or through RIDEA structures in our senior housing operating portfolio (“SHOP”) and continuing care retirement community (“CCRC”) segments. Under the life science and medical office segments, we invest through the acquisition, development and management of life science buildings and medical office buildings. We have other non-reportable segments that are comprised primarily of hospital properties and debt investments.
34

Table of Contents
At March 31, 2020, our portfolio of investments, including properties in our unconsolidated joint ventures, consisted of interests in 636 properties. The following table summarizes information for our reportable segments for the three months ended March 31, 2020 (dollars in thousands):

Segment |  | Total Portfolio Adjusted NOI(1) |  | Percentage of Total Portfolio Adjusted NOI(1) |  | Number of Properties
Senior housing triple-net |  | $ | 29,255 |  |  | 10 | % |  | 64 |
SHOP |  | 41,010 |  |  | 14 | % |  | 141 |
CCRC |  | 30,469 |  |  | 10 | % |  | 17 |
Life science |  | 94,367 |  |  | 32 | % |  | 134 |
Medical office |  | 87,382 |  |  | 30 | % |  | 269 |
Other non-reportable |  | 12,099 |  |  | 4 | % |  | 11 |
Totals |  | $ | 294,582 |  |  | 100 | % |  | 636 |

_______________________________________
(1) Total Portfolio metrics include results of operations from disposed properties and properties that transitioned segments through the disposition or transition date. See Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations–Non-GAAP Financial Measures for additional information regarding Adjusted NOI and see Note 13 to the Consolidated Financial Statements for a reconciliation of Adjusted NOI by segment to net income (loss).
For a description of our significant activities during 2020, see Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations–2020 Transaction Overview” in this report.
We invest in and manage our real estate portfolio for the long-term to maximize benefit to our stockholders and support the growth of our dividends. Our strategy consists of four core elements:

(i) | Our real estate: Our portfolio is grounded in high-quality properties in desirable locations. We focus on three purposely selected private pay asset classes, senior housing, life science and medical office, to provide stability through inevitable market cycles.

(ii) | Our financials: We maintain a strong investment-grade balance sheet with ample liquidity as well as long-term fixed-rate debt financing with staggered maturities to reduce our exposure to interest-rate volatility and refinancing risk.

(iii) | Our partnerships: We work with leading healthcare companies, operators and service providers and are responsive to their space and capital needs. We provide high-quality management services to encourage tenants to renew, expand and relocate into our properties, which drives increased occupancy, rental rates, and property values.

(iv) | Our platform: We have a people-first culture that we believe attracts, develops and retains top talent. We continually strive to create and maintain an industry-leading platform, with systems and tools that allow us to effectively and efficiently manage our assets and investment activity.

COVID-19 Update
Beginning in late 2019, a novel strain of Coronavirus (“COVID-19”) began to spread throughout the world, including the United States, ultimately being declared a pandemic by the World Health Organization. Over the past several months, global health concerns and increased efforts to reduce the spread of the COVID-19 pandemic have prompted federal, state, and local governments to restrict normal daily activities, and have resulted in travel bans, quarantines, “shelter-in-place” orders requiring individuals to remain in their homes other than to conduct essential services or activities, as well as business limitations and shutdowns. These health and safety measures, which may remain in place for a significant amount of time, are placing a substantial strain on the business operations of many of our tenants, operators, and borrowers.
SHOP, CCRC, and Senior Housing Triple-Net
Within our SHOP and CCRC properties, we expect occupancy rates to decline due to a reduction in new tenant move-ins due to “shelter-in-place” orders, stricter move-in criteria, lower inquiry volumes, and reduced in-person tours, as well as incidences of COVID-19 outbreaks at our facilities or the perception that outbreaks may occur. Outbreaks, which directly affect our residents and the employees at our senior housing facilities, could materially and adversely disrupt operations, as well as cause significant reputational harm to us, our operators, and our tenants. As of April 30, 2020, we had confirmed resident COVID-19 cases at 54 of our 222 senior housing properties. Our senior housing property operators are also facing significant cost increases as a result of higher demands for staffing, the implementation of increased health and safety measures and protocols, and increased usage and inventory of critical medical supplies and personal protective equipment. At our SHOP and CCRC facilities, we bear these significant cost increases.
35

Table of Contents
We also temporarily suspended development and redevelopment projects in the greater San Francisco and Boston areas as a result of “shelter-in-place” orders as well as across our senior housing portfolio in connection with state and federal guidelines. Although some of these development and redevelopment projects have been allowed to restart, future local, state or federal orders could cause us to re-suspend construction. Other projects remain suspended and we do not know when we will be able to restart construction. In locations where construction continues, construction workers are following applicable guidelines, including appropriate social distancing, limitations on large group gatherings in close proximity, and increased sanitation efforts, which may slow the pace of construction. Furthermore, our planned dispositions may not occur within the expected time or at all because of buyer terminations or withdrawals related to the pandemic, capital constraints or other factors relating to the pandemic.
Medical Office Portfolio
Within our medical office portfolio, since March 2020, many physician practices have discontinued nonessential surgeries and procedures due to “shelter-in-place” orders and other health and safety measures, which has negatively impacted their cash flows. However, we have also seen a slight increase in new leases and lease renewal requests in March and April and we expect that planned move-outs will be delayed during the COVID-19 pandemic, which is expected to slightly increase retention in this portfolio.
We have implemented a deferred rent program for May and June 2020 that is limited to certain non-health system and non-hospital tenants in good standing, which will impact our cash flows during those months, although we are requiring that the deferred rent be repaid ratably over the remaining months until the end of 2020. We are also experiencing and expect to continue to experience a decline in leasing activity through the duration of the COVID-19 pandemic.
Life Science Portfolio
Within our life science portfolio, we have numerous tenants that are working tirelessly to address critical research and testing needs in the fight against COVID-19. We are focused on providing our tenants with the necessary space to complete their critical work and are in continuous contact with our tenants regarding how we can help them meet their needs.
However, within our life science portfolio, we are experiencing and expect to continue to experience a decline in leasing activity through the duration of the COVID-19 pandemic. As a result of governmental restrictions on business activities, particularly in the greater San Francisco and Boston areas, we also temporarily suspended development, redevelopment, and tenant improvement projects at many of our life science properties and, in regions where we are able to continue such projects because they are considered “essential” (such as San Diego), we are experiencing time delays as a result of the implementation of health and safety protocols related to social distancing and proper hygiene and sanitization.
Liquidity
Although Moody’s changed its outlook on our long term issuer and senior unsecured debt ratings from “stable” to “negative” in March 2020, we believe that we are well positioned to manage the COVID-19 pandemic and measures to slow its spread while working closely with our tenants, operators, and borrowers as they navigate the pandemic. We had approximately $3.0 billion of liquidity available, including borrowing capacity under our unsecured revolving line of credit facility and cash and cash equivalents, as of April 30, 2020. While the change in outlook from Moody’s may ultimately lead to a downgrade in our credit rating, which would impact our cost of borrowing, we believe we continue to have access to the unsecured debt markets, and we could also seek to enter into one or more secured debt financings or issue additional securities, including under our 2020 ATM Program (as defined below), to fund future operating costs, capital expenditures, acquisitions, or dispositions, although no assurances can be made in this regard.
Future Rent Collections
The impact of COVID-19 on the ability of our tenants to pay rent in the future is currently unknown. We have, and will continue to monitor the credit quality of each of our tenants and write-off straight-line rent and accounts receivable as uncollectible in the future, as necessary. In the event that we conclude that either straight-line rent or accounts receivable are not probable of collection in the future, such amounts will be written off, which could have a material impact on our future results of operations.
Employee Update
We have taken, and will continue to take, proactive measures to provide for the well-being of our workforce. We have maximized our systems infrastructure as well as virtual and remote working technologies for our employees, including our executive team, to ensure productivity and connectivity internally, as well as with key third-party relationships.
The extent of the impact of the COVID-19 pandemic on our business and financial results will depend on future developments, including the duration, severity, and spread of the pandemic, health and safety actions taken to contain its spread, any possible resurgence of COVID-19 that may occur after the initial outbreak subsides, and how quickly and to what extent normal economic and operating conditions can resume within the markets in which we operate, each of which are highly uncertain at this time and outside of our control. See “Item 1A, Risk Factors” in this Quarterly Report on Form 10-Q for information regarding the risks we face as result of the COVID-19 pandemic.
36

Table of Contents
2020 Transaction Overview
Master Transaction and Cooperation Agreement with Brookdale
In January 2020, Healthpeak and Brookdale Senior Living Inc. (“Brookdale”) completed certain of the transactions governed by the previously announced Master Transactions and Cooperation Agreement (the “2019 MTCA”), which includes a series of transactions related to the previously jointly owned 15-campus CCRC portfolio (the “CCRC JV”) and the portfolio of senior housing properties that were triple-net leased to Brookdale. Specifically, the following transactions were completed on January 31, 2020:

• | We acquired Brookdale’s 51% interest in 13 of the 15 communities in the CCRC JV based on a valuation of $1.06 billion (the “CCRC Acquisition”) and transitioned management (under new management agreements) of those 13 communities to Life Care Services LLC (“LCS”);

• | We paid Brookdale $100 million to terminate the previous management agreements related to those 13 communities;

• | Brookdale acquired 18 of the triple-net lease properties (the “Brookdale Acquisition Assets”) from us for cash proceeds of $385 million;

• | The remaining 24 triple-net lease properties were restructured into a single master lease with 2.4% annual rent escalators and a maturity date of December 31, 2027 (the “2019 Amended Master Lease”);

• | A portion of annual rent (amount in excess of 6.5% of sales proceeds) related to 14 of the 18 Brookdale Acquisition Assets was reallocated to the remaining properties under the 2019 Amended Master Lease; and

• | Brookdale paid down $20 million of future rent under the 2019 Amended Master Lease.

The Post Acquisition

• | In January 2020, we entered into definitive agreements to acquire a life science campus in Waltham, Massachusetts for $320 million. We made a $20 million nonrefundable deposit upon completing due diligence in January 2020 and closed the transaction in April 2020.

Other Real Estate Transactions

• | During the first quarter of 2020, we sold seven SHOP assets for $36 million.

• | During the first quarter of 2020, we sold a hospital under a direct financing lease (“DFL”) for $82 million.

• | During the three months ended March 31, 2020, we transitioned six senior housing triple-net assets with Capital Senior Living Corporation (“CSL”) into a RIDEA structure, with CSL remaining as the manager, and transitioned one senior housing triple-net asset with CSL into a RIDEA structure with Discovery Senior Living, LLC as the operator. We expect to transition two senior housing triple-net assets to a RIDEA structure with Sunrise Senior Living, LLC as the operator during 2020.

• | In April 2020, we sold one SHOP asset for $12 million.

• | In April 2020, one of our tenants exercised its option to acquire three of our MOBs in San Diego, California for $106 million. We received a $5 million nonrefundable deposit in May 2020. The sale is scheduled to close during the second quarter of 2020.

Financing Activities

• | During the three months ended March 31, 2020, we utilized the forward provisions under the at-the-market equity offering program established in February 2019 (the “2019 ATM Program”) to allow for the sale of up to an aggregate of 2 million shares of our common stock at an initial weighted average net price of $35.23 per share, after commissions.

• | During the three months ended March 31, 2020, we settled all 32.5 million shares previously outstanding under (i) ATM forward contracts and (ii) a 2019 forward equity sales agreement at a weighted average net price of $32.73 per share, after commissions, resulting in net proceeds of $1.06 billion.

Development Activities

• | As part of the development program with HCA Healthcare Inc., at March 31, 2020, we had seven medical office building (“MOB”) developments under contract, six of which will be on-campus, with an aggregate total estimated cost of $166 million.

• | At March 31, 2020, we had six life science development projects in process with an aggregate total estimated cost of approximately $855 million.

37

Table of Contents
Dividends
The following table summarizes our common stock cash dividends declared in 2020:

Declaration Date |  | Record Date |  | Amount Per Share |  | Dividend Payment Date
January 30 |  | February 18 |  | $ | 0.37 |  |  | February 28
April 30 |  | May 8 |  | 0.37 |  |  | May 19

Results of Operations
We evaluate our business and allocate resources among our reportable business segments: (i) senior housing triple-net, (ii) SHOP, (iii) CCRC, (iv) life science, and (v) medical office. Our senior housing facilities, including CCRCs, are managed utilizing triple-net leases and RIDEA structures. Under the life science and medical office segments, we invest through the acquisition and development of life science facilities and MOBs, which generally require a greater level of property management. We have other non-reportable segments that are comprised primarily of our debt investments and hospital properties. We evaluate performance based upon: (i) property net operating income from continuing operations (“NOI”) and (ii) Adjusted NOI (Cash NOI) in each segment. The accounting policies of the segments are the same as those described in the summary of significant accounting policies in Note 2 to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission (“SEC”), as updated by Note 2 to the Consolidated Financial Statements herein.
Non-GAAP Financial Measures
Net Operating Income
NOI and Adjusted NOI are non-U.S. generally accepted accounting principles (“GAAP”) supplemental financial measures used to evaluate the operating performance of real estate. NOI is defined as real estate revenues (inclusive of rental and related revenues, resident fees and services, and income from direct financing leases and exclusive of interest income), less property level operating expenses (which exclude transition costs); NOI excludes all other financial statement amounts included in net income (loss) as presented in Note 13 to the Consolidated Financial Statements. Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense. NOI and Adjusted NOI include our share of income (loss) generated by unconsolidated joint ventures and exclude noncontrolling interests’ share of income (loss) generated by consolidated joint ventures. Adjusted NOI is oftentimes referred to as “Cash NOI.” Management believes NOI and Adjusted NOI are important supplemental measured because they provides relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and presenting them on an unlevered basis. We use NOI and Adjusted NOI to make decisions about resource allocations, to assess and compare property level performance, and to evaluate our Same-Store (“SS”) performance, as described below. We believe that net income (loss) is the most directly comparable GAAP measure to NOI and Adjusted NOI. NOI and Adjusted NOI should not be viewed as alternative measures of operating performance to net income (loss) as defined by GAAP since they do not reflect various excluded items. Further, our definitions of NOI and Adjusted NOI may not be comparable to the definitions used by other REITs or real estate companies, as they may use different methodologies for calculating NOI and Adjusted NOI. For a reconciliation of NOI and Adjusted NOI to net income (loss) by segment, refer to Note 13 to the Consolidated Financial Statements.
Operating expenses generally relate to leased medical office and life science properties, as well as SHOP and CCRC facilities. We generally recover all or a portion of our leased medical office and life science property expenses through tenant recoveries. We present expenses as operating or general and administrative based on the underlying nature of the expense.
Same-Store
Same-Store NOI and Adjusted (Cash) NOI information allows us to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our consolidated portfolio of properties. Same-Store Adjusted NOI excludes amortization of deferred revenue from tenant-funded improvements and certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis.
38

Table of Contents
Properties are included in Same-Store once they are stabilized for the full period in both comparison periods. Newly acquired operating assets are generally considered stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space) or 12 months from the acquisition date. Newly completed developments and redevelopments are considered stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. Properties that experience a change in reporting structure, such as a transition from a triple-net lease to a RIDEA reporting structure, are considered stabilized after 12 months in operations under a consistent reporting structure. A property is removed from Same-Store when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event that significantly impacts operations, a change in reporting structure (such as triple-net to SHOP) or operator transition has been agreed to, or a significant tenant relocates from a Same-Store property to a non Same-Store property and that change results in a corresponding increase in revenue. For a reconciliation of Same-Store to total portfolio Adjusted NOI and other relevant disclosures by segment, refer to our Segment Analysis below.
Funds From Operations (“FFO”)
FFO encompasses NAREIT FFO and FFO as Adjusted, each of which is described in detail below. We believe FFO applicable to common shares, diluted FFO applicable to common shares, and diluted FFO per common share are important supplemental non-GAAP measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. The term FFO was designed by the REIT industry to address this issue.
NAREIT FFO. FFO, as defined by the National Association of Real Estate Investment Trusts (“NAREIT”), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real estate, plus real estate and other real estate-related depreciation and amortization, and adjustments to compute our share of NAREIT FFO and FFO as Adjusted (see below) from joint ventures. Adjustments for joint ventures are calculated to reflect our pro-rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of NAREIT FFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. For consolidated joint ventures in which we do not own 100%, we reflect our share of the equity by adjusting our NAREIT FFO to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. Our pro-rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our actual ownership percentage for the period. We do not control the unconsolidated joint ventures, and the pro-rata presentations of reconciling items included in NAREIT FFO do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.
The presentation of pro-rata information has limitations, which include, but are not limited to, the following: (i) the amounts shown on the individual line items were derived by applying our overall economic ownership interest percentage determined when applying the equity method of accounting and do not necessarily represent our legal claim to the assets and liabilities, or the revenues and expenses and (ii) other companies in our industry may calculate their pro-rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro-rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro-rata financial information as a supplement.
NAREIT FFO does not represent cash generated from operating activities in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income (loss). We compute NAREIT FFO in accordance with the current NAREIT definition; however, other REITs may report NAREIT FFO differently or have a different interpretation of the current NAREIT definition from ours.
39

Table of Contents
FFO as Adjusted. In addition, we present NAREIT FFO on an adjusted basis before the impact of non-comparable items including, but not limited to, transaction-related items, impairments (recoveries) of non-depreciable assets, losses (gains) from the sale of non-depreciable assets, severance and related charges, prepayment costs (benefits) associated with early retirement or payment of debt, litigation costs (recoveries), casualty-related charges (recoveries), foreign currency remeasurement losses (gains), and changes in tax legislation (“FFO as Adjusted”). Transaction-related items include transaction expenses and gains/charges incurred as a result of mergers and acquisitions and lease amendment or termination activities. Prepayment costs (benefits) associated with early retirement of debt include the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of debt. Management believes that FFO as Adjusted provides a meaningful supplemental measurement of our FFO run-rate and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. At the same time that NAREIT created and defined its FFO measure for the REIT industry, it also recognized that “management of each of its member companies has the responsibility and authority to publish financial information that it regards as useful to the financial community.” We believe stockholders, potential investors, and financial analysts who review our operating performance are best served by an FFO run-rate earnings measure that includes certain other adjustments to net income (loss), in addition to adjustments made to arrive at the NAREIT defined measure of FFO. FFO as Adjusted is used by management in analyzing our business and the performance of our properties and we believe it is important that stockholders, potential investors, and financial analysts understand this measure used by management. We use FFO as Adjusted to: (i) evaluate our performance in comparison with expected results and results of previous periods, relative to resource allocation decisions, (ii) evaluate the performance of our management, (iii) budget and forecast future results to assist in the allocation of resources, (iv) assess our performance as compared with similar real estate companies and the industry in general, and (v) evaluate how a specific potential investment will impact our future results. Other REITs or real estate companies may use different methodologies for calculating an adjusted FFO measure, and accordingly, our FFO as Adjusted may not be comparable to those reported by other REITs. For a reconciliation of net income (loss) to NAREIT FFO and FFO as Adjusted and other relevant disclosure, refer to “Non-GAAP Financial Measures Reconciliations” below.
Adjusted FFO (“AFFO”)
AFFO is defined as FFO as Adjusted after excluding the impact of the following: (i) amortization of deferred compensation expense, (ii) amortization of deferred financing costs, net, (iii) straight-line rents, (iv) deferred income taxes, (v) amortization of acquired market lease intangibles, net, (vi) non-cash interest related to DFLs and lease incentive amortization (reduction of straight-line rents), (vii) actuarial reserves for insurance claims that have been incurred but not reported, and (viii) deferred revenues, excluding amounts amortized into rental income that are associated with tenant funded improvements owned/recognized by us and up-front cash payments made by tenants to reduce their contractual rents. Also, AFFO: (i) is computed after deducting recurring capital expenditures, including second generation leasing costs and second generation tenant and capital improvements and (ii) includes lease restructure payments and adjustments to compute our share of AFFO from our unconsolidated joint ventures. Certain prior period amounts in the “Non-GAAP Financial Measures Reconciliation” below for AFFO have been reclassified to conform to the current period presentation. More specifically, recurring capital expenditures, including second generation leasing costs and second generation tenant and capital improvements ("AFFO capital expenditures") excludes our share from unconsolidated joint ventures (reported in “other AFFO adjustments”). Adjustments for joint ventures are calculated to reflect our pro-rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of AFFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our AFFO to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods (reported in “other AFFO adjustments”). See FFO for further disclosure regarding our use of pro-rata share information and its limitations. Other REITs or real estate companies may use different methodologies for calculating AFFO, and accordingly, our AFFO may not be comparable to those reported by other REITs. Although our AFFO computation may not be comparable to that of other REITs, management believes AFFO provides a meaningful supplemental measure of our performance and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. We believe AFFO is an alternative run-rate earnings measure that improves the understanding of our operating results among investors and makes comparisons with: (i) expected results, (ii) results of previous periods, and (iii) results among REITs more meaningful. AFFO does not represent cash generated from operating activities determined in accordance with GAAP and is not necessarily indicative of cash available to fund cash needs as it excludes the following items which generally flow through our cash flows from operating activities: (i) adjustments for changes in working capital or the actual timing of the payment of income or expense items that are accrued in the period, (ii) transaction-related costs, (iii) litigation settlement expenses, (iv) severance-related expenses, and (v) actual cash receipts from interest income recognized on loans receivable (in contrast to our AFFO adjustment to exclude non-cash interest and depreciation related to our investments in direct financing leases). Furthermore, AFFO is adjusted for recurring capital expenditures, which are generally not considered when determining cash flows from operations or liquidity. AFFO is a non-GAAP supplemental financial measure and should not be considered as an alternative to net income (loss) determined in accordance with GAAP. For a reconciliation of net income (loss) to AFFO and other relevant disclosure, refer to “Non-GAAP Financial Measures Reconciliations” below.
40

Table of Contents
Comparison of the Three Months Ended March 31, 2020 to the Three Months Ended March 31, 2019
Overview

Three Months Ended March 31, 2020 and 2019
The following table summarizes results for the three months ended March 31, 2020 and 2019 (dollars in thousands):

| Three Months Ended March 31, |  |
| 2020 |  | 2019 |  | Change
Net income (loss) applicable to common shares | $ | 277,464 |  |  | $ | 61,029 |  |  | $ | 216,435 |
NAREIT FFO | 171,549 |  |  | 206,036 |  |  | (34,487 | )
FFO as Adjusted | 227,013 |  |  | 212,025 |  |  | 14,988 |
AFFO | 207,576 |  |  | 191,471 |  |  | 16,105 |

Net income (loss) applicable to common shares increased primarily as a result of the following:

• | an increase in other income, net as a result of (i) a gain on consolidation related to the acquisition of the outstanding equity interests in 13 CCRCs from Brookdale during the first quarter of 2020 and (ii) a gain on sale related to the sale of a hospital underlying a DFL during the first quarter of 2020;

• | an increase in net gain on sales of real estate during the first quarter of 2020;

• | an increase in income tax benefit as a result of the above-mentioned acquisition of Brookdale’s interest in 13 CCRCs and related management termination fee expense paid to Brookdale in connection with transitioning management to LCS during the first quarter of 2020 and the extension of the net operating loss carryback period provided by the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”); and

• | NOI generated from: (i) 2019 and 2020 acquisitions and consolidations of real estate, (ii) development and redevelopment projects placed in service during 2019 and 2020, and (iii) new leasing activity during 2019 and 2020.

The increase in net income (loss) applicable to common shares was partially offset by:

• | a reduction in income related to assets sold or deconsolidated during 2019 and 2020;

• | increased depreciation and amortization expense as a result of: (i) assets acquired during 2019 and 2020, (ii) the acquisition of Brookdale’s interest in and consolidation of 13 CCRCs during the first quarter of 2020, and (iii) development and redevelopment projects placed into service during 2019 and 2020, partially offset by dispositions of real estate throughout 2019 and 2020;

• | an increase in impairment charges related to real estate during the first quarter of 2020;

• | increased interest expense as a result of senior unsecured notes issuances and assumed mortgage debt in conjunction with real estate acquisitions, partially offset by senior unsecured notes redemptions, repurchases, and repayments during the third and fourth quarters of 2019; and

• | increased credit losses related to loans receivable as a result of adopting the new current expected credit losses model required under Accounting Standards Update No. 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) and the impact of COVID-19 on expected credit losses.

NAREIT FFO decreased primarily as a result of the aforementioned events impacting net income (loss) applicable to common shares, except for the following, which are excluded from NAREIT FFO:

• | impairments of real estate;

• | net gain on sales of real estate;

• | the gain on consolidation related to the acquisition of Brookdale’s interest in 13 CCRCs; and

• | depreciation and amortization expense.

FFO as Adjusted increased primarily as a result of the aforementioned events impacting NAREIT FFO, except for the following, which are excluded from FFO as adjusted:

• | the gain related to the sale of a hospital underlying a DFL; and

• | the increase in credit losses.

41

Table of Contents
AFFO increased primarily as a result of the aforementioned events impacting FFO as Adjusted, except for the impact of straight-line rents and the increase in deferred tax benefit, which are excluded from AFFO. The increase in AFFO was partially offset by increased AFFO capital expenditures.
Segment Analysis
The following tables provide selected operating information for our Same-Store and total property portfolio for each of our reportable segments. For the three months ended March 31, 2020, our Same-Store consists of 460 properties representing properties acquired or placed in service and stabilized on or prior to January 1, 2019 and that remained in operations under a consistent reporting structure through March 31, 2020. Our total property portfolio consisted of 636 and 663 properties at March 31, 2020 and 2019, respectively.
Senior Housing Triple-Net

The following table summarizes results at and for the three months ended March 31, 2020 and 2019 (dollars in thousands, except per unit data):

| SS |  | Total Portfolio(1)
| Three Months Ended March 31, |  | Three Months Ended March 31,
| 2020 |  | 2019 |  | Change |  | 2020 |  | 2019 |  | Change
Rental and related revenues | $ | 21,962 |  |  | $ | 20,212 |  |  | $ | 1,750 |  |  | $ | 33,135 |  |  | $ | 49,440 |  |  | $ | (16,305 | )
Income from direct financing leases | — |  |  | — |  |  | — |  |  | — |  |  | 9,391 |  |  | (9,391 | )
Noncontrolling interests' share of consolidated joint venture real estate revenues | — |  |  | — |  |  | — |  |  | — |  |  | (2 | ) |  | 2 |
Operating expenses | (49 | ) |  | (44 | ) |  | (5 | ) |  | (506 | ) |  | (994 | ) |  | 488 |
Adjustments to NOI | (531 | ) |  | 668 |  |  | (1,199 | ) |  | (3,374 | ) |  | 566 |  |  | (3,940 | )
Adjusted NOI | $ | 21,382 |  |  | $ | 20,836 |  |  | $ | 546 |  |  | 29,255 |  |  | 58,401 |  |  | (29,146 | )
Less: non-SS adjusted NOI |  |  |  |  |  |  |  |  |  | (7,873 | ) |  | (37,565 | ) |  | 29,692 |
SS adjusted NOI |  |  |  |  |  |  |  |  |  | $ | 21,382 |  |  | $ | 20,836 |  |  | $ | 546 |
Adjusted NOI % change |  |  |  |  |  |  | 2.6 | % |  |  |  |  |  |  |  |  |
Property count(2) | 52 |  |  | 52 |  |  |  |  |  | 64 |  |  | 126 |  |  |  |
Average capacity (units)(3) | 4,861 |  |  | 4,864 |  |  |  |  |  | 6,978 |  |  | 14,642 |  |  |  |
Average annual rent per unit | $ | 17,635 |  |  | $ | 17,171 |  |  |  |  |  | $ | 17,060 |  |  | $ | 16,226 |  |  |  |

_______________________________________

(1) | Total Portfolio includes results of operations from disposed properties and properties that transitioned segments through the disposition or transition date.

(2) | From our 2019 presentation of Same-Store, we removed 31 senior housing triple-net properties that were sold, 33 senior housing triple-net properties that were transitioned, or we agreed to transition, to SHOP, 9 senior housing triple-net properties that were classified as held for sale, and 1 senior housing triple-net property that was moved to other non-reportable.

(3) | Represents average capacity as reported by the respective tenants or operators for the three-month period.

Same-Store Adjusted NOI increased primarily as a result of annual rent escalations.
Total Portfolio Adjusted NOI decreased primarily as a result of the following Non-Same-Store impacts:

• | the transfer of 21 and 7 senior housing triple-net facilities to our SHOP segment during 2019 and 2020, respectively;

• | the transfer of two senior housing triple-net facilities to our CCRC segment during 2020, and

• | senior housing triple-net facilities sold during 2019 and 2020.

The decrease in Total Portfolio Adjusted NOI is partially offset by the aforementioned increases to Same-Store.
42

Table of Contents
Senior Housing Operating Portfolio

The following table summarizes results at and for the three months ended March 31, 2020 and 2019 (dollars in thousands, except per unit data):

| SS |  | Total Portfolio(1)
| Three Months Ended March 31, |  | Three Months Ended March 31,
| 2020 |  | 2019 |  | Change |  | 2020 |  | 2019 |  | Change
Resident fees and services | $ | 40,787 |  |  | $ | 39,870 |  |  | $ | 917 |  |  | $ | 170,961 |  |  | $ | 126,181 |  |  | $ | 44,780 |
Healthpeak’s share of unconsolidated joint venture real estate revenues | 20,101 |  |  | 20,220 |  |  | (119 | ) |  | 25,765 |  |  | 5,649 |  |  | 20,116 |
Noncontrolling interests' share of consolidated joint venture real estate revenues | (96 | ) |  | (97 | ) |  | 1 |  |  | (538 | ) |  | (472 | ) |  | (66 | )
Operating expenses | (30,145 | ) |  | (29,586 | ) |  | (559 | ) |  | (138,130 | ) |  | (96,947 | ) |  | (41,183 | )
Healthpeak's share of unconsolidated joint venture operating expenses | (12,659 | ) |  | (12,269 | ) |  | (390 | ) |  | (17,956 | ) |  | (4,161 | ) |  | (13,795 | )
Noncontrolling interests' share of consolidated joint venture operating expenses | 64 |  |  | 63 |  |  | 1 |  |  | 377 |  |  | 350 |  |  | 27 |
Adjustments to NOI | (114 | ) |  | 338 |  |  | (452 | ) |  | 531 |  |  | 1,182 |  |  | (651 | )
Adjusted NOI | $ | 17,938 |  |  | $ | 18,539 |  |  | $ | (601 | ) |  | 41,010 |  |  | 31,782 |  |  | 9,228 |
Less: non-SS adjusted NOI |  |  |  |  |  |  |  |  |  | (23,072 | ) |  | (13,243 | ) |  | (9,829 | )
SS adjusted NOI |  |  |  |  |  |  |  |  |  | $ | 17,938 |  |  | $ | 18,539 |  |  | $ | (601 | )
Adjusted NOI % change |  |  |  |  |  |  | (3.2 | )% |  |  |  |  |  |  |  |  |
Property count(2) | 50 |  |  | 50 |  |  |  |  |  | 141 |  |  | 112 |  |  |  |
Average Occupancy | 87.0 | % |  | 87.4 | % |  |  |  | 85.7 | % |  | 83.4 | % |  |
Average capacity (units)(3) | 6,675 |  |  | 6,676 |  |  |  |  |  | 16,268 |  |  | 12,326 |  |  |  |
Average annual rent per unit | $ | 48,319 |  |  | $ | 48,125 |  |  |  |  |  | $ | 53,852 |  |  | $ | 44,483 |  |  |  |

_______________________________________

(1) | Total Portfolio includes results of operations from disposed properties and properties that transitioned segments through the disposition or transition date.

(2) | From our 2019 presentation of Same-Store, we removed seven SHOP properties that were sold, five SHOP properties that were classified as held for sale, and two SHOP properties that were placed in redevelopment.

(3) | Represents average capacity as reported by the respective tenants or operators for the three-month period.

Same Store Adjusted NOI decreased primarily as a result of the following:

• | additional expenses related to COVID-19 and

• | higher labor costs, partially offset by

• | increased rates for resident fees.

Total Portfolio Adjusted NOI increased primarily as a result of the following Non-Same-Store impacts:

• | increased NOI from (i) 2019 acquisitions and (ii) the transfer of 21 and 7 senior housing triple-net assets to our SHOP segment during 2019 and 2020, respectively; partially offset by

• | decreased NOI from assets sold in 2019 and 2020.

43

Table of Contents
Continuing Care Retirement Community

The following table summarizes results at and for the three months ended March 31, 2020 and 2019 (dollars in thousands, except per unit data):

| SS(1) |  | Total Portfolio(2)
| Three Months Ended March 31, |  | Three Months Ended March 31,
| 2020 |  | 2019 |  | Change |  | 2020 |  | 2019 |  | Change
Resident fees and services | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 91,780 |  |  | $ | — |  |  | $ | 91,780 |
Healthpeak’s share of unconsolidated joint venture real estate revenues | — |  |  | — |  |  | — |  |  | 21,647 |  |  | 52,238 |  |  | (30,591 | )
Operating expenses | — |  |  | — |  |  | — |  |  | (156,482 | ) |  | — |  |  | (156,482 | )
Healthpeak's share of unconsolidated joint venture operating expenses | — |  |  | — |  |  | — |  |  | (18,037 | ) |  | (41,377 | ) |  | 23,340 |
Adjustments to NOI | — |  |  | — |  |  | — |  |  | 91,561 |  |  | 3,452 |  |  | 88,109 |
Adjusted NOI | $ | — |  |  | $ | — |  |  | $ | — |  |  | 30,469 |  |  | 14,313 |  |  | 16,156 |
Less: non-SS adjusted NOI |  |  |  |  |  |  |  |  |  | (30,469 | ) |  | (14,313 | ) |  | (16,156 | )
SS adjusted NOI |  |  |  |  |  |  |  |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Adjusted NOI % change |  |  |  |  |  |  | — | % |  |  |  |  |  |  |  |  |
Property count | — |  |  | — |  |  |  |  |  | 17 |  |  | 15 |  |  |  |
Average Occupancy | — |  |  | — |  |  |  |  | 86.2 | % |  | 85.8 | % |  |
Average capacity (units)(3) | — |  |  | — |  |  |  |  |  | 8,322 |  |  | 7,269 |  |  |  |
Average annual rent per unit | $ | — |  |  | $ | — |  |  |  |  |  | $ | 65,179 |  |  | $ | 62,600 |  |  |  |

_______________________________________

(1) | All CCRC properties have been removed from the Same-Store population as they are classified as held for sale, experienced a change in reporting structure, or underwent an operator transition during the periods presented. As such, no Same-Store results are presented in the table above.

(2) | Total Portfolio includes results of operations from disposed properties and properties that transitioned segments through the disposition or transition date.

(3) | Represents average capacity as reported by the respective tenants or operators for the three-month period.

Total Portfolio Adjusted NOI increased primarily as a result of the following:

• | the acquisition of the remaining 51% interest in 13 communities previously held in a joint venture; and

• | the transfer of two CCRC properties that transitioned from senior housing triple-net to RIDEA structures.

44

Table of Contents
Life Science

The following table summarizes results at and for the three months ended March 31, 2020 and 2019 (dollars and square feet in thousands, except per square foot data):

| SS |  | Total Portfolio(1)
| Three Months Ended March 31, |  | Three Months Ended March 31,
| 2020 |  | 2019 |  | Change |  | 2020 |  | 2019 |  | Change
Rental and related revenues | $ | 82,582 |  |  | $ | 80,093 |  |  | $ | 2,489 |  |  | $ | 128,883 |  |  | $ | 94,473 |  |  | $ | 34,410 |
Noncontrolling interests' share of consolidated joint venture real estate revenues | (31 | ) |  | (36 | ) |  | 5 |  |  | (52 | ) |  | (40 | ) |  | (12 | )
Operating expenses | (19,303 | ) |  | (18,380 | ) |  | (923 | ) |  | (30,201 | ) |  | (21,992 | ) |  | (8,209 | )
Noncontrolling interests' share of consolidated joint venture operating expenses | 11 |  |  | 11 |  |  | — |  |  | 17 |  |  | 13 |  |  | 4 |
Adjustments to NOI | (1,382 | ) |  | (1,662 | ) |  | 280 |  |  | (4,280 | ) |  | (2,479 | ) |  | (1,801 | )
Adjusted NOI | $ | 61,877 |  |  | $ | 60,026 |  |  | $ | 1,851 |  |  | 94,367 |  |  | 69,975 |  |  | 24,392 |
Less: non-SS adjusted NOI |  |  |  |  |  |  |  |  |  | (32,490 | ) |  | (9,949 | ) |  | (22,541 | )
SS adjusted NOI |  |  |  |  |  |  |  |  |  | $ | 61,877 |  |  | $ | 60,026 |  |  | $ | 1,851 |
Adjusted NOI % change |  |  |  |  |  |  | 3.1 | % |  |  |  |  |  |  |  |  |
Property count(2) | 95 |  |  | 95 |  |  |  |  |  | 134 |  |  | 125 |  |  |  |
Average occupancy | 95.2 | % |  | 96.2 | % |  |  |  |  | 95.0 | % |  | 96.6 | % |  |  |
Average occupied square feet | 5,756 |  |  | 5,818 |  |  |  |  |  | 8,053 |  |  | 6,655 |  |  |  |
Average annual total revenues per occupied square foot | $ | 56 |  |  | $ | 54 |  |  |  |  |  | $ | 62 |  |  | $ | 55 |  |  |  |
Average annual base rent per occupied square foot(3) | $ | 52 |  |  | $ | 53 |  |  |  |  |  | $ | 50 |  |  | $ | 44 |  |  |  |

_______________________________________

(1) | Total Portfolio includes results of operations from disposed properties through the disposition date.

(2) | From our 2019 presentation of Same-Store, we removed one life science facility that was sold, three life science facilities that were placed in redevelopment, one life science facility related to a significant tenant relocation, and one life science facility related to a casualty event.

(3) | Base rent does not include tenant recoveries, additional rents in excess of floors and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, DFL non-cash interest, and deferred revenues).

Same-Store Adjusted NOI increased primarily as a result of the following:

• | annual rent escalations;

• | new leasing activity; and

• | mark-to-market lease renewals.

Total Portfolio Adjusted NOI increased primarily as a result of the aforementioned impacts to Same-Store and the following Non-Same-Store impacts:

• | increased NOI from (i) increased occupancy in developments and redevelopments placed into service in 2019 and 2020 and (ii) acquisitions in 2019, partially offset by

• | decreased NOI from (i) decreased overall portfolio occupancy and (ii) the placement of facilities into redevelopment in 2019 and 2020.

45

Table of Contents
Medical Office

The following table summarizes results at and for the three months ended March 31, 2020 and 2019 (dollars and square feet in thousands, except per square foot data):

| SS |  | Total Portfolio(1)
| Three Months Ended March 31, |  | Three Months Ended March 31,
| 2020 |  | 2019 |  | Change |  | 2020 |  | 2019 |  | Change
Rental and related revenues | $ | 134,276 |  |  | $ | 132,103 |  |  | $ | 2,173 |  |  | $ | 145,146 |  |  | $ | 142,195 |  |  | $ | 2,951 |
Healthpeak’s share of unconsolidated joint venture real estate revenues | 673 |  |  | 683 |  |  | (10 | ) |  | 695 |  |  | 705 |  |  | (10 | )
Noncontrolling interests' share of consolidated joint venture real estate revenues | (8,528 | ) |  | (8,174 | ) |  | (354 | ) |  | (8,640 | ) |  | (8,303 | ) |  | (337 | )
Operating expenses | (45,433 | ) |  | (44,433 | ) |  | (1,000 | ) |  | (50,687 | ) |  | (48,987 | ) |  | (1,700 | )
Healthpeak's share of unconsolidated joint venture operating expenses | (275 | ) |  | (275 | ) |  | — |  |  | (275 | ) |  | (275 | ) |  | — |
Noncontrolling interests' share of consolidated joint venture operating expenses | 2,600 |  |  | 2,397 |  |  | 203 |  |  | 2,600 |  |  | 2,424 |  |  | 176 |
Adjustments to NOI | (1,214 | ) |  | (1,794 | ) |  | 580 |  |  | (1,457 | ) |  | (1,748 | ) |  | 291 |
Adjusted NOI | $ | 82,099 |  |  | $ | 80,507 |  |  | $ | 1,592 |  |  | 87,382 |  |  | 86,011 |  |  | 1,371 |
Less: non-SS adjusted NOI |  |  |  |  |  |  |  |  |  | (5,283 | ) |  | (5,504 | ) |  | 221 |
SS adjusted NOI |  |  |  |  |  |  |  |  |  | $ | 82,099 |  |  | $ | 80,507 |  |  | $ | 1,592 |
Adjusted NOI % change |  |  |  |  |  |  | 2.0 | % |  |  |  |  |  |  |  |  |
Property count(2) | 252 |  |  | 252 |  |  |  |  |  | 269 |  |  | 272 |  |  |  |
Average occupancy | 91.6 | % |  | 92.0 | % |  |  |  |  | 91.2 | % |  | 91.7 | % |  |  |
Average occupied square feet | 18,344 |  |  | 18,390 |  |  |  |  |  | 19,204 |  |  | 19,330 |  |  |  |
Average annual total revenues per occupied square foot | $ | 29 |  |  | $ | 28 |  |  |  |  |  | $ | 30 |  |  | $ | 29 |  |  |  |
Average annual base rent per occupied square foot(3) | $ | 25 |  |  | $ | 25 |  |  |  |  |  | $ | 26 |  |  | $ | 25 |  |  |  |

_______________________________________

(1) | Total Portfolio includes results of operations from disposed properties through the disposition date.

(2) | From our 2019 presentation of Same-Store, we removed six MOBs that were sold, two MOBs that were classified as held for sale, one MOB that was placed into redevelopment, and one MOB that we intend to demolish.

(3) | Base rent does not include tenant recoveries, additional rents in excess of floors and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, DFL non-cash interest, and deferred revenues).

Same-Store Adjusted NOI increased primarily as a result:

• | mark-to-market lease renewals and

• | annual rent escalations.

Total Portfolio Adjusted NOI increased primarily as a result of the aforementioned increases to Same-Store and the following Non-Same-Store impacts:

• | increased NOI from 2019 acquisitions; and

• | increased occupancy in former redevelopment and development properties that have been placed into service; partially offset by

• | decreased NOI from MOB sales during 2019 and 2020.

46

Table of Contents
Other Income and Expense Items

The following table summarizes the results of our other income and expense items for the three months ended March 31, 2020 and 2019 (in thousands):

| Three Months Ended March 31,
| 2020 |  | 2019 |  | Change
Interest income | $ | 3,688 |  |  | $ | 1,713 |  |  | $ | 1,975 |
Interest expense | 58,376 |  |  | 49,327 |  |  | 9,049 |
Depreciation and amortization | 189,276 |  |  | 131,951 |  |  | 57,325 |
General and administrative | 22,349 |  |  | 21,355 |  |  | 994 |
Transaction costs | 14,848 |  |  | 4,518 |  |  | 10,330 |
Impairments and loan loss reserves (recoveries), net | 39,123 |  |  | 8,858 |  |  | 30,265 |
Gain (loss) on sales of real estate, net | 164,869 |  |  | 8,044 |  |  | 156,825 |
Loss on debt extinguishments | 833 |  |  | — |  |  | 833 |
Other income (expense), net | 210,608 |  |  | 3,133 |  |  | 207,475 |
Income tax benefit (expense) | 33,044 |  |  | 3,458 |  |  | 29,586 |
Equity income (loss) from unconsolidated joint ventures | (11,979 | ) |  | (863 | ) |  | (11,116 | )
Noncontrolling interests’ share in earnings | (3,460 | ) |  | (3,520 | ) |  | 60 |

Interest income
Interest income increased for the three months ended March 31, 2020 primarily as a result of new development loans and additional funding of existing loans.
Interest expense
Interest expense increased for the three months ended March 31, 2020 as a result of: (i) senior unsecured notes and term loan issuances, (ii) assumed debt in conjunction with real estate acquisitions, and (iii) lower capitalized interest in 2020 as a result of developments placed into service. The increase in interest expense was partially offset by senior unsecured notes redemptions, repurchases, and repayments during 2019.
Depreciation and amortization expense
Depreciation and amortization expense increased for the three months ended March 31, 2020 primarily as a result of: (i) assets acquired during 2019 and 2020, (ii) the acquisition of Brookdale’s interest in and consolidation of 13 CCRCs during the first quarter of 2020, (iii) development and redevelopment projects placed into service during 2019 and 2020, and (iv) the conversion of 14 senior housing triple-net assets to a RIDEA structure in 2019, partially offset by dispositions of real estate throughout 2019 and 2020.
Transaction Costs
Transaction costs increased for the three months ended March 31, 2020 primarily as a result of costs associated with the transition of 13 CCRCs from Brookdale to LCS in January 2020.
Impairments and loan loss reserves (recoveries), net
Impairments and loan loss reserves (recoveries), net increased for the three months ended March 31, 2020 primarily as a result of: (i) committing to a formal plan to sell certain assets and therefore, classifying those assets as held for sale and (ii) the impact of COVID-19 on the estimated sales prices of assets classified as held for sale. While some properties that are classified as held for sale are expected to result in a gain recognized upon disposition, others had a carrying value that exceeded the expected sale proceeds less costs to sell, resulting in an impairment charge during the respective period. The impairment charges recognized in each period vary depending on facts and circumstances related to each asset and are impacted by negotiations with potential buyers, current operations of the assets, and other factors.
Additionally, on January 1, 2020, we adopted ASU 2016-13, which resulted in the implementation of the current expected credit losses model and, generally, the earlier recognition of credit losses (which are recorded in impairments and loan loss reserves (recoveries), net). Accordingly, we have recognized additional credit losses during the first quarter of 2020, which were further increased by the expected economic impact of COVID-19.
47

Table of Contents
Gain (loss) on sales of real estate, net
During the three months ended March 31, 2020, we sold 7 SHOP assets for $36 million and 18 senior housing triple-net for $385 million, resulting in total net gain on sales of real estate of $165 million.
During the three months ended March 31, 2019, we sold nine SHOP assets for $68 million, two senior housing triple-net assets for $26 million, and one undeveloped life science land parcel for $35 million, resulting in total net gain on sales of real estate of $8 million.
Other income (expense), net
Other income (expense), net, increased for the three months ended March 31, 2020 primarily as a result of a $170 million gain on consolidation related to the acquisition of the outstanding equity interests in 13 CCRCs from Brookdale during the first quarter of 2020 and a $42 million gain on sale related to the sale of a hospital underlying a DFL during the first quarter of 2020.
Income tax benefit (expense)
Income tax benefit increased for the three months ended March 31, 2020 primarily as a result of the tax benefits related to the transactions agreed to in the 2019 MTCA with Brookdale, including the management termination fee expense paid to Brookdale in connection with transitioning management of 13 CCRCs to LCS, and the extension of the net operating loss carryback period provided by the CARES Act.
Equity income (loss) from unconsolidated joint ventures
Equity income (loss) from unconsolidated joint ventures decreased for the three months ended March 31, 2020 as a result of net losses from an unconsolidated joint venture owning 19 SHOP assets that was formed in December 2019, partially offset by a gain on sale of one asset in an unconsolidated joint venture during the first quarter of 2020.
Liquidity and Capital Resources
We anticipate that our cash flow from operations, available cash balances and cash from our various financing activities will be adequate for at least the next 12 months for purposes of: (i) funding recurring operating expenses; (ii) meeting debt service requirements; and (iii) satisfying our distributions to our stockholders and non-controlling interest members. During the three months ended March 31, 2020, distributions to shareholders and noncontrolling interest holders exceeded cash flows from operations by approximately $102 million. Distributions were made using a combination of cash flows from operations, funds available under our revolving line of credit, proceeds from the sale of properties, and other sources of cash available to us.
Our principal investing liquidity needs for the next 12 months are to:

• | fund capital expenditures, including tenant improvements and leasing costs and

• | fund future acquisition, transactional and development activities.

We anticipate satisfying these future investing needs using one or more of the following:

• | cash flow from operations;

• | sale or exchange of ownership interests in properties or other investments;

• | borrowings under our revolving line of credit facility and unsecured commercial paper program;

• | issuance of additional debt, including unsecured notes, term loans and mortgage debt; and/or

• | issuance of common or preferred stock or its equivalent.

Access to capital markets impacts our cost of capital and ability to refinance maturing indebtedness, as well as our ability to fund future acquisitions and development through the issuance of additional securities or secured debt. Credit ratings impact our ability to access capital and directly impact our cost of capital as well. For example, our Revolving Facility and 2019 Term Loan accrue interest at a rate per annum equal to LIBOR plus a margin that depends upon the credit ratings of our senior unsecured long term debt. We also pay a facility fee on the entire revolving commitment that depends upon our credit ratings. As of May 4, 2020, we had long-term credit ratings of Baa1 from Moody’s and BBB+ from S&P Global and Fitch, and short-term credit ratings of P-2, A-2, and F2 from Moody’s, S&P Global, and Fitch, respectively.
A downgrade in credit ratings by Moody’s, S&P Global, and Fitch may have a negative impact on the interest rates and facility fees for our Revolving Facility and 2019 Term Loan. Refer to “COVID-19” above and “Item 1A, Risk Factors” for a more comprehensive discussion of the potential impact of COVID-19 on the Company’s business.
48

Table of Contents
Cash Flow Summary
The following summary discussion of our cash flows is based on the Consolidated Statements of Cash Flows and is not meant to be an all-inclusive discussion of the changes in our cash flows for the periods presented below.
The following table sets forth changes in cash flows (in thousands):

| Three Months Ended March 31,
| 2020 |  | 2019 |  | Change
Net cash provided by (used in) operating activities | $ | 95,042 |  |  | $ | 158,582 |  |  | $ | (63,540 | )
Net cash provided by (used in) investing activities | (151,011 | ) |  | (160,277 | ) |  | 9,266 |
Net cash provided by (used in) financing activities | 761,421 |  |  | 8,521 |  |  | 752,900 |

Operating Cash Flows
The decrease in operating cash flow is primarily the result of a reduction in income related to (i) the termination fee paid to Brookdale in conjunction with the CCRC Acquisition, (ii) dispositions during 2019 and 2020, (iii) occupancy declines and higher labor costs within our SHOP segment, (iv) additional expenses related to COVID-19, and (v) increased interest paid as a result of new debt issuances and debt assumed in conjunction with real estate acquisitions. The decrease in operating cash flow is partially offset by: (i) 2019 and 2020 acquisitions, (ii) annual rent increases, (iii) new leasing activity, and (iv) developments and redevelopments placed in service during 2019 and 2020. Our cash flow from operations is dependent upon the occupancy levels of our buildings, rental rates on leases, our tenants’ performance on their lease obligations, the level of operating expenses, and other factors.
Investing Cash Flows
The following are significant investing activities for the three months ended March 31, 2020:

• | made investments of $657 million primarily related to the acquisition, development, and redevelopment of real estate and funding of a participating development loan and

• | received net proceeds of $506 million primarily from sales of real estate assets.

The following are significant investing activities for the three months ended March 31, 2019:

• | made investments of $289 million primarily related to the acquisition, development, and redevelopment of real estate; and

• | received net proceeds of $129 million primarily from sales of real estate assets.

Financing Cash Flows
The following are significant financing activities for the three months ended March 31, 2020:

• | made net repayments of $98 million primarily under our bank line of credit and commercial paper program;

• | issued common stock of $1.1 billion; and

• | paid cash dividends on common stock of $189 million.

The following are significant financing activities for the three months ended March 31, 2019:

• | made net borrowings of $193 million under our bank line of credit, senior unsecured notes and mortgage debt; and

• | paid cash dividends on common stock of $177 million.

Debt
See Note 9 to the Consolidated Financial Statements for additional information about our outstanding debt.
Approximately 96% and 95% of our consolidated debt, inclusive of $42 million and $43 million of variable rate debt swapped to fixed through interest rate swaps, was fixed rate debt as of March 31, 2020 and 2019, respectively. At March 31, 2020, our fixed rate debt and variable rate debt had weighted average interest rates of 3.94% and 1.99%, respectively. At March 31, 2019, our fixed rate debt and variable rate debt had weighted average interest rates of 4.04% and 3.19%, respectively. For a more detailed discussion of our interest rate risk, see “Quantitative and Qualitative Disclosures About Market Risk” in Item 3 below.
49

Table of Contents
Equity
At March 31, 2020, we had 538 million shares of common stock outstanding, equity totaled $7.8 billion, and our equity securities had a market value of $13.0 billion.
At March 31, 2020, non-managing members held an aggregate of five million units in seven limited liability companies (“DownREITs”) for which we are the managing member. The DownREIT units are exchangeable for an amount of cash approximating the then-current market value of shares of our common stock or, at our option, shares of our common stock (subject to certain adjustments, such as stock splits and reclassifications). At March 31, 2020, the DownREIT units were convertible into approximately seven million shares of our common stock.
At-The-Market Program
In February 2020, we terminated our 2019 ATM Program and concurrently established a new at-the-market equity offering program (the “2020 ATM Program”). In addition to the issuance and sale of shares of our common stock, we may also enter into one or more forward sales agreements with sales agents for the sale of our shares of common stock under our 2020 ATM Program.
During the quarter ended March 31, 2020, we settled all 16.8 million shares previously outstanding under ATM forward contracts at a weighted average net price of $31.38 per share, after commissions, resulting in net proceeds of $528 million.
At March 31, 2020, approximately $1.25 billion of our common stock remained available for sale under the 2020 ATM Program. Actual future sales of our common stock will depend upon a variety of factors, including but not limited to market conditions, the trading price of our common stock, and our capital needs. We have no obligation to sell any of the remaining shares under our 2020 ATM Program.
See Note 11 to the Consolidated Financial Statements for additional information about our 2020 ATM Program, including equity sales during the three months ended March 31, 2020.
November 2019 Forward Equity Offering
In November 2019, we entered into a forward equity sales agreement to sell an aggregate of 15.6 million shares of our common stock (including shares sold through the exercise of underwriters’ options) at an initial net price of $34.46 per share, after underwriting discounts and commissions, which was subject to adjustments for: (i) accrued interest, (ii) the forward purchasers’ stock borrowing costs, and (iii) certain fixed price reductions during the term of the agreement. During the three months ended March 31, 2020, we settled all 15.6 million shares under the 2019 forward equity sales agreement at a weighted average net price of $34.18 per share resulting in net proceeds of $534 million.
Shelf Registration
In May 2018, we filed a prospectus with the SEC as part of a registration statement on Form S-3, using an automatic shelf registration process. This shelf registration statement expires in May 2021 and at or prior to such time, we expect to file a new shelf registration statement. Under the “shelf” process, we may sell any combination of the securities described in the prospectus through one or more offerings. The securities described in the prospectus include common stock, preferred stock, depositary shares, debt securities, and warrants.
Contractual Obligations and Off-Balance Sheet Arrangements
Our commitments related to development and redevelopment projects decreased by $77 million, to $284 million at March 31, 2020 when compared to December 31, 2019, primarily as a result of completed development and redevelopment projects. There have been no other material changes, outside of the ordinary course of business, to these contractual obligations during the three months ended March 31, 2020.
Our commitments related to debt have materially changed since December 31, 2019 as a result of paydowns on our Commercial Paper Program. As of March 31, 2020, we had no balance outstanding under our Commercial Paper Program. See Note 9 to the Consolidated Financial Statements for additional information about our debt commitments.
We own interests in certain unconsolidated joint ventures as described in Note 7 to the Consolidated Financial Statements. Except in limited circumstances, our risk of loss is limited to our investment in the joint ventures and any outstanding loans receivable. In addition, we have certain properties which serve as collateral for debt that is owed by a previous owner of certain of our facilities. Our risk of loss for these certain properties is limited to the outstanding debt balance plus penalties, if any. We have no other material off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources except for commitments and operating leases included in our Annual Report on Form 10-K for the year ended December 31, 2019 in “Contractual Obligations” under “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
50

Table of Contents
Non-GAAP Financial Measures Reconciliations
The following is a reconciliation from net income (loss) applicable to common shares, the most directly comparable financial measure calculated and presented in accordance with GAAP, to NAREIT FFO, FFO as Adjusted and AFFO (in thousands, except per share data):

| Three Months Ended March 31,
| 2020 |  | 2019
Net income (loss) applicable to common shares | $ | 277,464 |  |  | $ | 61,029 |
Real estate related depreciation and amortization | 189,276 |  |  | 131,951 |
Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures | 29,610 |  |  | 15,077 |
Noncontrolling interests' share of real estate related depreciation and amortization | (4,852 | ) |  | (4,920 | )
Other real estate-related depreciation and amortization | 1,237 |  |  | 2,085 |
Loss (gain) on sales of real estate, net | (164,869 | ) |  | (8,044 | )
Healthpeak's share of loss (gain) on sales of real estate, net, from unconsolidated joint ventures | (7,729 | ) |  | — |
Loss (gain) upon change of control, net(1) | (167,434 | ) |  | — |
Taxes associated with real estate dispositions | (11,876 | ) |  | — |
Impairments (recoveries) of depreciable real estate, net | 30,722 |  |  | 8,858 |
NAREIT FFO applicable to common shares | 171,549 |  |  | 206,036 |
Distributions on dilutive convertible units and other | 1,637 |  |  | 1,795 |
Diluted NAREIT FFO applicable to common shares | $ | 173,186 |  |  | $ | 207,831 |
Weighted average shares outstanding - diluted NAREIT FFO | 513,123 |  |  | 483,671 |
Impact of adjustments to NAREIT FFO: |  |  |  |  |
Transaction-related items(2) | $ | 92,379 |  |  | $ | 5,889 |
Other impairments (recoveries) and other losses (gains), net(3) | (33,306 | ) |  | — |
Loss on debt extinguishments | (833 | ) |  | — |
Litigation costs (recoveries) | 106 |  |  | 128 |
Foreign currency remeasurement losses (gains) | 10 |  |  | (28 | )
Tax rate legislation impact(4) | (2,892 | ) |  | — |
Total adjustments | $ | 55,464 |  |  | $ | 5,989 |
FFO as Adjusted applicable to common shares | $ | 227,013 |  |  | $ | 212,025 |
Distributions on dilutive convertible units and other | 1,549 |  |  | 1,780 |
Diluted FFO as Adjusted applicable to common shares | $ | 228,562 |  |  | $ | 213,805 |
Weighted average shares outstanding - diluted FFO as Adjusted | 513,123 |  |  | 483,671 |

51

Table of Contents

| Three Months Ended March 31,
| 2020 |  | 2019
FFO as Adjusted applicable to common shares | $ | 227,013 |  |  | $ | 212,025 |
Amortization of deferred compensation | 3,987 |  |  | 3,590 |
Amortization of deferred financing costs | 2,582 |  |  | 2,699 |
Straight-line rents | (6,229 | ) |  | (6,246 | )
AFFO capital expenditures | (21,791 | ) |  | (19,220 | )
Lease restructure payments | 291 |  |  | 288 |
CCRC entrance fees(5) | — |  |  | 3,496 |
Deferred income taxes(6) | 4,787 |  |  | (3,732 | )
Other AFFO adjustments(7) | (3,064 | ) |  | (1,429 | )
AFFO applicable to common shares | 207,576 |  |  | 191,471 |
Distributions on dilutive convertible units and other | 1,638 |  |  | 1,794 |
Diluted AFFO applicable to common shares | $ | 209,214 |  |  | $ | 193,265 |
Weighted average shares outstanding - diluted AFFO | 513,123 |  |  | 483,671 |

| Three Months Ended March 31,
| 2020 |  | 2019
Diluted earnings per common share | $ | 0.54 |  |  | $ | 0.13 |
Depreciation and amortization | 0.42 |  |  | 0.30 |
Loss (gain) on sales of real estate, net | (0.33 | ) |  | (0.02 | )
Loss (gain) upon change of control, net(1) | (0.33 | ) |  | — |
Taxes associated with real estate dispositions | (0.02 | ) |  | — |
Impairments (recoveries) of depreciable real estate, net | 0.06 |  |  | 0.02 |
Diluted NAREIT FFO per common share | $ | 0.34 |  |  | $ | 0.43 |
Transaction-related items(2) | 0.18 |  |  | 0.01 |
Other impairments (recoveries) and other losses (gains), net(3) | (0.06 | ) |  | — |
Tax rate legislation impact(4) | (0.01 | ) |  | — |
Diluted FFO as Adjusted per common share | $ | 0.45 |  |  | $ | 0.44 |

_______________________________________

(1) | For the three months ended March 31, 2020, relates to the gain on consolidation of 13 continuing care retirement communities in which we acquired Brookdale's interest and began consolidating during the first quarter of 2020. The gain upon change of control is included in other income (expense), net in the consolidated statements of operations.

(2) | For the three months ended March 31, 2020, includes the termination fee and transition fee expenses related to terminating the management agreements with Brookdale for 13 CCRCs and transitioning those communities to LCS, partially offset by the tax benefit recognized related to those expenses. The expense related to terminating the CCRC management agreements with Brookdale is included in operating expenses in the consolidated statement of operations for the three months ended March 31, 2020.

(3) | For the three months ended March 31, 2020, includes the gain on sale of a hospital that was in a direct financing lease ("DFL"), partially offset by $8 million of additional reserves for loan losses under the new current expected credit losses accounting standard in accordance with ASC 326, Financial Instruments – Credit Losses. The $42 million gain on sale of the hospital that was in a DFL is included in other income (expense), net in the consolidated statement of operations for the three months ended March 31, 2020.

(4) | For the three months ended March 31, 2020, represents the tax benefit of the CARES Act extending the net operating loss carryback period to five years.

(5) | I n connection with the acquisition of the remaining 51% interest in the CCRC JV in January 2020, we consolidated the 13 communities in the CCRC JV and recorded the assets and liabilities at their acquisition date relative fair values, including the CCRC contract liabilities associated with previously collected non-refundable entrance fees. In conjunction with increasing those CCRC contract liabilities to their fair value, we concluded that we will no longer adjust for the timing difference between non-refundable entrance fees collected and amortized as we believe the amortization of these fees is a meaningful representation of how we satisfy the performance obligations of the fees. As such, upon consolidation of the CCRC assets, we no longer exclude the difference between CCRC entrance fees collected and amortized from the calculation of AFFO. For comparative periods presented, the adjustment continues to represent our 49% share of non-refundable entrance fees collected by the CCRC JV, net of reserves and net of CCRC JV entrance fee amortization.

(6) | For the three months ended March 31, 2020, includes an $8 million current tax refund receivable due to the changes in tax legislation enacted under the CARES Act.

(7) | Primarily includes our share of AFFO capital expenditures from unconsolidated joint ventures, partially offset by noncontrolling interests' share of AFFO capital expenditures from consolidated joint ventures.

For a reconciliation of NOI and Adjusted NOI to net income (loss), refer to Note 13 to the Consolidated Financial Statements. For a reconciliation of Same-Store NOI and Adjusted NOI to total portfolio NOI and Adjusted NOI by segment, refer to the analysis of each segment in “Results of Operations” above.
52

Table of Contents
Critical Accounting Policies and Recent Accounting Pronouncements
The preparation of financial statements in conformity with U.S. GAAP requires our management to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our consolidated financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. A summary of our critical accounting policies is included in our Annual Report on Form 10-K for the year ended December 31, 2019 in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 2 to the Consolidated Financial Statements. There have been no significant changes to our critical accounting policies during 2020 other than those resulting from new accounting standards (see Note 2 to the Consolidated Financial Statements).
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to various market risks, including the potential loss arising from adverse changes in interest rates. We use derivative and other financial instruments in the normal course of business to mitigate interest rate risk. We do not use derivative financial instruments for speculative or trading purposes. Derivatives are recorded on the consolidated balance sheets at fair value (see Note 17 to the Consolidated Financial Statements).
To illustrate the effect of movements in the interest rate markets, we performed a market sensitivity analysis on our hedging instruments. We applied various basis point spreads to the underlying interest rate curves of the derivative portfolio in order to determine the change in fair value. Assuming a one percentage point change in the underlying interest rate curve, the estimated change in fair value of each of the underlying derivative instruments would not be material.
Interest Rate Risk. At March 31, 2020, our exposure to interest rate risk is primarily on our variable rate debt. At March 31, 2020, $42 million of our variable-rate debt was hedged by interest rate swap transactions. The interest rate swaps are designated as cash flow hedges, with the objective of managing the exposure to interest rate risk by converting the interest rates on our variable-rate debt to fixed interest rates.
Interest rate fluctuations will generally not affect our future earnings or cash flows on our fixed rate debt and assets until their maturity or earlier prepayment and refinancing. If interest rates have risen at the time we seek to refinance our fixed rate debt, whether at maturity or otherwise, our future earnings and cash flows could be adversely affected by additional borrowing costs. Conversely, lower interest rates at the time of refinancing may reduce our overall borrowing costs. However, interest rate changes will affect the fair value of our fixed rate instruments. A one percentage point increase or decrease in interest rates would change the fair value of our fixed rate debt by approximately $339 million and $364 million, respectively, and would not materially impact earnings or cash flows. Conversely, changes in interest rates on variable rate debt and investments would change our future earnings and cash flows, but not materially impact the fair value of those instruments. Assuming a one percentage point change in our interest rate related to the variable-rate debt and variable-rate investments, and assuming no other changes in the outstanding balance at March 31, 2020, our annual interest expense and interest income would increase by approximately $3 million and $1 million, respectively.
Market Risk. We have investments in marketable debt securities classified as held-to-maturity because we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are recorded at amortized cost and adjusted for the amortization of premiums and discounts through maturity. We consider a variety of factors in evaluating an other-than-temporary decline in value, such as: the length of time and the extent to which the market value has been less than our current adjusted carrying value; the issuer’s financial condition, capital strength, and near-term prospects; any recent events specific to that issuer and economic conditions of its industry; and our investment horizon in relationship to an anticipated near-term recovery in the market value, if any. At March 31, 2020, both the fair value and carrying value of marketable debt securities was $20 million.
53

Table of Contents
Item 4. Controls and Procedures
Disclosure Controls and Procedures. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2020. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2020.
Changes in Internal Control Over Financial Reporting. There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
54

Table of Contents
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
See the “Legal Proceedings” section of Note 10 to the Consolidated Financial Statements for information regarding legal proceedings, which information is incorporated by reference in this Item 1.
Item 1A. Risk Factors
The section below discusses the most significant risk factors that may materially adversely affect our business, results of operations and financial condition.
As set forth below, we believe that the risks we face generally fall into the following categories:

• | risks related to our business and operations;

• | risks related to our capital structure and market conditions;

• | risks related to other events; and

• | risks related to tax, including REIT-related risks.

Risks Related to Our Business and Operations

The COVID-19 pandemic and health and safety measures intended to reduce its spread have adversely affected, and may continue to adversely affect, our business, results of operations and financial condition.
Beginning in late 2019, a novel strain of Coronavirus (“COVID-19”) began to spread throughout the world, including the United States, ultimately being declared a pandemic by the World Health Organization. Over the past several months, global health concerns and increased efforts to reduce the spread of the COVID-19 pandemic have prompted federal, state and local governments to restrict normal daily activities, and have resulted in travel bans, quarantines, “shelter-in-place” orders requiring individuals to remain in their homes other than to conduct essential services or activities, as well as business limitations and shutdowns. These health and safety measures, which may remain in place for a significant amount of time, are placing a substantial strain on the business operations of many of our tenants and operators. In many cases, these measures have limited and continue to limit their ability to conduct their normal businesses operations and comply with their rent and other financial obligations to us.
Within our senior housing portfolio, we expect occupancy rates to decline due to a reduction in new tenant move-ins due to “shelter-in-place” orders, stricter move-in criteria, lower inquiry volumes, and reduced in-person tours, as well as incidences of COVID-19 outbreaks at our facilities or the perception that outbreaks may occur. Outbreaks, which directly affect our residents and the employees at our senior housing facilities, could materially and adversely disrupt operations, as well as cause significant reputational harm to us and our operators. Our senior housing property operators are also facing material cost increases as a result of higher demands for staffing and increased usage and inventory of critical medical supplies and personal protective equipment. At our SHOP facilities, we bear these material cost increases. We also temporarily suspended development and redevelopment projects in the greater San Francisco and Boston areas as a result of the “shelter-in-place” orders as well as across our senior housing portfolio in connection with state and federal guidelines. Although some of these development and redevelopment projects have been allowed to restart, future local, state or federal orders could cause us to re-suspend construction. Other projects remain suspended and we do not know when we will be able to restart construction. In locations where construction continues, construction workers are following applicable guidelines, including appropriate social distancing, limitations on large group gatherings in close proximity, and increased sanitation efforts, which may slow the pace of construction. Furthermore, our planned dispositions may not occur within the expected time or at all because of buyer terminations or withdrawals related to the pandemic, capital constraints or other factors relating to the pandemic.
Within our medical office portfolio, many physician practices have discontinued nonessential surgeries and procedures due to “shelter-in-place” and other health and safety measures, which has negatively impacted their cash flows. We have implemented a deferred rent program for May and June 2020 that is limited to certain non-health system and non-hospital tenants in good standing, which is estimated to reduce our cash flow during this period, although we are requiring that the deferred rent be repaid ratably over the remaining months until the end of 2020. We are also experiencing and expect to continue to experience a decline in new leasing activity through the duration of the COVID-19 pandemic.
55

Table of Contents
Within our life science portfolio, we are experiencing and expect to continue to experience a decline in new leasing activity through the duration of the COVID-19 pandemic. As a result of governmental restrictions on business activities, particularly in the greater San Francisco and Boston areas, we have also temporarily suspended development, redevelopment and tenant improvement projects at many of our life science properties and, in regions where we are able to continue such projects (such as San Diego), we are experiencing time delays as a result of the implementation of health and safety protocols related to social distancing and proper hygiene and sanitization.
The COVID-19 pandemic subjects our business and the businesses of our tenants and operators to various risks and uncertainties that have significantly affected and could materially adversely affect our business, results of operations and financial condition for at least the pendency of the COVID-19 pandemic and possibly longer, including the following:

• | rent deferrals or delays in rent commencement for many of our tenants, which we have granted to date for tenants within our medical office and life science segments, will result in a significant decrease in our cash receipts during the period of the deferrals;

• | material cost increases at our SHOP facilities, for which we are responsible;

• | non-payment of contractual obligations by our tenants or operators, and any limitations on our ability to enforce our lease agreements or management agreements with our tenants or operators, as applicable, as a result of any federal, state or local restrictions on tenant evictions for failure to make contractual rent payments, which may result in higher reserves for bad debt;

• | our tenants, operators or borrowers becoming insolvent or initiating bankruptcy or similar proceedings, which would adversely affect our ability to collect rent or interest payments from such tenants or borrowers, as applicable, and result in increased costs to us, as well as decreased revenues;

• | the complete or partial closures of, or other operational issues at, one or more of our properties resulting from government action or directives, which may intensify the risk of rent deferrals or non-payment of contractual obligations by our tenants or operators;

• | any possession taken of our properties, in whole or in part, by governmental authorities for public purposes in eminent domain proceedings;

• | the likelihood that we will amend existing lease agreements and existing rental terms, with our tenants, and management agreements and existing fee structures, with our RIDEA operators, particularly in our senior housing portfolio, which would have an adverse effect on our revenues and results of operations;

• | increased costs or delays that may result if we determine to reposition or transition any of our currently-leased properties to another tenant or operator, which could adversely impact our revenues and results of operations;

• | the impact on our results of operations and financial condition resulting from (i) suspensions or delays in development and redevelopment activities and tenant improvement projects, including due to shelter-in-place orders, local, state and federal guidelines, delays caused by slow-downs in construction as a result of implementing social distancing and other health and safety protocols, or delays caused by a shortage of construction materials or labor, as well as potential postponement of rent commencement dates due to delays in tenant improvement projects, and (ii) an expected decrease in acquisitions and dispositions of properties compared to historical levels;

• | the need to provide sell-side financing in order to dispose of certain properties in our portfolio at acceptable prices;

• | the impact on our tenants or operators, particularly in our senior housing portfolio, of lawsuits related to COVID-19 outbreaks that have occurred or may occur at our properties and the potential that insurance coverage may not be sufficient to cover any potential losses;

• | material increases in our insurance costs and larger deductibles;

• | significant expenses likely to be incurred in connection with our pursuit of creditor rights resulting from operator and tenant defaults and insolvency;

• | a potential downgrade of our issuer and long-term credit rating following the change in our outlook from “stable” to “negative” by Moody’s, which could increase our cost of capital and any future debt financing;

• | refusal or failure by one or more of our lenders under our credit facility to fund their financing commitments to us as a result of lender liquidity and/or viability challenges, which financing commitments we may not be able to replace on favorable terms, or at all;

• | the likelihood that conditions related to the COVID-19 pandemic may require us to recognize impairments of long-lived assets or credit losses related to loans receivable;

56

Table of Contents

• | the impact on our business if our executive officers, management team or a significant percentage of our employees are unable to continue to work because of illness caused by COVID-19, as well as the significant time and attention devoted by our management team to monitor the COVID-19 pandemic and seek to mitigate its effect on our business; and

• | the deterioration of state and local economic conditions and job losses, particularly in San Francisco, San Diego and Boston, which may decrease demand for and occupancy levels at our life science properties and cause our rental rates and property values to be negatively impacted.

The impact of the COVID-19 pandemic on our SHOP properties managed in RIDEA structures may have a more significant impact on our results of operations on a relative basis because we receive cash flow from the operations of the property (as compared to only receiving contractual rent from a third-party tenant-operator under a triple-net lease structure), and we also bear all operational risks and liabilities associated with the operation of those properties, other than those arising out of certain actions by our operator, such as gross negligence or willful misconduct. Accordingly, any impact from the COVID-19 pandemic directly affecting one of our SHOP properties, including lower net operating income caused by decreased revenues that may result from declines in occupancy or otherwise, and increased expenses, could have a more direct and immediate impact on our results of operations than such an impact affecting one of our triple-net leased properties in our senior housing portfolio. For example, increased operating expenses at our SHOP properties, including due to labor shortages, as well as increased screening and protective measures intended to prevent an outbreak and/or slow the spread of a COVID-19 outbreak, could adversely affect the cash flow from operations we receive from the affected SHOP property. Alternatively, our RIDEA operators who are adversely affected by the COVID-19 pandemic may request revisions to their management agreements and existing fee structures in order to reduce the amount of cash from operations that flows directly to us. In addition, because we bear all operational risks and liabilities related to our SHOP properties, other than those arising out of certain actions by our operator, such as gross negligence or willful misconduct, we may be directly adversely impacted by potential lawsuits related to COVID-19 outbreaks that have occurred or may occur at those properties, and our insurance coverage may not be sufficient to cover any potential losses. The same factors may also affect our triple net lease tenants and may limit their ability to pay the contractual rent when due.
Additionally, the COVID-19 pandemic could increase the magnitude of many of the other risks described herein and elsewhere in this Quarterly Report may have other adverse effects on our operations that we are not currently able to predict. For example, we may be required to delay or limit our acquisition and disposition strategies in the short and medium-term by, for example, redirecting significant resources and management attention away from seeking attractive acquisitions and limiting any plans for dispositions given a potentially smaller pool of potential buyers who could face difficulties in obtaining financing and the potential negative impact the pandemic could have on the value of any assets we are seeking to sell. The COVID-19 pandemic has also resulted in significant volatility in the local, national and global financial markets, and we may be unable to obtain any required financing on favorable terms or on a timely basis or at all.
The extent of the impact of the COVID-19 pandemic on our business and financial results will depend on future developments, including the duration, severity and spread of the pandemic, health and safety actions taken to contain its spread, any possible resurgence of COVID-19 that may occur after the initial outbreak subsides and how quickly and to what extent normal economic and operating conditions can resume within the markets in which we operate, each of which are highly uncertain at this time and outside of our control. Even after the COVID-19 pandemic has ultimately subsided, we may continue to experience adverse impacts to our business and financial results as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future. The adverse impact of the COVID-19 pandemic on our business, results of operations and financial condition could be material.
We assume operational risks with respect to our SHOP properties managed in RIDEA structures that could have a material adverse effect on our business, results of operations and financial condition.
RIDEA permits REITs, such as us, to own or partially own qualified healthcare properties in a structure through which we can participate directly in the cash flow of the properties’ operations (as compared to receiving only contractual rent payments under a triple-net lease) in compliance with REIT requirements. The criteria for operating a qualified healthcare property in a RIDEA structure requires us to lease the property to an affiliate TRS and for such affiliate TRS to engage an independent qualifying management company, or operator (also known as an eligible independent contractor) to manage and operate the day-to-day business of the property. The operator performs its services in exchange for a management fee. As a result, under a RIDEA structure, we are required to rely on our operator to manage and operate the property, including hiring and training all employees, entering into all third-party contracts for the benefit of the property, including resident/patient agreements, complying with laws, including but not limited to healthcare laws, and providing resident care.
57

Table of Contents
We have limited rights to direct or influence the business or operations of these properties. However, as the owner of the property under a RIDEA structure, our TRS, and hence we, are ultimately responsible for all operational risks and other liabilities of the property, other than those arising out of certain actions by our operator, such as gross negligence or willful misconduct. Operational risks include, and our resulting revenues therefore depend on, among other things: (i) occupancy rates; (ii) the entrance fees and rental rates charged to residents; (iii) Medicare and Medicaid reimbursement rates, to the extent applicable; (iv) our operators’ reputations and ability to attract and retain residents; (v) general economic conditions and market factors that impact seniors which may be exacerbated by the COVID-19 pandemic, including the ongoing economic downturn and high unemployment rates; (vi) competition from other senior housing providers; (vii) compliance with federal, state, local and industry-regulated licensure, certification and inspection laws, regulations and standards; (viii) litigation involving our properties or residents/patients, including but not limited to litigation related to COVID-19; (ix) the availability and cost of general and professional liability insurance coverage or increases in insurance policy deductibles; and (x) the ability to control operating expenses, which have increased and may materially increase due to the COVID-19 pandemic. Although we are permitted under a RIDEA structure to have certain general oversight approval rights (e.g., budgets, material contracts, etc.) and the right to review operational and financial reporting information, our operators are ultimately in control of the day-to-day business of the property. As a result, we have limited rights to direct or influence the business or operations of our properties in the SHOP segment and we depend on our operators to operate these properties in a manner that complies with applicable law, minimizes legal risk and maximizes the value of our investment. The failure by our operators to adequately manage these risks could have a material adverse effect on our business, results of operations and financial condition.
When we use a RIDEA structure, our TRS is generally required to be the holder of the applicable healthcare license and is the entity that is enrolled in government healthcare programs (e.g., Medicare, Medicaid), where applicable. As the holder of a healthcare license, our TRS and we (through our ownership interest in our TRS) are subject to various regulatory laws. Most states regulate and inspect healthcare property operations, patient care, construction and the safety of the physical environment. However, we are required under RIDEA to rely on our operators to oversee and direct these aspects of the properties’ operations to ensure compliance with these applicable laws and regulations including “shelter-in-place” orders and other health and safety measures. If one or more of our healthcare properties fails to comply with applicable laws, our TRS would be responsible (except in limited circumstances, such as the gross negligence or willful misconduct of our operators, where we would have a contractual claim against them), which could subject our TRS to penalties including loss or suspension of licenses and certificates of need, certification or accreditation, exclusion from government healthcare programs (i.e., Medicare, Medicaid), administrative sanctions and civil monetary penalties. Some states also reserve the right to sanction affiliates of a licensee when they take administrative action against the licensee. Additionally, when we receive individually identifiable health information relating to residents of our healthcare properties, we are subject to federal and state data privacy and security laws and rules, and could be subject to liability in the event of an audit, complaint, cybersecurity attack or data breach. Furthermore, our TRS has exposure to professional liability claims that could arise out of resident claims, such as quality of care, and the associated litigation costs.
Rents received from the TRS in a RIDEA structure are treated as qualifying rents from real property for REIT tax purposes only if (i) they are paid pursuant to a lease of a “qualified healthcare property” and (ii) the operator qualifies as an “eligible independent contractor,” as defined in the Internal Revenue Code of 1986, as amended (the “Code”). If either of these requirements are not satisfied, then the rents will not be qualifying rents.
Decreases in our tenants’, operators’ or borrowers’ revenues, or increases in their expenses, could affect their ability to meet their financial and other contractual obligations to us, and could result in amendments to these obligations that have a material adverse effect on our results of operations and financial condition.
Our leases consist of triple-net leases, in which we lease our properties directly to tenants and operators, as well as RIDEA leases, in which we lease our properties to an affiliate TRS that enters into a management agreement with an eligible independent contractor, or operator, to manage and oversee the day-to-day business and operations of the properties. We are also a direct or indirect lender to various tenants and operators and separately provide loans to certain third parties. We have very limited control over the success or failure of our tenants’, operators’ and borrowers’ businesses, regardless of the structure of our relationship with them. Any of our triple-net tenants or operators under a RIDEA structure may experience a downturn in their business that materially weakens their financial condition. For example, our triple-net tenants and operators under a RIDEA structure have experienced a significant downturn in their businesses due to the COVID-19 pandemic, including as a result of interruptions in their operations, lost revenues, increased costs, financing difficulties and labor shortages. As a result, they may be unable or unwilling to make payments or perform their obligations when due. Although we generally have arrangements and other agreements that give us the right under specified circumstances to terminate a lease, evict a tenant or terminate our operator, or demand immediate repayment of outstanding loan amounts or other obligations to us, we may not be able to enforce such rights or we may determine not to do so if we believe that enforcement of our rights would be more detrimental to our business than seeking alternative approaches.
58

Table of Contents
Our senior housing tenants and our SHOP segment under a RIDEA structure primarily depend on private sources for their revenues and the ability of their patients and residents to pay fees. Costs associated with independent and assisted living services are not generally reimbursable under governmental reimbursement programs such as Medicare and Medicaid. Accordingly, our tenants and operators of our SHOP segments depend on attracting seniors with appropriate levels of income and assets, which may be affected by many factors, including: (i) prevailing economic and market trends, including the ongoing economic downturn and high unemployment rates; (ii) consumer confidence; (iii) demographics; (iv) property condition and safety; (v) public perception about such properties; and (vi) social and environmental factors. Consequently, if our tenants or operators on our behalf fail to effectively conduct their operations, or to maintain and improve our properties, it could adversely affect our business reputation as the owner of the properties, as well as the business reputation of our tenants or operators and their ability to attract and retain patients and residents in our properties, which could have a materially adverse effect on our and our tenant’s or operator’s business, results of operations and financial condition. Further, if widespread default or nonpayment of outstanding obligations from a large number of tenants or operators occurs at a time when terminating such agreement or replacing such tenants or operators may be extremely difficult or impossible, including as a result of the COVID-19 pandemic, we may elect instead to amend such agreements with such tenants or operators. However, such amendment may be on terms that are less favorable to us than the original agreement and may have a material adverse effect on our results of operations and financial condition.
Our senior housing tenants and our SHOP segment under a RIDEA structure also rely on reimbursements from governmental programs for a portion of the revenues from certain properties. Changes in reimbursement policies and other governmental regulation, such as potential changes to, or repeal of, the Patient Protection and Affordable Care Act, along with the Health Care and Education Reconciliation Act of 2010 (the “Affordable Care Act”), that may result from actions by Congress or executive orders, may result in reductions in our tenants’ revenues or in our revenues from our RIDEA structures, operations and cash flows and affect our tenants’ ability to meet their obligations to us or our financial performance through a RIDEA structure. In addition, failure to comply with reimbursement regulations or other laws applicable to healthcare providers could result in penalties, fines, litigation costs, lost revenue or other consequences, which could adversely impact our tenants’ ability to make contractual rent payments to us under a triple-net lease or our cash flows from operations under a RIDEA structure. For a further discussion of the legislation and regulation that are applicable to us and our tenants, operators and borrowers, see “–The requirements of, or changes to, government reimbursement programs such as Medicare or Medicaid, may adversely affect our tenants’, operators’ and borrowers’ ability to meet their financial and other contractual obligations to us.”
Revenues of our senior housing tenants and our SHOP segment under a RIDEA structure are also dependent on a number of other factors, including licensed bed capacity, occupancy, the healthcare needs of residents, the rate of reimbursement, the income and assets of seniors in the regions in which we own properties, and social and environmental factors. For example, due to generally increased vulnerability to illness, COVID-19 has resulted, and another epidemic or pandemic, a severe flu season or any other widespread illness could result in early move-outs or delayed move-ins during quarantine periods or during periods when actual or perceived risks of such illnesses are heightened, which have, and could continue to reduce our operators’ revenues. Additionally, new and evolving payor and provider programs in the United States, including but not limited to Medicare Advantage, Dual Eligible, Accountable Care Organizations, Bundled Payments and other value-based reimbursement arrangements, have resulted in reduced reimbursement rates, average length of stay and average daily census, particularly for higher acuity patients. If our tenants fail to maintain revenues sufficient to meet their financial obligations to us, our business, results of operations and financial condition would be materially adversely affected. Similarly, if our operators under a RIDEA structure underperform, our business, results of operations and financial condition would also be materially adversely affected.
Our tenants and operators may seek to offset losses by obtaining funds under the recently adopted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) or other similar legislative initiatives at the state and local level. Receipt of these funds is subject to a detailed application and approval process and in some cases, entails certain operating restrictions. It is indeterminable when and if these government funds will ultimately flow to our tenants and operators as well as the effect that receipt of these funds may have (if any) in materially offsetting the cash flow disruptions experienced by them. If they are unable to obtain these funds within a reasonable time period or at all, or the conditions precedent to accepting these funds are overly burdensome or not feasible, it may substantially affect their ability to make payments or perform their obligations when due to us.
59

Table of Contents
Imposition of laws or regulations prohibiting eviction of our tenants, even on a temporary basis, could have a material adverse effect on our revenues if our tenants fail to make their contractual rent payments to us.
Various federal, state and local governments have enacted and may continue to enact laws, regulations and moratoriums or take other actions which could limit our ability to evict tenants until such laws, regulations or moratoriums are reversed or lifted. In particular, many state and local governments have implemented eviction moratoriums as a result of the COVID-19 pandemic which generally apply to both residential and commercial tenants. Although many of these moratoriums are expected to be temporary in nature, they may be extended for a significant period of time until the COVID-19 pandemic subsides. Although we generally have arrangements and other agreements that give us the right under specified circumstances to terminate a lease or evict a tenant for nonpayment of contractual rent, such laws, regulations and moratoriums will generally prohibit our ability to begin eviction proceedings even where no rent or only partial rent is being paid for so long as such law, regulation or moratorium remains in effect. Further, under current laws and regulations, eviction proceedings for delinquent tenants are already costly and time-consuming, and, if there are existing backlogs or backlogs develop in courts due to higher than normal eviction proceedings, whether or not due to an increase in eviction proceedings after the COVID-19 pandemic, we may incur significant costs and it may take a significant amount of time to ultimately evict any tenant who is not meeting their contractual rent obligations. If we are restricted, delayed or prohibited from evicting tenants for failing to make contractual rent payments, our business, results of operations and financial condition may be materially adversely impacted.
Increased competition, operating costs and market changes have resulted and may further result in lower net revenues for some of our tenants, operators and borrowers and may affect their ability to meet their financial and other contractual obligations to us.
The healthcare industry is highly competitive. The occupancy levels at, and rental income from, our properties are dependent on our ability and the ability of our tenants, operators and borrowers to compete with other tenants and operators on a number of different levels, including the quality of care provided, reputation, the physical appearance of a property, price, the range of services offered, family preference, alternatives for healthcare delivery, the supply of competing properties, physicians, staff, referral sources, location, and the size and demographics of the population in the surrounding area. In addition, our tenants, operators and borrowers face an increasingly competitive labor market for skilled management personnel and nurses, which has been compounded by the COVID-19 pandemic. An inability to attract and retain skilled management personnel and nurses and other trained personnel could negatively impact the ability of our tenants, operators and borrowers to meet their obligations to us. A shortage of nurses or other trained personnel, union activities or general inflationary pressures on wages may force tenants, operators and borrowers to enhance pay and benefits packages to compete effectively for skilled personnel, or to use more expensive contract personnel, but they be unable to offset these added costs by increasing the rates charged to residents. Any increase in labor costs and other property operating expenses or any failure by our tenants, operators or borrowers to attract and retain qualified personnel could adversely affect our cash flow and have a materially adverse effect on our business, results of operations and financial condition.
Our tenants, operators and borrowers also compete with numerous other companies providing similar healthcare services or alternatives such as home health agencies, life care at home, community-based service programs, retirement communities and convalescent centers. This competition, which is due, in part, to over-development in some segments in which we invest, as well as a result of COVID-19 outbreaks at senior housing communities or the negative public perception that such outbreak may occur, has caused the occupancy rate of newly constructed buildings to slow or decline, and the monthly rate that many newly built and previously existing properties were able to obtain for their services to decrease. Our tenants, operators and borrowers may be unable to achieve and maintain occupancy and rate levels, and to manage their expenses, in a way that will enable them to meet all of their obligations to us. Further, many competing companies may have resources and attributes that are superior to those of our tenants, operators and borrowers, which may also allow them to better withstand the impact of COVID-19. Our tenants, operators and borrowers may encounter increased competition that could limit their ability to maintain or attract residents or expand their businesses or to manage their expenses, which could materially adversely affect their ability to meet their financial and other contractual obligations to us, potentially decreasing our revenues, impairing our assets and/or increasing collection and dispute costs.
The financial deterioration, insolvency or bankruptcy of one or more of our major tenants, operators or borrowers could have a material adverse effect on our business, results of operations and financial condition.
A downturn in any of our tenants’, operators’ or borrowers’ businesses, including downturns currently being experienced due to the COVID-19 pandemic, has led and could continue to lead to voluntary or involuntary bankruptcy or similar insolvency proceedings, including but not limited to assignment for the benefit of creditors, liquidation, or winding-up. Bankruptcy and insolvency laws afford certain rights to a defaulting tenant, operator or borrower that has filed for bankruptcy or reorganization that may render certain of our remedies unenforceable or, at the least, delay our ability to pursue such remedies and realize any related recoveries. For example, we cannot evict a tenant or operator solely because of its bankruptcy filing.
60

Table of Contents
A debtor has the right to assume, or to assume and assign to a third party, or to reject its executory contracts and unexpired leases in a bankruptcy proceeding. If a debtor were to reject its leases with us, obligations under such rejected leases would cease. The claim against the rejecting debtor would be an unsecured claim, which would be limited by the statutory cap set forth in the U.S. Bankruptcy Code. This statutory cap may be substantially less than the remaining rent actually owed under the lease. In addition, a debtor may also assert in bankruptcy proceedings that leases should be re-characterized as financing agreements, which could result in our being deemed a lender instead of a landlord. A lender’s rights and remedies, as compared to a landlord’s, generally are materially less favorable, and our rights as a lender may be subordinated to other creditors’ rights.
Furthermore, the automatic stay provisions of the U.S. Bankruptcy Code would preclude us from enforcing our remedies unless we first obtain relief from the court having jurisdiction over the bankruptcy case. This would effectively limit or delay our ability to collect unpaid rent or interest payments, and we may ultimately not receive any payment at all. In addition, we would likely be required to fund certain expenses and obligations (e.g., real estate taxes, insurance, debt costs and maintenance expenses) to preserve the value of our properties, avoid the imposition of liens on our properties or transition our properties to a new tenant or operator. Additionally, we lease many of our properties to healthcare providers who provide long-term custodial care to the elderly. Evicting operators for failure to pay rent while the property is occupied typically involves specific procedural or regulatory requirements and may not be successful. Even if eviction is possible, we may determine not to do so due to reputational or other risks. Bankruptcy or insolvency proceedings typically also result in increased costs to the operator, significant management distraction and performance declines.
If we are unable to transition affected properties, they would likely experience prolonged operational disruption, leading to lower occupancy rates and further depressed revenues. Publicity about the operator’s financial condition and insolvency proceeds may also negatively impact their and our reputations, decreasing customer demand and revenues. Any or all of these risks could have a material adverse effect on our revenues, results of operations and cash flows. These risks would be magnified where we lease multiple properties to a single operator under a master lease, as an operator failure or default under a master lease would expose us to these risks across multiple properties.
We depend on investments in the healthcare property sector, making our profitability more vulnerable to a downturn or slowdown in that specific sector than if we were investing in multiple industries.
We concentrate our investments in the healthcare property sector. As a result, we are subject to risks inherent to investments in a single industry. A downturn or slowdown in the healthcare property sector, such as the current downturn related to the COVID-19 pandemic, has had and may continue to have a greater adverse impact on our business than if we had investments in multiple industries. Specifically, the current downturn related to the COVID-19 pandemic, including the ongoing economic downturn and high unemployment rates, or future downturns could negatively impact the ability of our tenants, operators and borrowers to meet their obligations to us, as well as the ability to maintain historical rental and occupancy rates, which would have a material adverse effect on our business, financial condition and results of operations. In addition, the current or a future downturn or slowdown in the healthcare property sector could have a material adverse effect on the value of our properties and our ability to sell properties at prices or on terms acceptable or favorable to us.
In addition, we are exposed to the risks inherent in concentrating our investments in real estate. Our real estate investments are relatively illiquid due to several factors including, but not limited to: (i) restrictions on our ability to sell properties under applicable REIT tax laws; (ii) other tax-related considerations; (iii) regulatory hurdles; and (iv) market conditions. Our ability to quickly sell or transition any of our properties in response to changes in the performance of our properties or economic and other conditions is limited. We may be unable to recognize full value for any property that we seek to sell for liquidity reasons. Our inability to timely respond to investment performance changes could have a material adverse effect on our financial condition and results of operations.
61

Table of Contents
Tenants and operators that fail to comply with federal, state, local and international laws and regulations, including resident health and safety requirements, as well as licensure, certification and inspection requirements, may cease to operate or be unable to meet their financial and other contractual obligations to us.
Our tenants, operators and borrowers are subject to or impacted by extensive, frequently changing federal, state, local and international laws and regulations. These laws and regulations include, among others: (i) laws protecting consumers against deceptive practices; (ii) laws relating to the operation of our properties and how our tenants and operators conduct their business, such as fire, health and safety, data security and privacy laws; (iii) federal and state laws affecting hospitals, clinics and other healthcare communities that participate in both Medicare and Medicaid that specify reimbursement rates, pricing, reimbursement procedures and limitations, quality of services and care, background checks, food service and physical plants, and similar foreign laws regulating the healthcare industry; resident rights laws (including abuse and neglect laws) and fraud laws; (iv) anti-kickback and physician referral laws; (v) the ADA and similar state and local laws; (vi) safety and health standards set by the Occupational Safety and Health Administration or similar foreign agencies; and (vii) recently enacted laws and orders intended to address the COVID-19 pandemic. Certain of our properties may also require a license, registration and/or certificate of need to operate.
Our tenants’, operators’ or borrowers’ failure to comply with any of these laws, regulations or requirements could result in: (i) loss of accreditation, denial of reimbursement; (ii) imposition of fines, suspension or decertification from government healthcare programs; (iii) civil liability; and (iv) in certain instances, criminal penalties, loss of license or closure of the property and/or the incurrence of considerable costs arising from an investigation or regulatory action, which may have an adverse effect on properties that we own and lease to a third party tenant, that we own and operate through a RIDEA structure or on which we hold a mortgage, and therefore may materially adversely impact us. See “Item 1-Business-Government Regulation, Licensing and Enforcement-Healthcare Licensure and Certificate of Need.”
We may have difficulty identifying and securing replacement tenants or operators, and we may be required to incur substantial renovation or tenant improvement costs to make our properties suitable for them.
Our tenants may not renew existing leases, and our operators may not renew their management agreements beyond their current terms. If we or our tenants or operators terminate or do not renew the leases or management agreements for our properties, we would attempt to reposition those properties with another tenant or operator. These difficulties may be exacerbated by the COVID-19 pandemic, as new operators or tenants may not be willing to take on the increased exposure, especially while active cases are occurring. We may also voluntarily change operators for a variety of reasons. For example, we transitioned a significant number of properties managed by Brookdale to other operators as part of our strategic plan to reduce our Brookdale concentration. Healthcare properties are typically highly customized, and the improvements generally required to conform a property to healthcare use, such as upgrading electrical, gas and plumbing infrastructure, are costly and at times tenant-specific and are typically subject to regulatory requirements. A new or replacement tenant or operator may require different features in a property, depending on that tenant’s or operator’s particular business. In addition, infrastructure improvements for life science properties typically are significantly more costly than improvements to other property types due to the highly specialized nature of the properties and the greater lease square footage often required by life science tenants. We may be unable to recover part or all of these higher costs. Therefore, if a current tenant or operator is unable to pay rent and/or vacates a property, we may incur substantial expenditures to modify a property and experience delays before we are able to secure another tenant or operator or to accommodate multiple tenants or operators. These expenditures, renovations and/or delays may be exacerbated if a significant number of properties need to be repositioned. These expenditures or renovations and delays may have a material adverse effect on our business, results of operations and financial condition.
Additionally, we may fail to identify suitable replacements or enter into leases, management agreements or other arrangements with new tenants or operators on a timely basis or on terms as favorable to us as our current leases, if at all. Furthermore, during transition periods to new tenants or operators, we anticipate that the attention of existing tenants or operators will be diverted from the performance of the properties and there may also be increased errors and delays as a result of the transition, which would cause the financial and operational performance at these properties to decline. Following a decline in performance, we may not be able to rehabilitate the property to previous performance levels, which would adversely impact our results of operations. We also may be required to fund certain expenses and obligations, such as real estate taxes, debt costs and maintenance expenses, to preserve the value of, and avoid the imposition of liens on, our properties while they are being repositioned. In addition, we may incur certain obligations and liabilities, including obligations to indemnify the replacement tenant or operator, which could have a material adverse effect on our business, results of operations and financial condition.
62

Table of Contents
We face additional risks associated with property development and redevelopment that can render a project less profitable or not profitable at all and, under certain circumstances, prevent completion of development or redevelopment activities once undertaken.
Property development and redevelopment is a significant component of our growth strategy. At March 31, 2020, our active development and redevelopment pipeline was approximately $1.2 billion with remaining costs to complete of approximately $0.7 billion. Large-scale, ground-up, healthcare property development presents additional risks for us, including risks that:

• | a development opportunity may be abandoned after expending significant resources resulting in the loss of deposits or failure to recover expenses already incurred;

• | the development and construction costs of a project may exceed original estimates due to increased interest rates, higher costs relating to materials, transportation, labor, leasing, negligent construction or construction defects, damage, vandalism or accidents, among others, and increased costs as a result of COVID-19 related delays and/or pressure on supply chains, which could make the completion of the development project less profitable;

• | the project may not be completed on schedule as a result of a variety of factors that are beyond our control, including natural disasters and other catastrophic events, health crises or other pandemics such as the COVID-19 pandemic and related restrictions on development and redevelopment activities, labor conditions, material shortages, regulatory hurdles, including the ability to obtain necessary zoning or land use permits, civil unrest and acts of war or terrorism, which result in increases in construction costs and debt service expenses or provide tenants or operators with the right to terminate pre-construction leases; and

• | demand for the new project may decrease prior to completion, due to competition or other developments such as the COVID-19 pandemic, and occupancy rates and rents at a newly completed property may not meet expected levels and could be insufficient to make the property profitable.

Any of the foregoing risks could result in not achieving our expected return on investment and have a material adverse effect on our business, results of operations and financial condition.
Changes within the life science industry may adversely impact our revenues and results of operations.
For the year ended December 31, 2019 and the quarter ended March 31, 2020, properties in our life science segment accounted for approximately 22% of our total revenues. Our life science investments could be adversely affected if the life science industry is impacted by an economic, financial, or banking crisis, a health crisis or pandemic, such as the COVID-19 pandemic, or if the life science industry migrates from the U.S. to other countries or to areas outside of primary life science markets in South San Francisco, California, San Diego, California, and greater Boston, Massachusetts. Our ability to negotiate contractual rent escalations on future leases and to achieve increases in rental rates will depend upon market conditions and the demand for life science properties at the time the leases are negotiated and the increases are proposed. If economic, financial or industry conditions adversely affect our life science tenants, we may not be able to lease or re-lease our properties in a timely manner or at favorable rates, which would negatively impact our revenues and results of operations. For example, some of our properties may be better suited for a particular life science industry client tenant and could require modification before we are able to re-lease vacant space to another life science industry client tenant, which may delay the re-leasing process and result in unrecovered costs. Additionally, some of our life science properties may not be suitable for lease to traditional office client tenants without significant expenditures on renovations, which could delay an attempt to reposition the property for rent to non-life science tenants. Because infrastructure improvements for life science properties typically are significantly more costly than improvements to other property types due to the highly specialized nature of the properties, and life science tenants typically require greater lease square footage relative to medical office tenants, repositioning efforts would have a disproportionate adverse effect on our life science segment performance. See “–We may have difficulty identifying and securing replacement tenants or operators, and we may be required to incur substantial renovation or tenant improvement costs to make our properties suitable for them.”
It is common for businesses in the life science industry to undergo mergers or consolidations. Future mergers or consolidations of life science entities could reduce the amount of rentable square footage requirements of our client tenants and prospective client tenants, which may adversely impact our revenues from lease payments and results of operations.
63

Table of Contents
Our tenants in the life science industry face high levels of regulation, funding requirements, expense and uncertainty.
Life science tenants, particularly those involved in developing and marketing pharmaceutical products, are subject to certain unique risks, including the following:

• | some of our tenants require significant funding for the research, development, clinical testing, manufacture and commercialization of their products and technologies, as well as to fund their obligations, including rent payments due to us, and our tenants’ ability to raise capital depends on the viability of their products and technologies, their financial and operating condition and outlook, and the overall financial, banking and economic environment. If venture capital firms, private investors, the public markets, companies in the life science industry, the government or other sources of funding are difficult to obtain or unavailable to support our tenants’ activities, including as a result of general economic conditions, adverse market conditions or government shutdowns that limit our tenants’ ability to raise capital, such as those resulting from the current COVID-19 pandemic, a tenant’s business would be adversely affected or fail;

• | the research, development, clinical testing, manufacture and marketing of some of our tenants’ products require federal, state and foreign regulatory approvals which may be costly or difficult to obtain, may take several years and be subject to delay, including delays brought on by the COVID-19 pandemic, may not be obtained at all, require validation through clinical trials that may face delays or difficulties resulting from the COVID-19 pandemic or otherwise, require the use of substantial resources, and may often be unpredictable;

• | even after a life science tenant gains regulatory approval and market acceptance, the product may still present significant regulatory and liability risks, including, among others, the possible later discovery of safety concerns and other defects and potential loss of approvals, competition from new products and the expiration of patent protection for the product;

• | our tenants with marketable products may be adversely affected by healthcare reform and the reimbursement policies of government or private healthcare payors;

• | our tenants with marketable products may be unable to successfully manufacture their drugs economically;

• | our tenants depend on the commercial success of certain products, which may be reliant on the efficacy of the product, as well as acceptance among doctors and patients; negative publicity or negative results or safety signals from the clinical trials of competitors may reduce demand or prompt regulatory actions; and

• | our tenants may be unable to adapt to the rapid technological advances in the industry and to adequately protect their intellectual property under patent, copyright or trade secret laws and defend against third-party claims of intellectual property violations.

If our tenants’ businesses are adversely affected, they may fail to make their rent payments to us, which could have a material adverse effect on our business, results of operations and financial condition.
The hospitals on whose campuses our MOBs are located and their affiliated healthcare systems could fail to remain competitive or financially viable, which could adversely impact their ability to attract physicians and physician groups to our MOBs and our other properties that serve the healthcare industry.
Our MOBs and other properties that serve the healthcare industry depend on the competitiveness and financial viability of the hospitals on whose campuses our MOBs are located and their affiliated healthcare systems in order to attract physicians and other healthcare-related users. The viability of these hospitals, in turn, depends on factors such as: (i) the quality and mix of healthcare services provided; (ii) competition for patients and physicians; (iii) demographic trends in the surrounding community; (iv) market position; and (v) growth potential, as well as the ability of the affiliated healthcare systems to provide economies of scale and access to capital. In addition, most of these hospitals are experiencing a significant reduction in revenue due to decreased volumes as well as increased costs as they provide care capacity for potential COVID-19 patients. If a hospital whose campus is located near one of our MOBs is unable to meet its financial obligations, and if an affiliated healthcare system is unable to support that hospital or goes bankrupt, the hospital may not be able to compete successfully or could be forced to close or relocate, which could adversely impact its ability to attract physicians and other healthcare-related users. Because we rely on our proximity to and affiliations with these hospitals to create tenant demand for space in our MOBs, their inability to remain competitive or financially viable, or to attract physicians and physician groups, could adversely affect our MOB operations and have a material adverse effect on us.
In addition, changes to or replacement of the Affordable Care Act and related regulations could result in significant changes to the scope of insurance coverage and reimbursement policies, which could put negative pressure on the operations and revenues of our MOBs.
64

Table of Contents
We may be unable to maintain or expand our relationships with our existing and future hospital and health system clients.
The success of our medical office portfolio depends, to a large extent, on past, current and future relationships with hospitals and their affiliated health systems. We invest significant amounts of time in developing relationships with both new and existing clients. If we fail to maintain these relationships, including through a lack of responsiveness, failure to adapt to the current market or employment of individuals with inadequate experience, our reputation and relationships will be harmed and we may lose business to competitors. If our relationships with hospitals and their affiliated health systems deteriorate, it could have a material adverse effect on us.
Economic and other conditions that negatively affect geographic areas from which a greater percentage of our revenue is recognized could have a material adverse effect on our business, results of operations and financial condition.
For both of the year ended December 31, 2019 and the quarter ended March 31, 2020, we derived 28% of our revenue from properties located in California, which is also where a large portion of our life science portfolio is located. As a result, we are subject to increased exposure to adverse conditions affecting California, including: (i) downturns in local economies and increases in unemployment rates; (ii) changes in local real estate conditions, including increases in real estate taxes; (iii) increased competition; (iv) decreased demand; (v) changes in state-specific legislation; and (vi) local climate events and natural disasters and other catastrophic events, such as health pandemics (including the COVID-19 pandemic in California and the resulting state-wide shutdown), earthquakes, windstorms, flooding, wildfires and mudslides. These risks could significantly disrupt our businesses in the region, harm our ability to compete effectively, result in increased costs, and divert management attention, any or all of which could have a material adverse effect on our business, results of operations and financial condition.
In addition, if significant changes in the climate occur in areas where we own property, this could result in physical damage to or a decrease in demand for properties located in these areas or affected by these conditions. If changes in the climate have material effects, such as property destruction, or occur for extended periods, this could have a material adverse effect on business, results of operations and financial condition. In addition, changes in federal, state and local legislation and regulation on climate change could require increased capital expenditures to improve the energy efficiency of our existing properties and could also cause increased costs for our new developments without a corresponding increase in revenue.
Uninsured or underinsured losses could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated expense.
We maintain and regularly review the comprehensive insurance coverage on our properties with terms, conditions, limits and deductibles that we believe have historically been adequate and appropriate on balance with respect to the relative risk and costs of such coverage. However, our current insurance coverage typically does not include damages from business interruptions, loss of revenue or earnings or any related effects caused by health pandemics, including the COVID-19 pandemic. We anticipate incurring significant costs related to the COVID-19 pandemic, including costs associated with legal proceedings or other claims from residents and patients at our properties. Depending on the magnitude of these costs, our existing insurance may be insufficient to cover such costs and we may be required to pay high deductibles.
Generally, insurance coverage for health pandemics has not previously been readily available and, if and when it does become available, may not be on commercially reasonable terms. Further, even if such coverage is available on commercially reasonable terms, we cannot assure you that we would receive insurance proceeds that will compensate us fully for our liabilities, costs and expenses in the event of a health pandemic. In addition, a large number of our properties are located in areas exposed to earthquake, windstorm, flood and other natural disasters. In particular, a significant portion of our life science development projects and approximately 81% of our existing life science portfolio (based on gross asset value) is concentrated in California, which is known to be subject to earthquakes, wildfires and other natural disasters. While we purchase insurance coverage for earthquake, fire, windstorm, flood and other natural disasters that we believe is adequate in light of current industry practice and analyses prepared by outside consultants, such insurance may not fully cover such losses. These losses can result in decreased anticipated revenues from a property and the loss of all or a portion of the capital we have invested in a property. Following these events, we may remain liable for any mortgage debt or other financial obligations related to the property.
Furthermore, the insurance market for natural disasters exposures can be volatile, and we may be unable to purchase the limits and terms we desire on a commercially reasonable basis. In addition, there are certain exposures for which we do not purchase insurance because we do not believe it is economically feasible to do so or there is no viable insurance market. We maintain earthquake insurance for our properties that are located in the vicinity of active earthquake zones in amounts and with deductibles we believe are commercially reasonable. Because of our significant concentration in the seismically active regions of South San Francisco, California and San Diego, California, a damaging earthquake in these areas could significantly impact multiple properties, which may amount to a significant portion of our life science portfolio. As a result, aggregate deductible amounts may be material, and our insurance coverage may be materially insufficient to cover our losses, either of which would adversely affect our business, financial condition, results of operations and cash flows.
65

Table of Contents
If one of our properties experiences a loss that is uninsured or that exceeds policy coverage limits, we could lose our investment in the damaged property as well as the anticipated future cash flows from such property. If the damaged property is subject to recourse indebtedness, we could continue to be liable for the indebtedness even if the property is irreparably damaged.
In addition, even if damage to our properties is covered by insurance, a disruption of business caused by a casualty event may result in loss of revenues for us. Any business interruption insurance may not fully compensate the lender or us for such loss of revenue.
Our use of joint ventures may limit our flexibility with jointly owned investments.
We have and may continue to develop and/or acquire properties in joint ventures with other persons or entities when circumstances warrant the use of these structures. Our participation in joint ventures is subject to risks that may not be present with other methods of ownership, including:

• | our joint venture partners could have investment and financing goals that are not consistent with our objectives, including the timing, terms and strategies for any investments, and what levels of debt to incur or carry;

• | we could experience an impasse on certain decisions because we do not have sole decision-making authority, which could require us to expend additional resources on resolving such impasses or potential disputes, including litigation or arbitration;

• | our joint venture partners may have competing interests in our markets that could create conflicts of interest;

• | our ability to transfer our interest in a joint venture to a third party may be restricted and the market for our interest may be limited and/or valued lower than fair market value;

• | our joint venture partners may be structured differently than us for tax purposes, and this could create conflicts of interest and risks to our REIT status; and

• | our joint venture partners might become insolvent, fail to fund their share of required capital contributions or fail to fulfill their obligations as a joint venture partner, which may require us to infuse our own capital into the venture on behalf of the partner despite other competing uses for such capital.

With respect to our joint ventures, we may be limited in our ability to control or influence operations, and in our ability to exit or transfer our interest in the joint venture to a third party. As a result, we may not receive full value for our ownership interest if we tried to sell it to a third party.
In addition, in some instances, we and/or our joint venture partner will have the right to cause us to sell our interest, or acquire our partner’s interest, at a time when we otherwise would not have initiated such a transaction. Our ability to acquire our partner’s interest will be limited if we do not have sufficient cash, available borrowing capacity or other capital resources. This would require us to sell our interest in the joint venture when we would otherwise prefer to retain it. Any of the foregoing risks could have a material adverse effect on our business, results of operations and financial condition.
We have now, and may have in the future, contingent rent provisions and/or rent escalators based on the Consumer Price Index, which could hinder our profitability and growth.
We derive a significant portion of our revenues from leasing properties pursuant to leases that generally provide for fixed rental rates, subject to annual escalations. Under certain leases, a portion of the tenant’s rental payment to us is based on the property’s revenues (i.e., contingent rent). If, as a result of weak economic conditions or other factors that may be outside of our control, the property’s revenue declines, our rental revenues would decrease and our results of operations could be materially adversely affected. Additionally, some of our leases provide that annual rent is modified based on changes in the Consumer Price Index or other thresholds (i.e., contingent rent escalators). If the Consumer Price Index does not increase or other applicable thresholds are not met, rental rates may not increase as anticipated or at all, which could have a material adverse effect on our results of operations. Furthermore, if strong economic conditions result in significant increases in the Consumer Price Index, but the escalations under our leases with contingent rent escalators are capped, our growth and profitability also may be limited.
66

Table of Contents
Competition may make it difficult to identify and purchase, or develop, suitable healthcare properties to grow our investment portfolio, to finance acquisitions on favorable terms, or to retain or attract tenants and operators.
We face significant competition from other REITs, investment companies, private equity and hedge fund investors, sovereign funds, healthcare operators, lenders, developers and other institutional investors, some of whom may have greater resources and lower costs of capital than we do. Increased competition makes it more challenging for us to identify and successfully capitalize on opportunities that meet our business goals and could improve the bargaining power of property owners seeking to sell, thereby impeding our investment, acquisition and development activities. Similarly, our properties face competition for tenants and operators from other properties in the same market, which may affect our ability to attract and retain tenants and operators, or may reduce the rents we are able to charge. If we cannot capitalize on our development pipeline, identify and purchase a sufficient quantity of healthcare properties at favorable prices, finance acquisitions on commercially favorable terms, or attract and retain profitable tenants and operators, our business, results of operations and financial condition may be materially adversely affected.
We expect to pursue fewer acquisitions and dispositions, as well as enter into fewer joint ventures, in at least the near term, which may delay or slow our growth.
We have historically engaged in acquisitions and dispositions and entered into joint ventures from time to time as part of our growth strategy. We expect that due to the COVID-19 pandemic, we will experience at least a short-term decrease in both the number and significance of acquisition and dispositions that we pursue. Additionally, the economic conditions created by the COVID-19 pandemic may necessitate the need for us to provide sell-side financing in order to dispose of certain properties within our portfolio at acceptable prices. Our review process for future acquisitions and/or dispositions may require significant management attention and a potential transaction could be abandoned or rejected by us or the other parties involved after we expend significant resources and time. In addition, future acquisitions may require the issuance of securities, the incurrence of debt, assumption of contingent liabilities or incurrence of significant expenditures, each of which could have a material adverse effect on our business, financial condition or results of operations. In addition, the financing required for acquisitions may not be available on commercially favorable terms, on terms consistent with our historical agreements or expectations or at all.
From time to time, we may acquire other companies, and if we are unable to successfully integrate these operations, our business, results of operations and financial condition may be materially adversely affected.
Acquisitions require the integration of companies that have previously operated independently. Successful integration of acquired companies depends primarily on our ability to consolidate operations, systems, procedures, properties and personnel, and to eliminate redundancies and reduce costs. We may encounter difficulties in these integrations. Potential difficulties associated with acquisitions include: (i) our ability to effectively monitor and manage our expanded portfolio of properties; (ii) the loss of key employees; (iii) the disruption of our ongoing business or that of the acquired entity; (iv) possible inconsistencies in standards, controls, procedures and policies; and (v) the assumption of unexpected liabilities, including:

• | liabilities relating to the cleanup or remediation of undisclosed environmental conditions;

• | unasserted claims of vendors, residents, patients or other persons dealing with the seller;

• | liabilities, claims and litigation, whether or not incurred in the ordinary course of business, relating to periods prior to our acquisition;

• | claims for indemnification by general partners, directors, officers and others indemnified by the seller;

• | claims for return of government reimbursement payments; and

• | liabilities for taxes relating to periods prior to our acquisition.

In addition, acquired companies and their properties may fail to perform as expected, including in respect of estimated cost savings. Inaccurate assumptions regarding future rental or occupancy rates could result in overly optimistic estimates of future revenues. Similarly, we may underestimate future operating expenses or the costs necessary to bring properties up to standards established for their intended use or for property improvements.
If we have difficulties with any of these areas, or if we later discover additional liabilities or experience unforeseen costs relating to our acquired companies, we may not achieve the anticipated economic benefits from our acquisitions, and this may have a material adverse effect on our business, results of operations and financial condition.
67

Table of Contents
Our tenants, operators and borrowers face litigation and may experience rising liability and insurance costs.
In some states, advocacy groups have been created to monitor the quality of care at healthcare properties, and these groups have brought litigation against the tenants and operators of such properties. We anticipate a material increase in litigation related to the COVID-19 pandemic. Also, in several instances, private litigation by patients, residents or “whistleblowers” has sought, and sometimes resulted in, large damage awards. See “–The requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid, may adversely affect our tenants’, operators’ and borrowers’ ability to meet their financial and other contractual obligations to us.” The size of jury verdicts in these types of lawsuits have also been increasing overall in recent years. The effect of litigation and other potential litigation may materially increase the costs incurred by our tenants, operators and borrowers for monitoring and reporting quality of care compliance, which under a RIDEA structure would be borne by us. In addition, their cost of professional liability, medical malpractice, property, business interruption, and insurance policies that may provide partial coverage for COVID-19 and other environmental or infectious disease outbreaks, epidemics and pandemics can be significant and may increase or not be available at a reasonable cost or at all. Cost increases could cause our tenants and borrowers to be unable to make their lease or mortgage payments or fail to purchase the appropriate liability and malpractice insurance, or cause our borrowers to be unable to meet their obligations to us, potentially decreasing our revenues and increasing our collection and litigation costs. Furthermore, with respect to our senior housing properties operated in RIDEA structures, we directly bear the costs of any such increases in litigation, monitoring, reporting and insurance due to our direct exposure to the cash flows of such properties.
In addition, as a result of our ownership of healthcare properties, we may be named as a defendant in lawsuits arising from the alleged actions of our tenants or operators. With respect to our triple-net leases, our tenants generally have agreed to indemnify us for various claims, litigation and liabilities in connection with their leasing and operation of our triple-net leased properties.
With respect to our RIDEA structured properties, we are responsible for these claims, litigation and liabilities, with limited indemnification rights against our operator typically based on the gross negligence or willful misconduct by the operator. Although our leases provide us with certain information rights with respect to our tenants, one or more of our tenants may be or become party to pending litigation or investigation to which we are unaware or do not have a right to participate or evaluate. In such cases, we would be unable to determine the potential impact of such litigation or investigation on our tenants or our business or results. Moreover, negative publicity of any of our operators’ or tenants’ litigation, other legal proceedings or investigations may also negatively impact their and our reputation, resulting in lower customer demand and revenues, which could have a material adverse effect on our financial condition, results of operations and cash flow.
Required regulatory approvals can delay or prohibit transfers of our healthcare properties.
Transfers of healthcare properties to successor tenants or operators are typically subject to regulatory approvals or ratifications, including, but not limited to, change of ownership approvals and Medicare and Medicaid provider arrangements that are not required for transfers of other types of commercial operations and other types of real estate. The replacement of any tenant or operator could be delayed by the regulatory approval process of any federal, state or local government agency necessary for the transfer of the property or the replacement of the operator licensed to manage the property, during which time the property may experience performance declines. The COVID-19 pandemic may materially delay necessary approvals, thereby lengthening the period of performance deterioration. If we are unable to find a suitable replacement tenant or operator upon favorable terms, or at all, we may take possession of a property, which could expose us to successor liability, require us to indemnify subsequent operators to whom we transfer the operating rights and licenses, or require us to spend substantial time and funds to preserve the value of the property and adapt the property to other uses, all of which could have a material adverse effect of our business, results of operations and financial condition.
Compliance with the Americans with Disabilities Act and fire, safety and other regulations may require us to make expenditures that adversely affect our cash flows.
Our properties must comply with applicable ADA and any similar state and local laws. This may require removal of barriers to access by persons with disabilities in public areas of our properties. Noncompliance could result in the incurrence of additional costs associated with bringing the properties into compliance, the imposition of fines or an award of damages to private litigants in individual lawsuits or as part of a class action. While the tenants to whom we lease our properties are obligated to comply with the ADA and similar state and local provisions, and typically under tenant leases are obligated to cover costs associated with compliance, if required changes involve greater expenditures than anticipated, or if the changes must be made on a more accelerated basis than anticipated, the ability of these tenants to cover costs could be adversely affected. As a result, we could be required to expend funds to comply with the provisions of the ADA and similar state and local laws on behalf of tenants, which could adversely affect our results of operations and financial condition. Additionally, with respect to our SHOP properties under RIDEA structures, we are ultimately responsible for such litigation and compliance costs.
68

Table of Contents
In addition, we are required to operate our properties in compliance with fire and safety regulations, building codes and other land use regulations. New and revised regulations and codes may be adopted by governmental agencies and bodies and become applicable to our properties. For example, new safety laws for senior housing properties were adopted following the particularly damaging 2018 hurricane season. Compliance could require substantial capital expenditures, and may restrict our ability to renovate our properties. These expenditures and restrictions could have a material adverse effect on our financial condition and cash flows.
The requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid, may adversely affect our tenants’, operators’ and borrowers’ ability to meet their financial and other contractual obligations to us.
Certain of our tenants, operators and borrowers are affected, directly or indirectly, by a complex set of federal, state and local laws and regulations pertaining to governmental reimbursement programs, including the recently enacted CARES Act and other similar relief legislation enacted in the wake of the COVID-19 pandemic. These laws and regulations are subject to frequent and substantial changes that are sometimes applied retroactively. See “Item 1-Business-Government Regulation, Licensing and Enforcement.” For example, to the extent that our tenants, operators or borrowers receive a significant portion of their revenues from governmental payors, primarily Medicare and Medicaid, they are generally subject to, among other things:

• | statutory and regulatory changes;

• | retroactive rate adjustments;

• | recovery of program overpayments or set-offs;

• | federal, state and local litigation and enforcement actions;

• | administrative proceedings;

• | policy interpretations;

• | payment or other delays by fiscal intermediaries or carriers;

• | government funding restrictions (at a program level or with respect to specific properties);

• | reduced reimbursement rates under managed care contracts;

• | interruption or delays in payments due to any ongoing governmental investigations and audits at such properties; and

• | reputational harm of publicly disclosed enforcement actions, audits or investigations related to billing and reimbursements.

The failure to comply with the extensive laws, regulations and other requirements applicable to their business and the operation of our properties could result in, among other challenges: (i) becoming ineligible to receive reimbursement from governmental reimbursement programs, including under the CARES Act; (ii) becoming subject to prepayment reviews or claims for overpayments; (iii) bans on admissions of new patients or residents; (iv) civil or criminal penalties; and (v) significant operational changes, including requirements to increase staffing or the scope of care given to residents. These laws and regulations are enforced by a variety of federal, state and local agencies and can also be enforced by private litigants through, among other things, federal and state false claims acts, which allow private litigants to bring qui tam or “whistleblower” actions.
We are unable to predict future changes to or interpretations of federal, state and local statutes and regulations, including the Medicare and Medicaid statutes and regulations, or the intensity of enforcement efforts with respect to such statutes and regulations. Any changes in the regulatory framework or the intensity or extent of governmental or private enforcement actions could have a material adverse effect on our tenants and operators. If, in turn, such tenants or operators fail to make contractual rent payments to us or, with respect to our SHOP segment, cash flows are adversely affected, it could have a material adverse effect on us.
Sometimes, governmental payors freeze or reduce payments to healthcare providers, or provide annual reimbursement rate increases that are smaller than expected, due to budgetary and other pressures. In addition, the federal government periodically makes changes in the statutes and regulations relating to Medicare and Medicaid reimbursement that may impact state reimbursement programs, particularly Medicaid reimbursement and managed care payments. We cannot make any assessment as to the ultimate timing or the effect that any future changes may have on our tenants’, operators’ and borrowers’ costs of doing business and on the amount of reimbursement by government and other third-party payors. The failure of any of our tenants, operators or borrowers to comply with these laws and regulations, and significant limits on the scope of services reimbursed, reductions in reimbursement rates and fees, or increases in provider or similar types of taxes, could materially adversely affect their ability to meet their financial and contractual obligations to us.
69

Table of Contents
Furthermore, executive orders and legislation may amend or repeal the Affordable Care Act and related regulations in whole or in part. We also anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative healthcare delivery and payment systems and may propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the healthcare system. For example, the Department of Health and Human Services has focused on tying Medicare payments to quality or value through alternative payment models, which generally aim to make providers attentive to the total costs of treatments. Medicare no longer reimburses hospitals for care related to certain preventable adverse events and imposes payment reductions on hospitals for preventable readmissions. These punitive approaches could be expanded to additional types of providers in the future. Additionally, the Centers for Medicare and Medicaid Services recently finalized a new patient driven payment model used to calculate reimbursement rates for patients in skilled nursing properties. While we cannot quantify or predict the likely impact of these changes on the revenues and profitability of our tenants, operators and borrowers, these provisions could result in decreases in payments to our operators and tenants or increase our operators’ and tenants’ costs. If any such changes significantly and adversely affect our tenants’ profitability, they could in turn negatively affect our tenants’ ability and willingness to comply with the terms of their leases with us and/or renew their leases with us upon expiration, which could impact our business, prospects, financial condition or results of operations.
Legislation to address federal government operations and administration decisions affecting the Centers for Medicare and Medicaid Services could have a material adverse effect on our tenants’, operators’ and borrowers’ liquidity, financial condition or results of operations.
Congressional consideration of legislation pertaining to the federal debt ceiling, the Affordable Care Act, tax reform and entitlement programs, including reimbursement rates for physicians, could have a material adverse effect on our tenants’, operators’ and borrowers’ liquidity, financial condition or results of operations. In particular, reduced funding for entitlement programs such as Medicare and Medicaid would result in increased costs and fees for programs such as Medicare Advantage Plans and additional reductions in reimbursements to providers. Amendments to or repeal of the Affordable Care Act in whole or in part and decisions by the Centers for Medicare and Medicaid Services could impact the delivery of services and benefits under Medicare, Medicaid or Medicare Advantage Plans and could affect our tenants and operators and the manner in which they are reimbursed by such programs. Such changes could have a material adverse effect on our tenants’, operators’ and borrowers’ liquidity, financial condition or results of operations, which could adversely affect their ability to satisfy their obligations to us and could have a material adverse effect on us.
We may be unable to successfully foreclose on the collateral securing our real estate-related loans, and even if we are successful in our foreclosure efforts, we may be unable to successfully operate, occupy or reposition the underlying real estate, which may adversely affect our ability to recover our investments.
If a tenant or operator defaults under one of our mortgages or mezzanine loans, we may have to foreclose on the loan or protect our interest by acquiring title to the collateral and thereafter making substantial improvements or repairs in order to maximize the property’s investment potential. In some cases, the collateral consists of the equity interests in an entity that directly or indirectly owns the applicable real property or interests in operating properties and, accordingly, we may not have full recourse to assets of that entity, or that entity may have incurred unexpected liabilities. Tenants, operators or borrowers may contest enforcement of foreclosure or other remedies, seek bankruptcy protection against our exercise of enforcement or other remedies and/or bring claims for lender liability in response to actions to enforce mortgage obligations. Foreclosure-related costs, high loan-to-value ratios or declines in the value of the property may prevent us from realizing an amount equal to our mortgage or mezzanine loan upon foreclosure, and we may be required to record a valuation allowance for such losses. Even if we are able to successfully foreclose on the collateral securing our real estate-related loans, we may inherit properties for which we may be unable to expeditiously secure tenants or operators, if at all, or we may acquire equity interests that we are unable to immediately resell due to limitations under the securities laws, either of which would adversely affect our ability to fully recover our investment.
Risks Related to Our Capital Structure and Market Conditions

An increase in our borrowing costs could materially adversely impact our ability to refinance existing debt, sell properties and conduct acquisition, investment and development activities, and could cause our stock price to decline.
An increase in our borrowing costs reduces the amount investors are willing to pay for our common stock. Because REIT stocks are often perceived as high-yield investments, investors may perceive less relative benefit to owning REIT stocks as borrowing costs increase.
70

Table of Contents
Additionally, we have existing debt obligations that are variable rate obligations with interest and related payments that vary with the movement of certain indices. If interest rates increase, so would our interest costs for any variable rate debt and for new debt. This increased cost would make the financing of any acquisition and development activity more costly. In addition, an increase in interest rates could decrease the amount third parties are willing to pay for our properties, thereby limiting our ability to reposition our portfolio promptly in response to changes in economic or other conditions.
Rising borrowing costs could limit our ability to refinance existing debt when it matures, or cause us to pay higher interest rates upon refinancing and increase interest expense on refinanced indebtedness. If our prevailing borrowing costs are higher than the interest rates of our senior notes at their maturity, we will incur additional interest expense upon any replacement debt.
We manage a portion of our exposure to interest rate risk by accessing debt with staggered maturities and through the use of derivative instruments, primarily interest rate swap agreements. However, no amount of hedging activity can fully insulate us from the risks associated with changes in interest rates. Swap agreements involve risk, including that counterparties may fail to honor their obligations under these arrangements, that these arrangements may not be effective in reducing our exposure to interest rate changes, that the amount of income we earn from hedging transactions may be limited by federal tax provisions governing REITs and that these arrangements may cause us to pay higher interest rates on our debt obligations than would otherwise be the case. Failure to hedge effectively against interest rate risk could adversely affect our results of operations and financial condition.
Cash available for distribution to stockholders may be insufficient to make dividend distributions at expected levels and are made at the discretion of our Board of Directors.
If cash available for distribution generated by our properties decreases, including decreases related to the COVID-19 pandemic or as a result of our announced pending dispositions that may not be consummated in the anticipated timeframe or at all, we may be unable to make dividend distributions at expected or historical levels. Our inability to make distributions commensurate with historical practices or market expectations would likely result in a decrease in the market price of our common stock. All distributions are made at the discretion of our Board of Directors in accordance with Maryland law and depend on: (i) our earnings; (ii) our financial condition; (iii) debt and equity capital available to us; (iv) our expectations for future capital requirements and operating performance; (v) restrictive covenants in our financial or other contractual arrangements, including those in our credit facility agreement; (vi) maintenance of our REIT qualification; (vii) restrictions under Maryland law; and (viii) other factors as our Board of Directors may deem relevant from time to time. Additionally, our ability to make distributions will be adversely affected if any of the risks described herein, or other significant adverse events, occur.
We rely on external sources of capital to fund future capital needs, and if access to such capital is unavailable on acceptable terms or at all, it could have a material adverse effect on our ability to meet commitments as they become due or make future investments necessary to grow our business.
We may not be able to fund all future capital needs, including capital expenditures, debt maturities and other commitments, from cash retained from operations and dispositions. If we are unable to obtain enough internal capital, we may need to rely on external sources of capital (including debt and equity financing) to fulfill our capital requirements. Our access to capital depends upon a number of factors, some of which we have little or no control over, including but not limited to:

• | general availability of capital, including less favorable terms, rising interest rates and increased borrowing costs;

• | the market price of the shares of our equity securities and the credit ratings of our debt and any preferred securities we may issue;

• | the market’s perception of our growth potential and our current and potential future earnings and cash distributions;

• | our degree of financial leverage and operational flexibility;

• | the financial integrity of our lenders, which might impair their ability to meet their commitments to us or their willingness to make additional loans to us, and our inability to replace the financing commitment of any such lender on favorable terms, or at all;

• | the stability of the market value of our properties;

• | the financial performance and general market perception of our tenants and operators;

• | changes in the credit ratings on U.S. government debt securities or default or delay in payment by the United States of its obligations;

71

Table of Contents

• | issues facing the healthcare industry, including, but not limited to, healthcare reform, changes in government reimbursement policies and the unique challenges posed by the COVID-19 pandemic; and

• | the performance of the national and global economies generally, including the ongoing economic downturn and volatility in the financial markets as a result of the COVID-19 pandemic.

If access to capital is unavailable on acceptable terms or at all, it could have a material adverse impact on our ability to fund operations, repay or refinance our debt obligations, fund dividend payments, acquire properties and make the investments needed to grow our business.
Adverse changes in our credit ratings could impair our ability to obtain additional debt and equity financing on favorable terms, if at all, and negatively impact the market price of our securities, including our common stock.
Our credit ratings can affect the amount and type of capital we can access, as well as the terms of any financing we may obtain. The credit ratings of our senior unsecured debt are based on, among other things, our operating performance, liquidity and leverage ratios, overall financial position, level of indebtedness and pending or future changes in the regulatory framework applicable to our operators and our industry. We may be unable to maintain our current credit ratings, and in the event that our current credit ratings deteriorate, we would likely incur higher borrowing costs, which would make it more difficult or expensive to obtain additional financing or refinance existing obligations and commitments. As a result of the potential impact of the COVID-19 pandemic, in March 2020, Moody’s changed its outlook on our long-term issuer and senior unsecured debt ratings from “stable” to “negative.” Such change in outlook may ultimately lead to a downgrade in our credit ratings. A downgrade in our credit ratings would trigger additional borrowing costs or other potentially negative consequences under our current credit facilities and debt instruments. Also, if our credit ratings are downgraded, or general market conditions were to ascribe higher risk to our ratings, our industry, or us, our access to capital and the cost of any future debt financing will be further negatively impacted. In addition, the terms of future debt agreements could include more restrictive covenants, or require incremental collateral, which may further restrict our business operations or be unavailable due to our covenant restrictions then in effect. There is no guarantee that debt or equity financings will be available in the future to fund future acquisitions or general operating expenses, or that such financing will be available on terms consistent with our historical agreements or expectations.
Our level of indebtedness may increase and materially adversely affect our future operations.
Our outstanding indebtedness as of March 31, 2020 was approximately $6.4 billion. We may incur additional indebtedness, including in connection with the development or acquisition of properties, which may be substantial. We may also increase our indebtedness to cover reduced cash receipts during periods of tenant and operator rent deferrals related to the COVID-19 pandemic. Any significant additional indebtedness would likely negatively affect the credit ratings of our debt and require us to dedicate a substantial portion of our cash flow to interest and principal payments due on our indebtedness. Greater demands on our cash resources may reduce funds available to us to pay dividends, conduct development activities, make capital expenditures and acquisitions or carry out other aspects of our business strategy. Increased indebtedness can also make us more vulnerable to general adverse economic and industry conditions and create competitive disadvantages for us compared to other companies with comparatively lower debt levels. Increased future debt service obligations may limit our operational flexibility, including our ability to finance or refinance our properties, contribute properties to joint ventures or sell properties as needed.
Covenants in our debt instruments limit our operational flexibility, and breaches of these covenants could materially adversely affect our business, results of operations and financial condition.
The terms of our current secured and unsecured debt instruments and other indebtedness that we may incur, require or will require us to comply with a number of customary financial and other covenants, such as maintaining leverage ratios, minimum tangible net worth requirements, REIT status and certain levels of debt service coverage. Our continued ability to incur additional debt and to conduct business in general is subject to compliance with these financial and other covenants, which limit our operational flexibility. For example, mortgages on our properties contain customary covenants such as those that limit or restrict our ability, without the consent of the lender, to further encumber or sell the applicable properties, or to replace the applicable tenant or operator. Breaches of certain covenants may result in defaults under the mortgages on our properties and cross-defaults under certain of our other indebtedness, even if we satisfy our payment obligations to the respective obligee. Covenants that limit our operational flexibility as well as defaults resulting from the breach of any of these covenants could materially adversely affect our business, results of operations and financial condition.
72

Table of Contents
Volatility, disruption or uncertainty in the financial markets may impair our ability to raise capital, obtain new financing or refinance existing obligations and fund real estate and development activities.
We may be affected by general market and economic conditions. Increased or prolonged market disruption, volatility or uncertainty, including disruption caused by the COVID-19 pandemic, could materially adversely impact our ability to raise capital, obtain new financing or refinance our existing obligations as they mature and fund real estate and development activities. For example, as a result of the potential or perceived impact of the pandemic on our business, lenders and other financial institutions could require us to agree to more restrictive covenants, grant liens on our assets as collateral and/or accept other terms that are not commercially beneficial to us in order to obtain financing. One or more of our lenders under our credit facility could refuse or fail to fund their financing commitment to us as a result of lender liquidity and/or viability challenges, which financing commitments we may not be able to replace on favorable terms, or at all. Market volatility could also lead to significant uncertainty in the valuation of our investments and those of our joint ventures, which may result in a substantial decrease in the value of our properties and those of our joint ventures. As a result, we may be unable to recover the carrying amount of such investments and the associated goodwill, if any, which may require us to recognize impairment charges in earnings.
Risks Related to Other Events

We rely on information technology in our operations, and any material failure, inadequacy, interruption or security failure of that technology could harm our business.
We rely on information technology networks and systems, including the Internet, to process, transmit and store electronic information, and to manage or support a variety of business processes, including financial transactions and records, and to maintain personal identifying information and tenant and lease data. We purchase some of our information technology from vendors, on whom our systems depend. We rely on commercially available systems, software, tools and monitoring to provide security for the processing, transmission and storage of confidential tenant and customer data, including individually identifiable information relating to financial accounts. Although we have taken steps to protect the security of our information systems and the data maintained in those systems, it is possible that our safety and security measures will not prevent the systems’ improper functioning or damage, or the improper access or disclosure of personally identifiable information such as in the event of cyber-attacks. The risk of security breaches has generally increased as the number, intensity and sophistication of attacks and intrusions have increased, and we have seen a significant increase in cyber phishing attacks since the onset of the COVID-19 pandemic. The risk of security breaches has also increased with our increased dependence on the Internet while our employees work remotely due to shelter-in-place orders and our health and safety policies. In addition, the pace and unpredictability of cyber threats generally quickly renders long-term implementation plans designed to address cybersecurity risks obsolete. Because our operators also rely on information technology networks, systems and software, we may be exposed to cyber-attacks on our operators.
Security breaches of our or our operators’ networks and systems, including those caused by physical or electronic break-ins, computer viruses, malware, worms, attacks by hackers or foreign governments, disruptions from unauthorized access and tampering, including through social engineering such as phishing attacks, coordinated denial-of-service attacks and similar breaches, could result in, among other things, system disruptions, shutdowns, unauthorized access to or disclosure of confidential information, misappropriation of our or our business partners’ proprietary or confidential information, breach of our legal, regulatory or contractual obligations, inability to access or rely upon critical business records or systems or other delays in our operations. In some cases, it may be difficult to anticipate or immediately detect such incidents and the damage they cause. We may be required to expend significant financial resources to protect against or to remediate such security breaches. In addition, our technology infrastructure and information systems are vulnerable to damage or interruption from natural disasters, power loss and telecommunications failures. Any failure to maintain proper function, security and availability of our and our operators’ information systems and the data maintained in those systems could interrupt our operations, damage our reputation, subject us to liability claims or regulatory penalties, harm our business relationships or increase our security and insurance costs, which could have a material adverse effect on our business, financial condition and results of operations.
We are subject to certain provisions of Maryland law and our charter relating to business combinations which may prevent a transaction that may otherwise be in the interest of our stockholders.
The Maryland Business Combination Act (the “MBCA”) provides that unless exempted, a Maryland corporation may not engage in business combinations, including a merger, consolidation, share exchange or, in circumstances specified in the statute, an asset transfer or issuance or reclassification of equity securities with an “interested stockholder” or an affiliate of an interested stockholder for five years after the most recent date on which the interested stockholder became an interested stockholder, and thereafter unless specified criteria are met. An interested stockholder is generally a person owning or controlling, directly or indirectly, 10% or more of the voting power of the outstanding voting stock of a Maryland corporation. Unless our Board of Directors takes action to exempt us, generally or with respect to certain transactions, from the MBCA, it will be applicable to business combinations between us and other persons.
73

Table of Contents
In addition to the restrictions on business combinations contained in the MBCA, our charter also contains restrictions on business combinations. Our charter requires that, except in certain circumstances, “business combinations,” including a merger or consolidation, and certain asset transfers and issuances of securities, with a “related person,” including a beneficial owner of 10% or more of our outstanding voting stock, be approved by the affirmative vote of the holders of at least 90% of our outstanding voting stock.
The restrictions on business combinations provided under Maryland law and contained in our charter may delay, defer or prevent a change of control or other transaction even if such transaction involves a premium price for our common stock or our stockholders believe that such transaction is otherwise in their best interests.
Unfavorable resolution of litigation matters and disputes could have a material adverse effect on our financial condition.
From time to time, we are involved in legal proceedings, lawsuits and other claims. We may also be named as defendants in lawsuits arising out of our alleged actions or the alleged actions of our tenants and operators for which such tenants and operators have agreed to indemnify, defend and hold us harmless. Furthermore, we anticipate a material increase in legal proceedings, lawsuits and other claims related to the COVID-19 pandemic. An unfavorable resolution of any such litigation may have a material adverse effect on our business, results of operations and financial condition. Regardless of the outcome, litigation or other legal proceedings may result in substantial costs, disruption of our normal business operations, and the diversion of management attention. We may be unable to prevail in, or achieve a favorable settlement of, any pending or future legal action against us. See "Part II–Item 1–Legal Proceedings" of this Quarterly Report on Form 10-Q.
The loss or limited availability of our key personnel could disrupt our operations and have a material adverse effect on our business, results of operations, financial condition, and the value of our common stock.
We depend on the efforts of our executive officers for the success of our business, and competition for these individuals is intense. Although they are covered by our Executive Severance Plan and Change in Control Plan, which provide many of the benefits typically found in executive employment agreements, none of our executive officers have employment agreements with us. Any outbreak of COVID-19 or other epidemic among our executive management, senior leaders or other personnel could inhibit our ability to conduct our business, as well as our ability to recruit, attract and retain skilled employees. The loss or limited availability of the services of any of our executive officers, or our inability to recruit and retain qualified personnel, could, at least temporarily, have a material adverse effect on our business, results of operations and financial condition and the value of our common stock.
Environmental compliance costs and liabilities associated with our real estate-related investments may be substantial and may materially impair the value of those investments.
Federal, state and local laws, ordinances and regulations may require us, as a current or previous owner of real estate, to investigate and clean up certain hazardous or toxic substances or petroleum released at a property. We may be held liable to a governmental entity or to third parties for property damage and for investigation and cleanup costs incurred by the third parties in connection with the contamination. The costs of cleanup and remediation could be substantial. In addition, some environmental laws create a lien on the contaminated site in favor of the government for damages and the costs it incurs in connection with the contamination.
Although we currently carry environmental insurance on our properties in an amount that we believe is commercially reasonable and generally require our tenants and operators to indemnify us for environmental liabilities they cause, such liabilities could exceed the amount of our insurance, the financial ability of the tenant or operator to indemnify us or the value of the contaminated property. As the owner of a site, we may also be held liable to third parties for damages and injuries resulting from environmental contamination emanating from the site. We may also experience environmental liabilities arising from conditions not known to us. The cost of defending against these claims, complying with environmental regulatory requirements, conducting remediation of any contaminated property, or paying personal injury or other claims or fines could be substantial and could have a materially adverse effect on our business, results of operations and financial condition.
In addition, the presence of contamination or the failure to remediate contamination may materially adversely affect our ability to use, sell or lease the property or to borrow using the property as collateral.
74

Table of Contents
Risks Related to Tax, including REIT-Related Risks

Loss of our tax status as a REIT would substantially reduce our available funds and would have materially adverse consequences for us and the value of our common stock.
Qualification as a REIT involves the application of numerous highly technical and complex provisions of the Internal Revenue Code of 1986, as amended (the “Code”), for which there are limited judicial and administrative interpretations, as well as the determination of various factual matters and circumstances not entirely within our control. We intend to continue to operate in a manner that enables us to qualify as a REIT. However, our qualification and taxation as a REIT depend upon our ability to meet, through actual annual operating results, asset diversification, distribution levels and diversity of stock ownership, the various qualification tests imposed under the Code.
For example, to qualify as a REIT, at least 95% of our gross income in any year must be derived from qualifying sources, and we must make distributions to our stockholders aggregating annually to at least 90% of our REIT taxable income, excluding net capital gains. Rents we receive from a TRS in a RIDEA structure are treated as qualifying rents from real property for REIT tax purposes only if (i) they are paid pursuant to a lease of a “qualified healthcare property,” and (ii) the operator qualifies as an “eligible independent contractor,” as defined in the Code. If either of these requirements are not satisfied, then the rents will not be qualifying rents. Furthermore, new legislation, regulations, administrative interpretations or court decisions could change the tax laws or interpretations of the tax laws regarding qualification as a REIT, or the federal income tax consequences of that qualification, in a manner that is materially adverse to our stockholders. Accordingly, there is no assurance that we have operated or will continue to operate in a manner so as to qualify or remain qualified as a REIT.
If we lose our REIT status, we will face serious tax consequences that will substantially reduce the funds available to make payments of principal and interest on the debt securities we issue and to make distributions to stockholders. If we fail to qualify as a REIT:

• | we will not be allowed a deduction for distributions to stockholders in computing our taxable income;

• | we will be subject to corporate-level income tax on our taxable income at regular corporate rates;

• | we will be subject to increased state and local income taxes; and

• | unless we are entitled to relief under relevant statutory provisions, we will be disqualified from taxation as a REIT for the four taxable years following the year during which we fail to qualify as a REIT.

As a result of all these factors, our failure to qualify as a REIT could also impair our ability to expand our business and raise capital and could materially adversely affect the value of our common stock.
Further changes to U.S. federal income tax laws could materially and adversely affect us and our stockholders.
The present federal income tax treatment of REITs may be modified, possibly with retroactive effect, by legislative, judicial or administrative action at any time, which could affect the federal income tax treatment of an investment in us. The federal income tax rules dealing with U.S. federal income taxation and REITs are constantly under review by persons involved in the legislative process, the U.S. Internal Revenue Service (the “IRS”) and the U.S. Treasury Department, which results in statutory changes as well as frequent revisions to regulations and interpretations. We cannot predict how changes in the tax laws might affect our investors or us. Revisions in federal tax laws and interpretations thereof could significantly and negatively affect our ability to qualify as a REIT, as well as the tax considerations relevant to an investment in us, or could cause us to change our investments and commitments.
We could have potential deferred and contingent tax liabilities from corporate acquisitions that could limit, delay or impede future sales of our properties.
If, during the five-year period beginning on the date we acquire certain companies, we recognize a gain on the disposition of any property acquired, then, to the extent of the excess of (i) the fair market value of such property as of the acquisition date over (ii) our adjusted income tax basis in such property as of that date, we will be required to pay a corporate-level federal income tax on this gain at the highest regular corporate rate. There can be no assurance that these triggering dispositions will not occur, and these requirements could limit, delay or impede future sales of our properties.
In addition, the IRS may assert liabilities against us for corporate income taxes for taxable years prior to the time that we acquire certain companies, in which case we will owe these taxes plus interest and penalties, if any.
75

Table of Contents
There are uncertainties relating to the calculation of non-REIT tax earnings and profits (“E&P”) in certain acquisitions, which may require us to distribute E&P.
In order to remain qualified as a REIT, we are required to distribute to our stockholders all of the accumulated non-REIT E&P of certain companies that we acquire, prior to the close of the first taxable year in which the acquisition occurs. Failure to make such E&P distributions would result in our disqualification as a REIT. The determination of the amount to be distributed in such E&P distributions is a complex factual and legal determination. We may have less than complete information at the time we undertake our analysis, or we may interpret the applicable law differently from the IRS. We currently believe that we have satisfied the requirements relating to such E&P distributions. There are, however, substantial uncertainties relating to the determination of E&P, including the possibility that the IRS could successfully assert that the taxable income of the companies acquired should be increased, which would increase our non-REIT E&P. Moreover, an audit of the acquired company following our acquisition could result in an increase in accumulated non-REIT E&P, which could require us to pay an additional taxable distribution to our then-existing stockholders, if we qualify under rules for curing this type of default, or could result in our disqualification as a REIT.
Thus, we might fail to satisfy the requirement that we distribute all of our non-REIT E&P by the close of the first taxable year in which the acquisition occurs. Moreover, although there are procedures available to cure a failure to distribute all of our E&P, we cannot now determine whether we will be able to take advantage of these procedures or the economic impact on us of doing so.
Our charter contains ownership limits with respect to our common stock and other classes of capital stock.
Our charter contains restrictions on the ownership and transfer of our common stock and preferred stock that are intended to assist us in preserving our qualification as a REIT. Under our charter, subject to certain exceptions, no person or entity may own, actually or constructively, more than 9.8% (by value or by number of shares, whichever is more restrictive) of the outstanding shares of our common stock or any class or series of our preferred stock.
Additionally, our charter has a 9.9% ownership limitation on the direct or indirect ownership of our voting shares, which may include common stock or other classes of capital stock. Our Board of Directors, in its sole discretion, may exempt a proposed transferee from either ownership limit. The ownership limits may delay, defer or prevent a transaction or a change of control that might involve a premium price for our common stock or might otherwise be in the best interests of our stockholders.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a)
None.
(b)
None.
(c)
The following table sets forth information with respect to purchases of our common stock made by us or on our behalf during the three months ended March 31, 2020.

Period Covered |  | Total Number Of Shares Purchased(1) |  | Average Price Paid Per Share |  | Total Number Of Shares (Or Units) Purchased As Part Of Publicly Announced Plans Or Programs |  | Maximum Number (Or Approximate Dollar Value) Of Shares (Or Units) That May Yet Be Purchased Under The Plans Or Programs
January 1-31, 2020 |  | 112,704 |  |  | $ | 36.71 |  |  | — |  |  | — |
February 1-29, 2020 |  | 129,673 |  |  | 37.17 |  |  | — |  |  | — |
March 1-31, 2020 |  | 24,595 |  |  | 31.64 |  |  | — |  |  | — |
Total |  | 266,972 |  |  | $ | 36.47 |  |  | — |  |  | — |

_______________________________________

(1) | Represents shares of our common stock withheld under our equity incentive plans to offset tax withholding obligations that occur upon vesting of restricted shares. The value of the shares withheld is based on the closing price of our common stock on the last trading day prior to the date the relevant transaction occurred.

76

Table of Contents
Item 6. Exhibits

3.1 |  | Articles of Restatement of Healthpeak Properties, Inc. (formerly HCP, Inc.) dated June 1, 2012, as supplemented by the Articles Supplementary, dated July 31, 2017, and as amended by the Articles of Amendment, dated October 30, 2019 (incorporated herein by reference to Exhibit 3.1 to Healthpeak’s Annual Report on Form 10-K filed February 13, 2020).
3.2 |  | Articles of Amendment to Articles of Restatement of Healthpeak Properties, Inc. (formerly HCP, Inc.), dated October 30, 2019 (incorporated herein by reference to Exhibit 3.1 to Healthpeak’s Current Report on Form 8-K filed October 30, 2019).
3.3 |  | Sixth Amended and Restated Bylaws of Healthpeak Properties, Inc., dated October 30, 2019 (incorporated herein by reference to Exhibit 3.2 to Healthpeak’s Current Report on Form 8-K filed October 30, 2019).
10.1 |  | At-the-Market Equity Offering Sales Agreement, dated February 19, 2020, among the Company, the Sales Agents, the Forward Sellers and the Forward Purchasers (incorporated herein by reference to Exhibit 1.1 to Healthpeak’s Current Report on Form 8-K filed on February 19, 2020).
31.1 |  | Certification by Thomas M. Herzog, Healthpeak’s Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(a).*
31.2 |  | Certification by Peter A. Scott, Healthpeak’s Principal Financial Officer, Pursuant to Securities Exchange Act Rule 13a-14(a).*
32.1 |  | Certification by Thomas M. Herzog, Healthpeak’s Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.**
32.2 |  | Certification by Peter A. Scott, Healthpeak’s Principal Financial Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.**
101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.*
101.SCH |  | XBRL Taxonomy Extension Schema Document.*
101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB |  | XBRL Taxonomy Extension Labels Linkbase Document.*
101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document.*
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

_______________________________________
* Filed herewith.
** Furnished herewith.
77

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 6, 2020 | Healthpeak Properties, Inc.
| (Registrant)
| /s/ THOMAS M. HERZOG
| Thomas M. Herzog
| Chief Executive Officer
| (Principal Executive Officer)
| /s/ PETER A. SCOTT
| Peter A. Scott
| Executive Vice President and
| Chief Financial Officer
| (Principal Financial Officer)
| /s/ SHAWN G. JOHNSTON
| Shawn G. Johnston
| Executive Vice President and
| Chief Accounting Officer
| (Principal Accounting Officer)

78